EurekaMag PDF full texts Chapter 56,988

Gyetvai, B.; Simonyi, A.; Oros, M.; Saito, M.; Smiley, J.; Vadász, C. 2011: MGluR7 genetics and alcohol: intersection yields clues for addiction. Neurochemical Research 36(6): 1087-1100

Voytenko, S.V.; Galazyuk, A.V. 2011: MGluRs modulate neuronal firing in the auditory midbrain. Neuroscience Letters 492(3): 145-149

Zhang, F.; Liu, B.; Lei, Z.; Wang, J.-H. 2012: MGluR₁,5 activation improves network asynchrony and GABAergic synapse attenuation in the amygdala: implication for anxiety-like behavior in DBA/2 mice. Molecular Brain 5: 20

Larkin, H. 2011: MHealth. Hospitals and Health Networks 85(4): 22-6 2

Handel, M.J. 2011: MHealth (mobile health)-using Apps for health and wellness. Explore 7(4): 256-261

Akter, S.; Ray, P. 2010: MHealth - an Ultimate Platform to Serve the Unserved. Yearbook of Medical Informatics 2010: 94-100

Becker, S.; Miron-Shatz, T.; Schumacher, N.; Krocza, J.; Diamantidis, C.; Albrecht, U.-V. 2014: MHealth 2.0: Experiences, Possibilities, and Perspectives. Jmir Mhealth and Uhealth 2(2): E24

Bajwa, M. 2014: MHealth Security. Pakistan Journal of Medical Sciences 30(4): 904-907

van Velthoven, M.Helena.; Li, Y.; Wang, W.; Du, X.; Chen, L.; Wu, Q.; Majeed, A.; Zhang, Y.; Car, J. 2013: MHealth Series: Factors influencing sample size calculations for mHealth-based studies - A mixed methods study in rural China. Journal of global health 3(2): 020404

Zhang, Y.; Chen, L.; van Velthoven, M.H.M.M.T.; Wang, W.; Liu, L.; Du, X.; Wu, Q.; Li, Y.; Car, J. 2013: MHealth Series: Measuring maternal newborn and child health coverage by text messaging - a county-level model for China. Journal of global health 3(2): 020402

Du, X.; Wang, W.; Helena van Velthoven, M.; Chen, L.; Scherpbier, R.W.; Zhang, Y.; Wu, Q.; Li, Y.; Rao, X.; Car, J. 2013: MHealth Series: Text messaging data collection of infant and young child feeding practice in rural China - a feasibility study. Journal of global health 3(2): 020403

van Velthoven, M.Helena.; Li, Y.; Wang, W.; Du, X.; Wu, Q.; Chen, L.; Majeed, A.; Rudan, I.; Zhang, Y.; Car, J. 2013: MHealth Series: mHealth project in Zhao County, rural China - Description of objectives, field site and methods. Journal of global health 3(2): 020401

Chib, A.; van Velthoven, M.Helena.; Car, J. 2015: MHealth adoption in low-resource environments: a review of the use of mobile healthcare in developing countries. Journal of Health Communication 20(1): 4-34

Destigter, K. 2012: MHealth and developing countries: a successful obstetric care model in Uganda. Biomedical Instrumentation and Technology Suppl: 41-44

Farrington, C.; Aristidou, A.; Ruggeri, K. 2014: MHealth and global mental health: still waiting for the mH2 wedding?. Globalization and Health 10: 17

Migo, E.M.; Haynes, B.I.; Harris, L.; Friedner, K.; Humphreys, K.; Kopelman, M.D. 2015: MHealth and memory aids: levels of smartphone ownership in patients. Journal of Mental Health 24(5): 266-270

Lewis, T.L.; Wyatt, J.C. 2014: MHealth and mobile medical Apps: a framework to assess risk and promote safer use. Journal of Medical Internet Research 16(9): E210

Yan, P.; Kurillo, G.; Bajcsy, R.; Abresch, R.T.; Nicorici, A.; Johnson, L.; Han, J.J. 2013: MHealth application for upper extremity range of motion and reachable workspace. Studies in Health Technology and Informatics 184: 478-480

McCurdie, T.; Taneva, S.; Casselman, M.; Yeung, M.; McDaniel, C.; Ho, W.; Cafazzo, J. 2012: MHealth consumer apps: the case for user-centered design. Biomedical Instrumentation and Technology Suppl: 49-56

Shishido, H.Yoshikazu.; Alves da Cruz de Andrade, R.; Eler, G.Jacklin. 2014: MHealth data collector: an application to collect and report indicators for assessment of cardiometabolic risk. Studies in Health Technology and Informatics 201: 425-432

Luxton, D.D.; Kayl, R.A.; Mishkind, M.C. 2012: MHealth data security: the need for HIPAA-compliant standardization. Telemedicine Journal and E-Health: the Official Journal of the American Telemedicine Association 18(4): 284-288

Ben-Zeev, D. 2014: MHealth for dual diagnosis: considering long-term implementation. Journal of Dual Diagnosis 10(1): 30-31

Folaranmi, T. 2014: MHealth in Africa: challenges and opportunities. Perspectives in Public Health 134(1): 14-15

Betjeman, T.J.; Soghoian, S.E.; Foran, M.P. 2013: MHealth in Sub-Saharan Africa. International Journal of Telemedicine and Applications 2013: 482324

Labrique, A.B.; Vasudevan, L.; Kochi, E.; Fabricant, R.; Mehl, G. 2013: MHealth innovations as health system strengthening tools: 12 common applications and a visual framework. Global Health Science and Practice 1(2): 160-171

Shaw, R.J.; Steinberg, D.M.; Zullig, L.L.; Bosworth, H.B.; Johnson, C.M.; Davis, L.L. 2014: MHealth interventions for weight loss: a guide for achieving treatment fidelity. Journal of the American Medical Informatics Association: Jamia 21(6): 959-963

L'Engle, K.; Raney, L.; D'Adamo, M. 2014: MHealth resources to strengthen health programs. Global Health Science and Practice 2(1): 130-131

van Velthoven, M.Helena.; Car, J.; Zhang, Y.; Marušić, A. 2013: MHealth series: New ideas for mHealth data collection implementation in low- and middle-income countries. Journal of global health 3(2): 020101

Littman-Quinn, R.; Luberti, A.A.; Kovarik, C. 2013: MHealth to revolutionize information retrieval in low and middle income countries: introduction and proposed solutions using Botswana as reference point. Studies in Health Technology and Informatics 192: 894-898

Slaper, M.R.; Conkol, K. 2014: MHealth tools for the pediatric patient-centered medical home. Pediatric Annals 43(2): E39-E43

Morrissey, J. 2013: MHealth: Managing data on the go. Hospitals and Health Networks 87(7): 22-23

Okuboyejo, S.; Eyesan, O. 2014: MHealth: Using Mobile Technology to Support Healthcare. Online Journal of Public Health Informatics 5(3): 233

De la Vega, R.ío.; Miró, J. 2014: MHealth: a strategic field without a solid scientific soul. a systematic review of pain-related apps. Plos one 9(7): E101312

Prabhu, A. 2013: MHealth: the emerging sub-segment of eHealth. Journal of Contemporary Dental Practice 14(3): i

Waegemann, C.P. 2010: MHealth: the next generation of telemedicine?. Telemedicine Journal and E-Health: the Official Journal of the American Telemedicine Association 16(1): 23-25

Ahnn, J.Hoon.; Potkonjak, M. 2013: MHealthMon: toward energy-efficient and distributed mobile health monitoring using parallel offloading. Journal of Medical Systems 37(5): 9957

Habuchi, S.; Tsutsui, H.; Kochaniak, A.B.; Miyawaki, A.; van Oijen, A.M. 2008: MKikGR, a monomeric photoswitchable fluorescent protein. Plos one 3(12): E3944

Mowers, P. 2011: ML or uL?. Mlo: Medical Laboratory Observer 43(7): 8

Chou, C.-K.; Lee, H.-H.; Tsou, P.-H.; Chen, C.-T.; Hsu, J.-M.; Yamaguchi, H.; Wang, Y.-N.; Lee, H.-J.; Hsu, J.L.; Lee, J.-F.; Kameoka, J.; Hung, M.-C. 2014: MMAPS: a flow-proteometric technique to analyze protein-protein interactions in individual signaling complexes. Science Signaling 7(315): Rs1

Qiao, H.; Lin, C.; Ji, L.; Jiang, Z. 2012: MMWeb--an online platform for employing multiple ecological niche modeling algorithms. Plos one 7(8): E43327

McEvoy, A.L.; Hoi, H.; Bates, M.; Platonova, E.; Cranfill, P.J.; Baird, M.A.; Davidson, M.W.; Ewers, H.; Liphardt, J.; Campbell, R.E. 2012: MMaple: a photoconvertible fluorescent protein for use in multiple imaging modalities. Plos one 7(12): E51314

Strohalm, M.; Kavan, D.; Novák, P.; Volný, M.; Havlícek, V.ír. 2010: MMass 3: a cross-platform software environment for precise analysis of mass spectrometric data. Analytical Chemistry 82(11): 4648-4651

Niedermeyer, T.H.J.; Strohalm, M. 2012: MMass as a software tool for the annotation of cyclic peptide tandem mass spectra. Plos one 7(9): E44913

Strohalm, M.; Hassman, M.; Kosata, B.; Kodícek, M. 2008: MMass data miner: an open source alternative for mass spectrometric data analysis. Rapid Communications in Mass Spectrometry: Rcm 22(6): 905-908

Miyazaki, A.; Ishii, K.; Yamashita, S.; Nejigane, S.; Matsukawa, S.; Ito, Y.; Onuma, Y.; Asashima, M.; Michiue, T. 2012: MNanog possesses dorsal mesoderm-inducing ability by modulating both BMP and Activin/nodal signaling in Xenopus ectodermal cells. Plos one 7(10): E46630

Colton, C.A.; Wilson, J.G.; Everhart, A.; Wilcock, D.M.; Puoliväli, J.; Heikkinen, T.; Oksman, J.; Jääskeläinen, O.; Lehtimäki, K.; Laitinen, T.; Vartiainen, N.; Vitek, M.P. 2014: MNos2 deletion and human NOS2 replacement in Alzheimer disease models. Journal of Neuropathology and Experimental Neurology 73(8): 752-769

Dolyniuk, J.-A.; Kaseman, D.C.; Sen, S.; Zhao, J.; Osterloh, F.E.; Kovnir, K. 2014: MP-BaP₃: a new phase from an old binary system. Chemistry 20(34): 10829-10837

Reyes-Reveles, J.; Sedaghat-Herati, R.; Gilley, D.R.; Schaeffer, A.M.; Ghosh, K.C.; Greene, T.D.; Gann, H.E.; Dowler, W.A.; Kramer, S.; Dean, J.M.; Delong, R.K. 2013: MPEG-PAMAM-G4 nucleic acid nanocomplexes: enhanced stability, RNase protection, and activity of splice switching oligomer and poly I:C RNA. Biomacromolecules 14(11): 4108-4115

Wang, S.; Chen, R.; Morott, J.; Repka, M.A.; Wang, Y.; Chen, M. 2015: MPEG-b-PCL/TPGS mixed micelles for delivery of resveratrol in overcoming resistant breast cancer. Expert Opinion on Drug Delivery 12(3): 361-373

Nakanishi, M.; Gokhale, V.; Meuillet, E.J.; Rosenberg, D.W. 2010: MPGES-1 as a target for cancer suppression: a comprehensive invited review "Phospholipase A2 and lipid mediators". Biochimie 92(6): 660-664

Jia, Z.; Aoyagi, T.; Kohan, D.E.; Yang, T. 2010: MPGES-1 deletion impairs aldosterone escape and enhances sodium appetite. American Journal of Physiology. Renal Physiology 299(1): F155-F166

Soodvilai, S.; Jia, Z.; Wang, M.-H.; Dong, Z.; Yang, T. 2009: MPGES-1 deletion impairs diuretic response to acute water loading. American Journal of Physiology. Renal Physiology 296(5): F1129-F1135

Nonaka, K.; Fujioka, H.; Takii, Y.; Abiru, S.; Migita, K.; Ito, M.; Kanematsu, T.; Ishibashi, H. 2010: MPGES-1 expression in non-cancerous liver tissue impacts on postoperative recurrence of HCC. World Journal of Gastroenterology 16(38): 4846-4853

Rouaud, P.; Guerin, E.; Bordessoule, D.; Turlure, P.; Trimoreau, F.; Denizot, Y. 2012: MPGES-1 in leukemic cells of AML patients. International Journal of Hematology 95(1): 115-116

Pecchi, E.; Dallaporta, M.; Jean, A.; Thirion, S.; Troadec, J.D. 2008: MPGES-1 knock-out mice are resistant to cancer-induced anorexia despite the absence of central mPGES-1 up-regulation in wild-type anorexic mice. Journal of Neuroimmunology 199(1-2): 104-114

McCann, M.R.; Monemdjou, R.; Ghassemi-Kakroodi, P.; Fahmi, H.; Perez, G.; Liu, S.; Shi-Wen, X.; Parapuram, S.K.; Kojima, F.; Denton, C.P.; Abraham, D.J.; Martel-Pelletier, J.; Crofford, L.J.; Leask, A.; Kapoor, M. 2011: MPGES-1 null mice are resistant to bleomycin-induced skin fibrosis. Arthritis Research and Therapy 13(1): R6

Jia, Z.; Aoyagi, T.; Yang, T. 2010: MPGES-1 protects against DOCA-salt hypertension via inhibition of oxidative stress or stimulation of NO/cGMP. Hypertension 55(2): 539-546

Kamata, H.; Hosono, K.; Suzuki, T.; Ogawa, Y.; Kubo, H.; Katoh, H.; Ito, Y.; Uematsu, S.; Akira, S.; Watanabe, M.; Majima, M. 2010: MPGES-1-expressing bone marrow-derived cells enhance tumor growth and angiogenesis in mice. Biomedicine and PharmacoTherapy 64(6): 409-416

Pecchi, E.; Dallaporta, M.; Thirion, S.; Jean, A.é; Troadec, J.D. 2009: MPGES-1: it makes us sick!. Medecine Sciences: M/S 25(5): 451-454

Sun, Y.; Jia, Z.; Yang, G.; Kakizoe, Y.; Liu, M.; Yang, K.T.; Liu, Y.; Yang, B.; Yang, T. 2014: MPGES-2 deletion remarkably enhances liver injury in streptozotocin-treated mice via induction of GLUT2. Journal of Hepatology 61(6): 1328-1336

Dabrowski, P.W.; Nitsche, A. 2012: MPSQed: a software for the design of multiplex pyrosequencing assays. Plos one 7(6): E38140

Links, M.G.; Chaban, B.; Hemmingsen, S.M.; Muirhead, K.; Hill, J.E. 2013: MPUMA: a computational approach to microbiota analysis by de novo assembly of operational taxonomic units based on protein-coding barcode sequences. Microbiome 1(1): 23

Naito, K.; Monden, Y.; Yasuda, K.; Saito, H.; Okumoto, Y. 2014: MPing: the bursting transposon. Breeding Science 64(2): 109-114

Lin, L-Ting.; Wang, B-Sheng.; Chen, J-Cheng.; Liu, C-Hsien.; Chou, C.; Chiu, S-Jun.; Chang, W-Yi.; Liu, R-Shyan.; Allen Chang, C.; Lee, Y-Jang. 2013: MPlum-IFP 1.4 fluorescent fusion protein may display Förster resonance energy transfer associated properties that can be used for near-infrared based reporter gene imaging. Journal of Biomedical Optics 18(12): 126013

Valeri, C.Robert.; Vournakis, J.N. 2011: MRDH bandage for surgery and trauma: data summary and comparative review. Journal of Trauma 71(2 Suppl. 1): S162-S166

Prajapati, H.J.; Spivey, J.R.; Hanish, S.I.; El-Rayes, B.F.; Kauh, J.S.; Chen, Z.; Kim, H.S. 2013: MRECIST and EASL responses at early time point by contrast-enhanced dynamic MRi predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Annals of Oncology: Official Journal of the European Society for Medical Oncology 24(4): 965-973

Moschouris, H.; Malagari, K.; Papadaki, M.G.; Kornezos, I.; Stamatiou, K.; Anagnostopoulos, A.; Chatzimichael, K.; Kelekis, N. 2014: MRECIST criteria and contrast-enhanced US for the assessment of the response of hepatocellular carcinoma to transarterial chemoembolization. Diagnostic and Interventional Radiology 20(2): 136-142

Ruepp, M.-D.; Schümperli, D.; Barabino, S.M.L. 2011: MRNA 3' end processing and more--multiple functions of mammalian cleavage factor I-68. Wiley Interdisciplinary Reviews. Rna 2(1): 79-91

Darmon, S.K.; Lutz, C.S. 2012: MRNA 3' end processing factors: a phylogenetic comparison. Comparative and Functional Genomics 2012: 876893

Hollerer, I.; Grund, K.; Hentze, M.W.; Kulozik, A.E. 2014: MRNA 3'end processing: a tale of the tail reaches the clinic. Embo Molecular Medicine 6(1): 16-26

Araujo, P.Pereira.Costa.; Marcello, M.Alana.; Tincani, A.Jose.; Guilhen, A.Carolina.Trindade.; Morari, E.Cristina.; Ward, L.Sterian. 2012: mRNA BRAF expression helps to identify papillary thyroid carcinomas in thyroid nodules independently of the presence of BRAFV600E mutation. Pathology Research and Practice 208(8): 489-492

Akgül, B.ün.; Tu, C.-P.D. 2008: MRNA Decay analysis in Drosophila melanogaster drug-induced changes in glutathione S-transferase D21 mRNA stability. Methods in Enzymology 448: 285-297

Simone, C.B.; John-Aryankalayil, M.; Palayoor, S.T.; Makinde, A.Y.; Cerna, D.; Falduto, M.T.; Magnuson, S.R.; Coleman, C.N. 2013: MRNA Expression Profiles for Prostate Cancer following Fractionated Irradiation Are Influenced by p53 Status. Translational Oncology 6(5): 573-585

Ha, Y.-S.; Kim, M.-J.; Yoon, H.-Y.; Kang, H.-W.; Kim, Y.-J.; Yun, S.-J.; Lee, S.-C.; Kim, W.-J. 2010: MRNA Expression of S100A8 as a Prognostic Marker for Progression of Non-Muscle-Invasive Bladder Cancer. Korean Journal of Urology 51(1): 15-20

Palin, M.-F.; Côrtes, C.; Benchaar, C.; Lacasse, P.; Petit, H.él.èn.V. 2014: MRNA Expression of lipogenic enzymes in mammary tissue and fatty acid profile in milk of dairy cows fed flax hulls and infused with flax oil in the abomasum. British Journal of Nutrition 111(6): 1011-1020

Doucet, J.-D.; Gauchat, D.; Lapointe, R.éj. 2013: MRNA PCR-based epitope chase method. Methods in Molecular Biology 969: 305-320

Pawlikowska-Warych, M.łg.; Deptuła, W.ła. 2014: MRNA Regulatory elements and bacterial virulence. Acta Biochimica Polonica 61(1): 63-65

Tellam, J.T.; Zhong, J.; Lekieffre, L.; Bhat, P.; Martinez, M.; Croft, N.P.; Kaplan, W.; Tellam, R.L.; Khanna, R. 2014: MRNA Structural constraints on EBNA1 synthesis impact on in vivo antigen presentation and early priming of CD8+ T cells. Plos Pathogens 10(10): E1004423

Han, L.Q.; Li, H.J.; Wang, Y.Y.; Zhu, H.S.; Wang, L.F.; Guo, Y.J.; Lu, W.F.; Wang, Y.L.; Yang, G.Y. 2010: MRNA abundance and expression of SLC27A, ACC, SCD, FADS, LPIN, INSIG, and PPARGC1 gene isoforms in mouse mammary glands during the lactation cycle. Genetics and molecular research: GMR 9(2): 1250-1257

Lemor, A.; Mielenz, M.; Altmann, M.; von Borell, E.; Sauerwein, H. 2010: MRNA abundance of adiponectin and its receptors, leptin and visfatin and of G-protein coupled receptor 41 in five different fat depots from sheep. Journal of Animal Physiology and Animal Nutrition 94(5): E96-101

Bartlett, J.M. 2001: MRNA analyses : a technical overview. Methods in Molecular Medicine 39: 399-409

Suthar, C.; Rana, T.; Singh, U.B.; Singh, M.; Ramesh, V.; Sharma, V.K.; Ramam, M. 2013: MRNA and DNA PCR tests in cutaneous tuberculosis. Indian Journal of Dermatology Venereology and Leprology 79(1): 65-69

Spathis, A.; Kottaridi, C.; Chranioti, A.; Meristoudis, C.; Chrelias, C.; Panayiotides, I.G.; Paraskevaidis, E.; Karakitsos, P. 2012: MRNA and DNA detection of human papillomaviruses in women of all ages attending two colposcopy clinics. Plos one 7(11): E49205

Li, A.; Liu, D.; Wu, J.; Zhao, X.; Hao, M.; Geng, S.; Yan, J.; Jiang, X.; Zhang, L.; Wu, J.; Yin, L.; Zhang, R.; Wu, L.; Zheng, Y.; Mao, L. 2014: MRNA and Small RNA Transcriptomes Reveal Insights into Dynamic Homoeolog Regulation of Allopolyploid Heterosis in Nascent Hexaploid Wheat. Plant Cell 26(5): 1878-1900

Plönes, T.; Elze, M.; Kayser, G.; Pfeifer, D.; Burger, M.; Zissel, G. 2014: MRNA and miRNA analyses in cytologically positive endobronchial ultrasound-guided transbronchial needle aspiration: implications for molecular staging in lung cancer patients. Cancer Cytopathology 122(4): 292-298

Nonn, L.; Vaishnav, A.; Gallagher, L.; Gann, P.H. 2010: MRNA and micro-RNA expression analysis in laser-capture microdissected prostate biopsies: valuable tool for risk assessment and prevention trials. Experimental and Molecular Pathology 88(1): 45-51

Zsippai, A.; Szabó, D.R.; Szabó, P.M.; Tömböl, Z.óf.; Bendes, M.R.; Nagy, Z.án.; Rácz, K.ár.; Igaz, P. 2011: MRNA and microRNA expression patterns in adrenocortical cancer. American Journal of Cancer Research 1(5): 618-628

Sieuwerts, A.M.; Mostert, B.; Bolt-de Vries, J.; Peeters, D.; de Jongh, F.E.; Stouthard, J.M.L.; Dirix, L.Y.; van Dam, P.A.; Van Galen, A.; de Weerd, V.; Kraan, J.; van der Spoel, P.; Ramírez-Moreno, R.; van Deurzen, C.H.M.; Smid, M.; Yu, J.X.; Jiang, J.; Wang, Y.; Gratama, J.W.; Sleijfer, S.; Foekens, J.A.; Martens, J.W.M. 2011: MRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 17(11): 3600-3618

Liu, H.; D'Andrade, P.; Fulmer-Smentek, S.; Lorenzi, P.; Kohn, K.W.; Weinstein, J.N.; Pommier, Y.; Reinhold, W.C. 2010: MRNA and microRNA expression profiles of the NCI-60 integrated with drug activities. Molecular Cancer Therapeutics 9(5): 1080-1091

Kirchner, B.; Paul, V.; Riedmaier, I.; Pfaffl, M.W. 2014: MRNA and microRNA purity and integrity: the key to success in expression profiling. Methods in Molecular Biology 1160: 43-53

Becker, C.; Hammerle-Fickinger, A.; Riedmaier, I.; Pfaffl, M.W. 2010: MRNA and microRNA quality control for RT-qPCR analysis. Methods 50(4): 237-243

Chrusciel, M.; Rekawiecki, R.; Ziecik, A.J.; Andronowska, A. 2010: MRNA and protein expression of FGF-1, FGF-2 and their receptors in the porcine umbilical cord during pregnancy. Folia Histochemica et Cytobiologica 48(4): 572-580

Lu, J.-y.; Wu, Z.-q.; Tan, L.-n.; Chen, J.; Xiang, Y.-p.; Zuo, C.-x.; Huang, J.-h.; Jiang, X.-z. 2007: MRNA and protein expression of haptoglobin in lesions of condyloma acuminatum. Zhong Nan da Xue Xue Bao. Yi Xue Ban 32(6): 1020-1025

Fatemi, S.H.; Reutiman, T.J.; Folsom, T.D.; Rooney, R.J.; Patel, D.H.; Thuras, P.D. 2010: MRNA and protein levels for GABAAalpha4, alpha5, beta1 and GABABR1 receptors are altered in brains from subjects with autism. Journal of Autism and Developmental Disorders 40(6): 743-750

Spitzer, J.I.; Ugras, S.; Runge, S.; Decarolis, P.; Antonescu, C.; Tuschl, T.; Singer, S. 2011: MRNA and protein levels of FUS, EWSR1, and TAF15 are upregulated in liposarcoma. Genes Chromosomes and Cancer 50(5): 338-347

Tavernier, G.; Andries, O.; Demeester, J.; Sanders, N.N.; De Smedt, S.C.; Rejman, J. 2011: MRNA as gene therapeutic: how to control protein expression. Journal of Controlled Release: Official Journal of the Controlled Release Society 150(3): 238-247

Percipalle, P. 2014: MRNA biogenesis, from the gene to polysomes. Seminars in Cell and Developmental Biology 32: 1

Kuhn, J.M.; Hugouvieux, V.; Schroeder, J.I. 2008: MRNA cap binding proteins: effects on abscisic acid signal transduction, mRNA processing, and microarray analyses. Current Topics in Microbiology and Immunology 326: 139-150

Ma, Y.; Wei, Y.; Zhang, X.; Zhang, Y.; Cai, H.; Zhu, Y.; Shilo, K.; Oglesbee, M.; Krakowka, S.; Whelan, S.P.J.; Li, J. 2014: MRNA cap methylation influences pathogenesis of vesicular stomatitis virus in vivo. Journal of Virology 88(5): 2913-2926

Yu, H.; Kim, K.Sik. 2012: MRNA context dependent regulation of cytotoxic necrotizing factor 1 translation by GidA, a tRNA modification enzyme in Escherichia coli. Gene 491(2): 116-122

Van der Laan, A.M.A.; van Gemert, A.M.C.; Dirks, R.W.; Noordermeer, J.N.; Fradkin, L.G.; Tanke, H.J.; Jost, C.R. 2012: MRNA cycles through hypoxia-induced stress granules in live Drosophila embryonic muscles. International Journal of Developmental Biology 56(9): 701-709

Wolf, J.; Passmore, L.A. 2014: MRNA deadenylation by Pan2-Pan3. Biochemical Society Transactions 42(1): 184-187

Dougherty, J.D.; Reineke, L.C.; Lloyd, R.E. 2014: MRNA decapping enzyme 1a (Dcp1a)-induced translational arrest through protein kinase R (PKR) activation requires the N-terminal enabled vasodilator-stimulated protein homology 1 (EVH1) domain. Journal of Biological Chemistry 289(7): 3936-3949

Shiflett, L.A.; Read, G.Sullivan. 2013: MRNA decay during herpes simplex virus (HSV) infections: mutations that affect translation of an mRNA influence the sites at which it is cleaved by the HSV virion host shutoff (Vhs) protein. Journal of Virology 87(1): 94-109

Lin, J.-Y.; Li, M.-L.; Brewer, G. 2014: MRNA decay factor AUF1 binds the internal ribosomal entry site of enterovirus 71 and inhibits virus replication. Plos one 9(7): E103827

López-Rosas, I.; Orozco, E.; Marchat, L.A.; García-Rivera, G.; Guillen, N.; Weber, C.; Carrillo-Tapia, E.; Hernández de la Cruz, O.; Pérez-Plasencia, C.; López-Camarillo, C.és. 2012: MRNA decay proteins are targeted to poly(A)+ RNA and dsRNA-containing cytoplasmic foci that resemble P-bodies in Entamoeba histolytica. Plos one 7(9): E45966

Legendre, M.; Audic, S.ép.; Poirot, O.; Hingamp, P.; Seltzer, V.; Byrne, D.; Lartigue, A.; Lescot, M.; Bernadac, A.; Poulain, J.; Abergel, C.; Claverie, J.-M. 2010: MRNA deep sequencing reveals 75 new genes and a complex transcriptional landscape in Mimivirus. Genome Research 20(5): 664-674

Uehata, T.; Akira, S. 2013: MRNA degradation by the endoribonuclease Regnase-1/ZC3H12a/MCPIP-1. Biochimica et Biophysica Acta 1829(6-7): 708-713

't Hoen, P.A.C.; Hirsch, M.; de Meijer, E.J.; de Menezes, R.ée.X.; van Ommen, G.J.; den Dunnen, J.T. 2011: MRNA degradation controls differentiation state-dependent differences in transcript and splice variant abundance. Nucleic Acids Research 39(2): 556-566

Graham, J.R.; Hendershott, M.C.; Terragni, J.; Cooper, G.M. 2010: MRNA degradation plays a significant role in the program of gene expression regulated by phosphatidylinositol 3-kinase signaling. Molecular and Cellular Biology 30(22): 5295-5305

Bremer, K.; Moyes, C.D. 2014: MRNA degradation: an underestimated factor in steady-state transcript levels of cytochrome c oxidase subunits?. Journal of Experimental Biology 217(Part 12): 2212-2220

Zohra, F.Tuj.; Maitani, Y.; Akaike, T. 2012: MRNA delivery through fibronectin associated liposome-apatite particles: a new approach for enhanced mRNA transfection to mammalian cell. Biological and Pharmaceutical Bulletin 35(1): 111-115

Breinig, F.; Breinig, T.; Schmitt, M.J. 2013: MRNA delivery to human dendritic cells by recombinant yeast and activation of antigen-specific memory T cells. Methods in Molecular Biology 969: 163-184

Eichhorn, S.W.; Guo, H.; McGeary, S.E.; Rodriguez-Mias, R.A.; Shin, C.; Baek, D.; Hsu, S.-H.; Ghoshal, K.; Villén, J.; Bartel, D.P. 2014: MRNA destabilization is the dominant effect of mammalian micro RNAs by the time substantial repression ensues. Molecular Cell 56(1): 104-115

Anne Waller, H.; Kay Savage, A. 2001: MRNA detection by in situ rt-PCR. Methods in Molecular Medicine 39: 417-429

Stahl, Y.; Simon, Rüdiger. 2010: MRNA detection by whole mount in situ hybridization (WISH) or sectioned tissue in situ hybridization (SISH) in Arabidopsis. Methods in Molecular Biology 655: 239-251

Dilão, R.; Muraro, D. 2010: MRNA diffusion explains protein gradients in Drosophila early development. Journal of Theoretical Biology 264(3): 847-853

Liao, H.-I.; Olson, C.A.; Hwang, S.; Deng, H.; Wong, E.; Baric, R.S.; Roberts, R.W.; Sun, R. 2009: MRNA display design of fibronectin-based intrabodies that detect and inhibit severe acute respiratory syndrome coronavirus nucleocapsid protein. Journal of Biological Chemistry 284(26): 17512-17520

Menegatti, S.; Hussain, M.; Naik, A.D.; Carbonell, R.G.; Rao, B.M. 2013: MRNA display selection and solid-phase synthesis of Fc-binding cyclic peptide affinity ligands. Biotechnology and Bioengineering 110(3): 857-870

Matsumura, N.; Tsuji, T.; Sumida, T.; Kokubo, M.; Onimaru, M.; Doi, N.; Takashima, H.; Miyamoto-Sato, E.; Yanagawa, H. 2010: MRNA display selection of a high-affinity, Bcl-X(L)-specific binding peptide. Faseb Journal: Official Publication of the Federation of American Societies for Experimental Biology 24(7): 2201-2210

Olson, C.Anders.; Liao, H-I.; Sun, R.; Roberts, R.W. 2008: MRNA display selection of a high-affinity, modification-specific phospho-IkappaBalpha-binding fibronectin. Acs Chemical Biology 3(8): 480-485

Shiheido, H.; Takashima, H.; Doi, N.; Yanagawa, H. 2011: MRNA display selection of an optimized MDM2-binding peptide that potently inhibits MDM2-p53 interaction. Plos one 6(3): E17898

Wang, R.; Cotten, S.W.; Liu, R. 2012: MRNA display using covalent coupling of mRNA to translated proteins. Methods in Molecular Biology 805: 87-100

Cotten, S.W.; Zou, J.; Wang, R.; Huang, B-Cheng.; Liu, R. 2012: MRNA display-based selections using synthetic peptide and natural protein libraries. Methods in Molecular Biology 805: 287-297

Josephson, K.; Ricardo, A.; Szostak, J.W. 2014: MRNA display: from basic principles to macrocycle drug discovery. Drug Discovery Today 19(4): 388-399

Stark, K.; Wu, Z.-L.; Bartleson, C.J.; Guengerich, F.P. 2008: MRNA distribution and heterologous expression of orphan cytochrome P450 20A1. Drug Metabolism and Disposition: the Biological Fate of Chemicals 36(9): 1930-1937

Bhatt, D.K.; Gupta, S.; Ploug, K.B.; Jansen-Olesen, I.; Olesen, J. 2014: MRNA distribution of CGRP and its receptor components in the trigeminovascular system and other pain related structures in rat brain, and effect of intracerebroventricular administration of CGRP on Fos expression in the TNC. Neuroscience Letters 559: 99-104

Aizawa, M.; Abe, Y.; Ito, T.; Handa, H.; Nawa, H. 2011: MRNA distribution of the thalidomide binding protein cereblon in adult mouse brain. Neuroscience Research 69(4): 343-347

Mountz, J.D. 2011: MRNA editing, FAS, and systemic lupus erythematosus. Human Mutation 32(11): V-Vi

Cools, N.; Van Camp, K.; Van Tendeloo, V.; Berneman, Z. 2013: MRNA electroporation as a tool for immunomonitoring. Methods in Molecular Biology 969: 293-303

Willett, M.; Brocard, M.; Pollard, H.J.; Morley, S.J. 2013: MRNA encoding WAVE-Arp2/3-associated proteins is co-localized with foci of active protein synthesis at the leading edge of MRC5 fibroblasts during cell migration. Biochemical Journal 452(1): 45-55

Unsworth, H.; Raguz, S.; Edwards, H.J.; Higgins, C.F.; Yagüe, E. 2010: MRNA escape from stress granule sequestration is dictated by localization to the endoplasmic reticulum. Faseb Journal: Official Publication of the Federation of American Societies for Experimental Biology 24(9): 3370-3380

Siddiqui, N.; Borden, K.L.B. 2012: MRNA export and cancer. Wiley Interdisciplinary Reviews. Rna 3(1): 13-25

Meier, I. 2012: MRNA export and sumoylation-Lessons from plants. Biochimica et Biophysica Acta 1819(6): 531-537

Wickramasinghe, V.O.; McMurtrie, P.I.A.; Mills, A.D.; Takei, Y.; Penrhyn-Lowe, S.; Amagase, Y.; Main, S.; Marr, J.; Stewart, M.; Laskey, R.A. 2010: MRNA export from mammalian cell nuclei is dependent on GANP. Current Biology: Cb 20(1): 25-31

Linder, P. 2008: MRNA export: RNP remodeling by DEAD-box proteins. Current Biology: Cb 18(7): R297-R299

Gaouar, O.; Germain, H. 2013: MRNA export: threading the needle. Frontiers in Plant Science 4: 59

Galamb, O. 2008: MRNA expression analysis and classification of colonic biopsy samples using oligonucleotide and cDNA microarray techniques. Orvosi Hetilap 149(29): 1373-1377

Schraenen, A.; de Faudeur, G.; Thorrez, L.; Lemaire, K.; Van Wichelen, G.; Granvik, M.; Van Lommel, L.; in't Veld, P.; Schuit, F. 2010: MRNA expression analysis of cell cycle genes in islets of pregnant mice. Diabetologia 53(12): 2579-2588

Struckmann, K.; Mertz, K.; Staller, P.; Krek, W.; Schraml, P.; Moch, H. 2005: MRNA expression analysis of metastatic markers in clear-cell renal cell carcinoma. Verhandlungen der Deutschen Gesellschaft für Pathologie 89: 178-183

Kitago, M.; Koyanagi, K.; Nakamura, T.; Goto, Y.; Faries, M.; O'Day, S.J.; Morton, D.L.; Ferrone, S.; Hoon, D.S.B. 2009: MRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. Clinical Chemistry 55(4): 757-764

Shao, X.-L.; He, S.-Y.; Zhuang, X.-Y.; Fan, Y.; Li, Y.-H.; Yao, Y.-G. 2014: MRNA expression and DNA methylation in three key genes involved in caste differentiation in female honeybees (Apis mellifera). Dong Wu Xue Yan Jiu 35(2): 92-98

Yan, F.-L.; Zhang, J.; Guan, X.-N.; Hong, Z. 2007: MRNA expression and activity of ADAM17 in hippocampus after chronic cerebral hypoperfusion: experiment with aged rats. Zhonghua Yi Xue Za Zhi 87(35): 2515-2517

Han, Y.; Wang, X.-B.; Xiao, N.; Liu, Z.-D. 2013: MRNA expression and clinical significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in postoperative patients with non-small cell lung cancer. Asian Pacific Journal of Cancer Prevention: Apjcp 14(5): 2987-2990

Li, C.; Wang, L.; Su, J.; Zhang, R.; Fu, L.; Zhou, Y. 2013: MRNA expression and hypermethylation of tumor suppressor genes apoptosis protease activating factor-1 and death-associated protein kinase in oral squamous cell carcinoma. Oncology Letters 6(1): 280-286

Shinomiya, T.; Kawaguchi, M.; Okubo, M.; Kosuge, Y.; Yoshikawa, M. 2014: MRNA expression and localization of LPS-induced β-defensin isoforms in rat salivary glands. Bulletin of Tokyo Dental College 55(3): 139-147

Tian, J.-f.; Cao, P.; Yu, X.-y.; Peng, C.-h.; Yang, X.-j.; Yan, H.-t. 2011: MRNA expression and methylation status of p15 promoter in mouse bone marrow cells exposed to 1,4-benzoquinone. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 29(1): 28-32

Soltanpour, M.S.; Amirizadeh, N.; Zaker, F.; Oodi, A.; Nikougoftar, M.; Kazemi, A. 2013: MRNA expression and promoter DNA methylation status of CDKi p21 and p57 genes in ex vivo expanded CD34 (+) cells following co-culture with mesenchymal stromal cells and growth factors. Hematology 18(1): 30-38

Fujiwara, T.; Kubo, T.; Koyama, Y.; Tomita, K.; Yano, K.; Tohyama, M.; Hosokawa, K. 2008: MRNA expression changes of slit proteins following peripheral nerve injury in the rat model. Journal of Chemical Neuroanatomy 36(3-4): 170-176

Janusicova, V.; Mendelova, A.; Zubor, P.; Kapustova, I.; Svecova, I.; Kudela, E.; Burjanivova, T.; Lasabova, Z.; Danko, J. 2014: MRNA expression in cervical specimens for determination of severe dysplasia or worse in HPV-16/18-positive squamous lesions. Journal of Lower Genital Tract Disease 18(3): 273-280

Hébrant, A.; Dom, G.èv.; Dewaele, M.; Andry, G.; Trésallet, C.; Leteurtre, E.; Dumont, J.E.; Maenhaut, C. 2012: MRNA expression in papillary and anaplastic thyroid carcinoma: molecular anatomy of a killing switch. Plos one 7(10): E37807

Llobat, L.; Marco-Jiménez, F.; Peñaranda, D.S.; Thieme, R.; Navarrete, A.; Vicente, J.S. 2012: MRNA expression in rabbit blastocyst and endometrial tissue of candidate gene involved in gestational losses. Reproduction in Domestic Animals 47(2): 281-287

Hogberg, H.T.; Kinsner-Ovaskainen, A.; Coecke, S.; Hartung, T.; Bal-Price, A.K. 2010: MRNA expression is a relevant tool to identify developmental neurotoxicants using an in vitro approach. Toxicological Sciences: An Official Journal of the Society of Toxicology 113(1): 95-115

Zhang, G.-y.; Chen, P.-p.; Li, S.-l.; Yin, L.; Gao, D.-l.; Le, X.-p.; Chen, K.-s.; Zhang, Y.-h.; Zhang, Q.-x. 2008: MRNA expression level of nucleostemin in esophageal squamous cell carcinoma tissue. Zhonghua Yi Xue Za Zhi 88(9): 602-605

Wang, Q.; Ye, R.; Ye, Y.-J.; Wan, J.-X.; Sun, P.; Zhu, Y.; Au, W.; Xia, Z.-L. 2012: MRNA expression levels among cell regulatory and DNA damage genes in benzene-exposed workers in China. Journal of Occupational and Environmental Medicine 54(12): 1467-1470

Santarpia, M.; Magri, I.; Sanchez-Ronco, M.; Costa, C.; Molina-Vila, M.A.; Gimenez-Capitan, A.; Bertran-Alamillo, J.; Mayo, C.; Benlloch, S.; Viteri, S.; Gasco, A.; Mederos, N.; Carcereny, E.; Taron, M.; Rosell, R. 2011: MRNA expression levels and genetic status of genes involved in the EGFR and NF-κB pathways in metastatic non-small-cell lung cancer patients. Journal of Translational Medicine 9: 163

Walmsley, J.; Rodriguez, J.F.; Mirams, G.R.; Burrage, K.; Efimov, I.R.; Rodriguez, B. 2013: MRNA expression levels in failing human hearts predict cellular electrophysiological remodeling: a population-based simulation study. Plos one 8(2): E56359

Török, R.; Kónya, J.úl.A.; Zádori, D.én.; Veres, G.áb.; Szalárdy, L.; Vécsei, L.ás.ó; Klivényi, P.ét. 2015: MRNA expression levels of PGC-1α in a transgenic and a toxin model of Huntington's disease. Cellular and Molecular Neurobiology 35(2): 293-301

Ye, R.; Pan, J.-c.; Cao, J.-z.; Guan, J.-r.; Xie, X.-m.; Yu, A.-x.; Wu, L.; He, Y.-l.; Xia, Z.-l. 2008: MRNA expression levels of p53 and DNA damage and repair genes in peripheral blood lymphocytes of benzene-exposed workers. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 26(4): 219-222

Kotzsch, M.; Dorn, J.; Doetzer, K.; Schmalfeldt, B.; Krol, J.; Baretton, G.; Kiechle, M.; Schmitt, M.; Magdolen, V. 2011: MRNA expression levels of the biological factors uPAR, uPAR-del4/5, and rab31, displaying prognostic value in breast cancer, are not clinically relevant in advanced ovarian cancer. Biological Chemistry 392(11): 1047-1051

Amrutkar, D.V.; Ploug, K.B.; Hay-Schmidt, A.; Porreca, F.; Olesen, J.; Jansen-Olesen, I. 2012: MRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system. Pain 153(4): 830-838

Zheng, H.-y.; Chen, Q.; Ye, Y.-b.; Huang, W.-w. 2008: MRNA expression of CK19 and CEA in peripheral blood of patients with breast cancer detected by real-time quantitative PCR. Zhonghua Yi Xue Za Zhi 88(32): 2267-2270

Zhang, X.; Xie, J.; Yu, C.; Yan, L.; Yang, Z. 2014: MRNA expression of CK19, EGFR and LUNX in patients with lung cancer micrometastasis. Experimental and Therapeutic Medicine 7(2): 360-364

Ghanem, T.; Bracken, J.; Kasem, A.; Jiang, W.G.; Mokbel, K. 2014: MRNA expression of DOK1-6 in human breast cancer. World Journal of Clinical Oncology 5(2): 156-163

Naher, L.; Tan, S.G.; Ho, C.L.; Yusuf, U.K.; Ahmad, S.H.; Abdullah, F. 2012: MRNA expression of EgCHI1, EgCHI2, and EgCHI3 in oil palm leaves (Elaeis guineesis Jacq.) after treatment with Ganoderma boninense pat. and Trichoderma harzianum Rifai. Thescientificworldjournal 2012: 647504

Pantazis, E.; Soulitzis, N.; Soufla, G.; Karyotis, I.; Delakas, D.; Spandidos, D.A. 2011: MRNA expression of G(1)-phase cell cycle regulatory molecules in bladder cancer. Journal of BUON: Official Journal of the Balkan Union of Oncology 16(2): 323-330

Guo, J.-f.; Li, Z.-s.; Jin, Z.-d.; Gao, J.; Gong, Y.-f.; Jin, J.; Man, X.-h. 2007: MRNA expression of GLI1 in pancreatic carcinoma and clinical significance thereof. Zhonghua Yi Xue Za Zhi 87(12): 826-828

Guilgur, L.G.; Strüssmann, C.A.; Somoza, G.M. 2009: MRNA expression of GnRH variants and receptors in the brain, pituitary and ovaries of pejerrey (Odontesthes bonariensis) in relation to the reproductive status. Fish Physiology and Biochemistry 35(1): 157-166

Liu, R.; Hu, L.-L.; Sun, A.; Cao, Y.-J.; Tang, T.; Zhang, X.-P.; Zhang, Q.-H. 2014: MRNA expression of IGF-1 and IGF-1R in patients with colorectal adenocarcinoma and type 2 diabetes. Archives of Medical Research 45(4): 318-324

Wang, H.; Jiang, G.; Wang, D.; Liu, J.; Wang, J. 2006: MRNA expression of MAGE genes in benign and malignant pleural effusion. Zhongguo Fei Ai Za Zhi 9(4): 329-332

Fakhoury, M.; de Beaumais, T.; Guimiot, F.; Azougagh, S.; Elie, V.; Medard, Y.; Delezoide, A.-L.; Jacqz-Aigrain, E. 2009: MRNA expression of MDR1 and major metabolising enzymes in human fetal tissues. Drug Metabolism and Pharmacokinetics 24(6): 529-536

Padmavati, P.; Savita, S.; Shivaprasad, B.M.; Kripal, K.; Rithesh, K. 2013: MRNA expression of MMP-28 (Epilysin) in gingival tissues of chronic and aggressive periodontitis patients: a reverse transcriptase PCR study. Disease Markers 35(2): 113-118

Shimizu, J.; Horio, Y.; Osada, H.; Hida, T.; Hasegawa, Y.; Shimokata, K.; Takahashi, T.; Sekido, Y.; Yatabe, Y. 2008: MRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines. Respirology 13(4): 510-517

Nakamori, T.; Fujimori, A.; Kinoshita, K.; Ban-nai, T.; Kubota, Y.; Yoshida, S. 2010: MRNA expression of a cadmium-responsive gene is a sensitive biomarker of cadmium exposure in the soil collembolan Folsomia candida. Environmental Pollution 158(5): 1689-1695

Zhang, P.-s.; Wang, F.; Liu, Q.-z.; Xu, W.-z.; Qi, J.-h.; Liu, Z.; Sun, T. 2010: MRNA expression of activity-regulated cytoskeletal-associated protein in hippocampus induced by insular-kindled rats. Zhonghua Yi Xue Za Zhi 90(39): 2782-2786

D'Attilio, L.; D'Attlio, L.; Trini, E.; Bongiovanni, B.; Dídoli, G.; Gardeñez, W.; Nannini, L.J.; Giri, A.; Bottasso, O.A.; Bay, Mía.Luisa. 2011: MRNA expression of alpha and beta isoforms of glucocorticoid receptor in peripheral blood mononuclear cells of patients with tuberculosis and its relation with components of the immunoendocrine response. Brain Behavior and Immunity 25(3): 461-467

Ru, G.-q.; Zhao, Z.-s.; Tang, Q.-l.; Xu, W.-j. 2008: MRNA expression of basic fibroblast growth factor and hepatocyte growth factor in gastric carcinoma and significance thereof. Zhonghua Yi Xue Za Zhi 88(29): 2030-2035

Markić, D.; Ćelić, T.; Gršković, A.; Španjol, J.; Fučkar, Že.; Grahovac, B.že.; Dorđević, G.; Bobinac, D. 2011: MRNA expression of bone morphogenetic proteins and their receptors in human renal cell carcinoma. Urologia Internationalis 87(3): 353-358

Roshwalb, S.; Gorman, S.; Hurst, S.; Bartges, J.; Agarwal, S.; Sommardahl, C.; Odoi, A.; Dhar, M.S. 2011: MRNA expression of canine ATP10C, a P4-type ATPase, is positively associated with body condition score. Veterinary Journal 190(1): 173-175

Li, Y.-M.; Chen, Z.-Q.; Yao, X.; Yang, A.-Z.; Li, A.-S.; Liu, D.-M.; Gong, J.-Q. 2010: MRNA expression of chemokine receptors on peripheral blood mononuclear cells and correlation with clinical features in systemic lupus erythematosus patients. Chinese Medical Sciences Journal 25(3): 162-168

Cespedes, I.C.; de Oliveira, A.R.; da Silva, J.M.; da Silva, A.é V.; Sita, L.V.; Bittencourt, J.C. 2010: MRNA expression of corticotropin-releasing factor and urocortin 1 after restraint and foot shock together with alprazolam administration. Peptides 31(12): 2200-2208

Huang, D.-Y.; Yang, W.-Y.; Guo, W.-W.; Han, D.-Y. 2007: MRNA expression of extracellular matrix proteins of vocal fold polyps and Reinke edema. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 42(11): 843-848

Ringseis, R.; Heller, K.; Kluge, H.; Eder, K. 2011: MRNA expression of genes involved in fatty acid utilization in skeletal muscle and white adipose tissues of sows during lactation. Comparative Biochemistry and Physiology. Part a Molecular and Integrative Physiology 158(4): 450-454

Kelly, A.K.; Waters, S.M.; McGee, M.; Fonseca, R.G.; Carberry, C.; Kenny, D.A. 2011: MRNA expression of genes regulating oxidative phosphorylation in the muscle of beef cattle divergently ranked on residual feed intake. Physiological Genomics 43(1): 12-23

Mei, B.; Chen, Y.; Liu, W.; Li, L.; Wang, C. 2015: MRNA expression of glucocorticoid receptor and serological and virological markers of chronic hepatitis B. Molecular Medicine Reports 11(3): 2215-2220

Duan, Q.; Lv, W.; Wang, L.; Gong, Z.; Wang, Q.; Song, H.; Wang, H. 2013: MRNA expression of interleukins and Th1/Th2 imbalance in patients with pulmonary embolism. Molecular Medicine Reports 7(1): 332-336

Han, L.-Q.; Li, H.-J.; Wang, Y.-Y.; Wang, L.-F.; Yang, G.-Q.; Wang, Y.-L.; Yang, G.-Y. 2012: MRNA expression of lipogenic genes in mouse mammary gland in different lactation stages. Yi Chuan 34(3): 335-341

Mizobe, Y.; Oikawa, D.; Tsuyama, S.; Akimoto, Y.; Hamasu, K.; Onitsuka, E.; Sato, M.; Takahata, Y.; Morimatsu, F.; Furuse, M. 2008: MRNA expression of lysyl oxidase and matrix metalloproteinase-12 in mouse skin. Bioscience Biotechnology and Biochemistry 72(11): 3067-3070

Scrideli, C.A.; Cortez, M.A.él.A.; Yunes, J.é A.; Queiróz, R.G.d.P.; Valera, E.T.; da Mata, J.F.ça.; Toledo, S.R.C.; Pavoni-Ferreira, P.; Lee, M.L.úc.d.M.; Petrilli, A.S.ér.; Brandalise, S.R.; Tone, L.G. 2010: MRNA expression of matrix metalloproteinases (MMPs) 2 and 9 and tissue inhibitor of matrix metalloproteinases (TIMPs) 1 and 2 in childhood acute lymphoblastic leukemia: potential role of TIMP1 as an adverse prognostic factor. Leukemia Research 34(1): 32-37

Kölln, C.; Reichl, S. 2012: MRNA expression of metabolic enzymes in human cornea, corneal cell lines, and hemicornea constructs. Journal of Ocular Pharmacology and Therapeutics: the Official Journal of the Association for Ocular Pharmacology and Therapeutics 28(3): 271-277

Wang, Y.; Li, Y.; Zhang, W.-Y.; Xia, Q.-J.; Li, H.-G.; Wang, R.; Yang, L.; Sun, X.-F.; Zhou, Z.-G. 2009: MRNA expression of minichromosome maintenance 2 in colonic adenoma and adenocarcinoma. European Journal of Cancer Prevention: the Official Journal of the European Cancer Prevention Organisation 18(1): 40-45

Ghaderi, H.; Kiany, F.; Razmkhah, M.; Dadras, S.; Chenari, N.; Hosseini, A.; Younesi, V.; Ghaderi, A. 2014: MRNA expression of pattern recognition receptors and their signaling mediators in healthy and diseased gingival tissues. Journal of Indian Society of Periodontology 18(2): 150-154

Erben, P.; Horisberger, K.; Muessle, B.; Müller, M.C.; Treschl, A.; Ernst, T.; Kähler, G.; Ströbel, P.; Wenz, F.; Kienle, P.; Post, S.; Hochhaus, A.; Willeke, F.; Hofheinz, R.-D. 2008: MRNA expression of platelet-derived growth factor receptor-beta and C-KIT: correlation with pathologic response to cetuximab-based chemoradiotherapy in patients with rectal cancer. International Journal of Radiation Oncology Biology Physics 72(5): 1544-1550

Yu, H.-Y.; Li, H.; Chen, D.-f.; Cheng, H. 2007: MRNA expression of procollagen and SMADs in lesional skin of progressive systemic sclerosis. Zhonghua Yi Xue Za Zhi 87(8): 546-549

Dornelles, A.S.; Garcia, V.A.; de Lima, M.N.M.; Vedana, G.; Alcalde, L.A.; Bogo, M.íc.R.; Schröder, N. 2010: MRNA expression of proteins involved in iron homeostasis in brain regions is altered by age and by iron overloading in the neonatal period. Neurochemical Research 35(4): 564-571

Ye, F.; He, Y.-M.; Li, G.-X.; Wang, L.-N.; Jia, N.; Ma, R.-X.; Ma, Y.-P. 2013: MRNA expression of telomere protection protein TIN2 and POT1 in bone marrow of patients with myelodysplastic syndrome. Zhongguo Shi Yan Xue Ye Xue Za Zhi 21(1): 110-115

Li, J.-n.; Feng, C.-j.; Lu, Y.-j.; Li, H.-j.; Tu, Z.; Liao, G.-q.; Liang, C. 2008: MRNA expression of the DNA replication-initiation proteins in epithelial dysplasia and squamous cell carcinoma of the tongue. Bmc Cancer 8: 395

Akiyama, K.; Isao, T.; Ide, S.; Ishikawa, M.; Saito, A. 2008: MRNA expression of the Nurr1 and NGFI-B nuclear receptor families following acute and chronic administration of methamphetamine. Progress in Neuro-Psychopharmacology and Biological Psychiatry 32(8): 1957-1966

Ji, Y.; Zhang, W.; Wang, J.; Gu, L. 2010: MRNA expression of the XAGE-1 gene in human acute leukemia. International Journal of Hematology 91(2): 209-212

Schneider, J.; Gómez-Esquer, F.; Díaz-Gil, G.; Torrejón, R.; Pollán, M. 2011: MRNA expression of the putative antimetastatic gene BRMS1 and of apoptosis-related genes in breast cancer. Cancer Genomics and Proteomics 8(4): 195-197

Lai, X.; Zhang, C.; Wang, J.; Wang, C.; Lan, X.; Zhang, C.; Lei, C.; Chen, H. 2013: MRNA expression pattern and association study with growth traits of bovine vaspin gene. Molecular Biology Reports 40(7): 4499-4505

Kwon, H.; Choi, D.-H.; Bae, J.-H.; Kim, J.-H.; Kim, Y.-S. 2010: MRNA expression pattern of insulin-like growth factor components of granulosa cells and cumulus cells in women with and without polycystic ovary syndrome according to oocyte maturity. Fertility and Sterility 94(6): 2417-2420

Macejová, D.; Galbavý, S.; Podoba, J.án.; Bialešová, L.; Brtko, J.úl. 2013: MRNA expression pattern of retinoic acid and retinoid X nuclear receptor subtypes in human thyroid papillary carcinoma. Oncology Reports 30(5): 2371-2378

Cortez, M.A.A.; Scrideli, C.A.; Yunes, J.é A.; Valera, E.T.; Toledo, S.íl.R.C.; Pavoni-Ferreira, P.íc.C.B.; Lee, M.L.M.; Petrilli, A.ôn.S.; Brandalise, S.R.; Tone, L.G. 2009: MRNA expression profile of multidrug resistance genes in childhood acute lymphoblastic leukemia. Low expression levels associated with a higher risk of toxic death. Pediatric Blood and Cancer 53(6): 996-1004

Rahgozar, S.; Moafi, A.; Abedi, M.; Entezar-E-Ghaem, M.; Moshtaghian, J.; Ghaedi, K.; Esmaeili, A.; Montazeri, F. 2014: MRNA expression profile of multidrug-resistant genes in acute lymphoblastic leukemia of children, a prognostic value for ABCA3 and ABCA2. Cancer Biology and Therapy 15(1): 35-41

Panariti, A.; Miserocchi, G.; Rivolta, I. 2013: MRNA expression profile of selected oxygen sensing genes in the lung during recovery from chronic hypoxia. Biological Research 46(2): 169-176

Shukla, R.; Watakabe, A.; Yamamori, T. 2014: MRNA expression profile of serotonin receptor subtypes and distribution of serotonergic terminations in marmoset brain. Frontiers in Neural Circuits 8: 52

Yao, M.; Dai, M.; Liu, Z.; Cui, W.; Li, D.; Zhang, H.; Li, J.; Liu, Y.; Yuan, Z. 2012: MRNA expression profiles of P450 3A enzymes in the liver and small intestine of the domestic pig. Research in Veterinary Science 93(1): 360-365

Zhang, Z.-C.; Xiao, L.-H.; Wang, Y.; Chen, S.-Y.; Yang, Z.-Q.; Zhao, X.-L.; Zhu, Q.; Liu, Y.-P. 2012: MRNA expression profiles of calmodulin and liver receptor homolog-1 genes in chickens. Genetics and Molecular Research: Gmr 11(3): 3482-3489

Bao, X.N.; Mu, C.K.; Zhang, C.; Wang, Y.F.; Song, W.W.; Li, R.H.; Wang, C.L. 2014: MRNA expression profiles of heat shock proteins of wild and salinity-tolerant swimming crabs, Portunus trituberculatus, subjected to low salinity stress. Genetics and Molecular Research: Gmr 13(3): 6837-6847

Cheng, C.; Fu, X.; Alves, P.; Gerstein, M. 2009: MRNA expression profiles show differential regulatory effects of micro RNAs between estrogen receptor-positive and estrogen receptor-negative breast cancer. Genome Biology 10(9): R90

Jones, A.M.; Mitter, R.; Poulsom, R.; Gillett, C.; Hanby, A.M.; Tomlinson, I.P.M.; Sawyer, E.J.; Walker, R.; Pinder, S.; Jones, L.; Ellis, I.; Tan, P.H.; Macartney, J.; Green, D.; Hales, S.; Harding-Mackean, C.; Colclough, A.; MacNeill, F.; Rowlands, D.; Smith, C.; Fentiman, I.; Cane, P.; Desai, A.; Goderya, R.; Nerurkar, A.; Kissin, M.; Jackson, P. 2008: MRNA expression profiling of phyllodes tumours of the breast: identification of genes important in the development of borderline and malignant phyllodes tumours. Journal of Pathology 216(4): 408-417

Nicolas, F.E.; Pais, H.; Schwach, F.; Lindow, M.; Kauppinen, S.; Moulton, V.; Dalmay, T. 2011: MRNA expression profiling reveals conserved and non-conserved miR-140 targets. Rna Biology 8(4): 607-615

Kunkel, S.D.; Suneja, M.; Ebert, S.M.; Bongers, K.S.; Fox, D.K.; Malmberg, S.E.; Alipour, F.; Shields, R.K.; Adams, C.M. 2011: MRNA expression signatures of human skeletal muscle atrophy identify a natural compound that increases muscle mass. Cell Metabolism 13(6): 627-638

Shen, C.; Wang, D.; Jiang, G.; Liu, J.; Zhang, G. 2003: MRNA expressions of MAGE genes in human lung cancer. Zhongguo Fei Ai Za Zhi 6(4): 268-271

Oztuzcu, S.; Igci, Y.Z.; Arslan, A.; Sivasli, E.; Ozkara, E.; Igci, M.; Demiryürek, S.; Cengiz, B.; Gogebakan, B.; Namiduru, M.; Coskun, M.Y.; Cakmak, E.A. 2011: MRNA expressions of inducible nitric oxide synthase, endothelial nitric oxide synthase, and neuronal nitric oxide synthase genes in meningitis patients. Genetic Testing and Molecular Biomarkers 15(3): 147-152

Denti, M.A.; Viero, G.; Provenzani, A.; Quattrone, A.; Macchi, P. 2013: MRNA fate: Life and death of the mRNA in the cytoplasm. Rna Biology 10(3): 360-366

Ross, J.R.; Porter, B.E.; Buckley, P.T.; Eberwine, J.H.; Robinson, M.B. 2011: MRNA for the EAAC1 subtype of glutamate transporter is present in neuronal dendrites in vitro and dramatically increases in vivo after a seizure. Neurochemistry International 58(3): 366-375

Jakubowska, J.; Maciejewska, A.; Bielawski, K.P.; Pawłowski, R. 2014: MRNA heptaplex protocol for distinguishing between menstrual and peripheral blood. Forensic Science International. Genetics 13: 53-60

Choder, M. 2011: MRNA imprinting: Additional level in the regulation of gene expression. Cellular Logistics 1(1): 37-40

Bernet, L.; Martinez Benaclocha, M.; Castera, C.; Cano Muñoz, R.; Sevilla, F.; Alba, J.; de Dios Barranco, J.; Cordoba, A.; Garcia-Caballero, T.; Hardisson, D.; de Francisco Hernandez, J.M.; Lazaro, J.M.; Polo, L.; Riu, F.; Rezola, R.; Rojo, F.; Ruiz, I.; Hernándiz, A.; de la Cámara de Las Heras, J.M.; Coupe, V.M. 2012: MRNA in situ hybridization (HistoSonda): a new diagnostic tool for HER2-status in breast cancer-a multicentric Spanish study. Diagnostic Molecular Pathology: the American Journal of Surgical Pathology Part B 21(2): 84-92

Yamaguchi, Y.; Inouye, M. 2009: MRNA interferases, sequence-specific endoribonucleases from the toxin-antitoxin systems. Progress in Molecular Biology and Translational Science 85: 467-500

Liu, L.; Fang, C.; Dong, H.-J.; Wang, D.-M.; Zhu, D.-X.; Qiao, C.; Fan, L.; Miao, K.-R.; Liu, P.; Xu, W.; Li, J.-Y. 2011: MRNA levels detected by real-time quantitative RT-PCR in chronic lymphocytic leukemia and their clinical significance. Zhongguo Shi Yan Xue Ye Xue Za Zhi 19(5): 1145-1149

Boutros, P.C.; Moffat, I.D.; Okey, A.B.; Pohjanvirta, R. 2011: MRNA levels in control rat liver display strain-specific, hereditary, and AHR-dependent components. Plos one 6(7): E18337

Beyer, N.; Coulson, D.T.R.; Quinn, J.G.; Brockbank, S.; Hellemans, J.; Irvine, G.B.; Ravid, R.; Johnston, J.A. 2014: MRNA levels of BACE1 and its interacting proteins, RTN3 and PPIL2, correlate in human post mortem brain tissue. Neuroscience 274: 44-52

Strijbos, M.H.; van Krimpen, B.A.; Debets, R.; Kraan, J.; Sleijfer, S.; Gratama, J.W.; Lamers, C.H.J. 2010: MRNA levels of CD31, CD144, CD146 and von Willebrand factor do not serve as surrogate markers for circulating endothelial cells. Thrombosis and Haemostasis 104(2): 318-326

Garza-González, E.; Bocanegra-García, V.; Bosques-Padilla, F.-J.; Flores-Gutiérrez, J.-P.; Moreno, F.; Perez-Perez, G.-I. 2008: MRNA levels of TLR4 and TLR5 are independent of H pylori. World Journal of Gastroenterology 14(34): 5306-5310

De Armas, R.; Durand, K.; Guillaudeau, A.él.; Weinbreck, N.; Robert, S.; Moreau, J.-J.; Caire, F.ço.; Acosta, G.; Pebet, M.; Chaunavel, A.; Marin, B.ît.; Labrousse, F.ço.; Denizot, Y. 2010: MRNA levels of enzymes and receptors implicated in arachidonic acid metabolism in gliomas. Clinical Biochemistry 43(10-11): 827-835

Ohga, H.; Adachi, H.; Matsumori, K.; Kodama, R.; Nyuji, M.; Selvaraj, S.; Kato, K.; Yamamoto, S.; Yamaguchi, A.; Matsuyama, M. 2015: MRNA levels of kisspeptins, kisspeptin receptors, and GnRH1 in the brain of chub mackerel during puberty. Comparative Biochemistry and Physiology. Part a Molecular and Integrative Physiology 179: 104-112

Bogdanova, K.; Uherkova, L.; Poczatkova, H.; Rypka, M.; Vesely, J. 2007: MRNA levels of peroxisome proliferator-activated receptors and their coactivators are affected by glucose deprivation and oleate in human hepatoma hepG2 cells. Biomedical Papers of the Medical Faculty of the University Palacky Olomouc Czechoslovakia 151(2): 237-245

Sike, A.ám.; Nagy, E.ő; Vedelek, B.áz.; Pusztai, D.áv.; Szerémy, P.ét.; Venetianer, A.ó; Boros, I.M. 2014: MRNA levels of related Abcb genes change opposite to each other upon histone deacetylase inhibition in drug-resistant rat hepatoma cells. Plos one 9(1): E84915

Alves, L.R.; Guerra-Slompo, E.P.; de Oliveira, A.V.; Malgarin, J.S.; Goldenberg, S.; Dallagiovanna, B. 2013: MRNA localization mechanisms in Trypanosoma cruzi. Plos one 8(12): E81375

Simpson, C.E.; Lui, J.; Kershaw, C.J.; Sims, P.F.G.; Ashe, M.P. 2014: MRNA localization to P-bodies in yeast is bi-phasic with many mRNAs captured in a late Bfr1p-dependent wave. Journal of Cell Science 127(Part 6): 1254-1262

Bonnet, C.; Kaltimbacher, V.ér.; Ellouze, S.; Forster, V.ér.; Sahel, J.é-A.; Corral-Debrinski, M. 2007: MRNA localization to the mitochondrial surface: a tool to treat retinal pathologies due to mitochondrial DNA mutations. Journal de la Societe de Biologie 201(1): 69-74

Xing, L.; Bassell, G.J. 2013: MRNA localization: an orchestration of assembly, traffic and synthesis. Traffic 14(1): 2-14

Hurt, J.A.; Silver, P.A. 2008: MRNA nuclear export and human disease. Disease Models and Mechanisms 1(2-3): 103-108

Carmody, S.R.; Wente, S.R. 2009: MRNA nuclear export at a glance. Journal of Cell Science 122(Part 12): 1933-1937

Niño, C.A.; Hérissant, L.; Babour, A.; Dargemont, C. 2013: MRNA nuclear export in yeast. Chemical Reviews 113(11): 8523-8545

Tasat, D.R.; Lezón, C.E.; Astort, F.; Pintos, P.M.; Macri, E.V.; Friedman, S.M.; Boyer, P.M. 2014: MRNA of cytokines in bone marrow and bone biomarkers in response to propranolol in a nutritional growth retardation model. Pharmacological Reports: Pr 66(5): 867-873

Pretheeban, T.; Balendran, A.; Gordon, M.B.; Rajamahendran, R. 2010: MRNA of luteal genes associated with progesterone synthesis, maintenance, and apoptosis in dairy heifers and lactating dairy cows. Animal Reproduction Science 121(3-4): 218-224

Schmidt, M.; Hoffmann, B.; Kimmig, R.; Kasimir-Bauer, S. 2009: MRNA of placental origin in maternal serum of women with normal and preeclamptic pregnancies. Fetal Diagnosis and Therapy 25(2): 269-276

Eliscovich, C.; Buxbaum, A.R.; Katz, Z.B.; Singer, R.H. 2013: MRNA on the move: the road to its biological destiny. Journal of Biological Chemistry 288(28): 20361-20368

Corradi, N.; Burri, L.; Keeling, P.J. 2008: MRNA processing in Antonospora locustae spores. Molecular Genetics and Genomics: Mgg 280(6): 565-574

Ibelli, A.M.G.; Nakata, L.C.; Andréo, R.; Coutinho, L.L.; Oliveira, M.C.S.; Amarante, A.F.T.; Furlong, J.; Zaros, L.G.; Regitano, L.C.A. 2011: MRNA profile of Nellore calves after primary infection with Haemonchus placei. Veterinary Parasitology 176(2-3): 195-200

Gao, J.; Yang, A.; Chen, M.; Li, A.; Yao, X.; Li, Y.; Xie, S.; Yang, X.; Zhong, L.; Chen, Z. 2011: MRNA profiles of cytokine receptors in unstimulated peripheral blood mononuclear cells from patients with chronic idiopathic urticaria. Journal of Biomedical Research 25(2): 141-147

Haas, C.; Klesser, B.; Maake, C.; Bär, W.; Kratzer, A. 2009: MRNA profiling for body fluid identification by reverse transcription endpoint PCR and realtime PCR. Forensic Science International. Genetics 3(2): 80-88

Haas, C.; Hanson, E.; Bär, W.; Banemann, R.; Bento, A.M.; Berti, A.; Borges, E.; Bouakaze, C.; Carracedo, A.; Carvalho, M.; Choma, A.; Dötsch, M.; Durianciková, M.; Hoff-Olsen, P.; Hohoff, C.; Johansen, P.; Lindenbergh, P.A.; Loddenkötter, B.; Ludes, B.; Maroñas, O.; Morling, N.; Niederstätter, H.; Parson, W.; Patel, G.; Popielarz, C.; Salata, E.; Schneider, P.M.; Sijen, T.; Sviezená, B.; Zatkalíková, L.; Ballantyne, J. 2011: MRNA profiling for the identification of blood--results of a collaborative EDNAP exercise. Forensic Science International. Genetics 5(1): 21-26

Vennemann, M.; Koppelkamm, A. 2010: MRNA profiling in forensic genetics I: Possibilities and limitations. Forensic Science International 203(1-3): 71-75

Roeder, A.D.; Haas, C. 2013: MRNA profiling using a minimum of five mRNA markers per body fluid and a novel scoring method for body fluid identification. International Journal of Legal Medicine 127(4): 707-721

Zhai, L.-t.; Xiang, S. 2014: MRNA quality control at the 5' end. Journal of Zhejiang University. Science. B 15(5): 438-443

Kilchert, C.; Vasiljeva, L. 2013: MRNA quality control goes transcriptional. Biochemical Society Transactions 41(6): 1666-1672

Maruo, R.; Yamada, H.; Watanabe, M.; Hidaka, Y.; Iwatani, Y.; Takano, T. 2011: MRNA quantification after fluorescence activated cell sorting using locked nucleic acid probes. Molecular Biotechnology 49(1): 42-47

Jung, A.; Jaitner, S.; Schäffauer, A.J.; Kirchner, T. 2010: MRNA quantification. the next challenge in routine diagnostics. Der Pathologe 31(Suppl 2): 280-284

Brewer, C.J.; Wood, R.I.; Wood, J.C. 2014: MRNA regulation of cardiac iron transporters and ferritin subunits in a mouse model of iron overload. Experimental Hematology 42(12): 1059-1067

Kojima, K.K.; Okada, N. 2009: MRNA retrotransposition coupled with 5' inversion as a possible source of new genes. Molecular Biology and Evolution 26(6): 1405-1420

Pandey, J.Prakash.; Gorla, P.; Manavathi, B.; Siddavattam, D. 2009: MRNA secondary structure modulates the translation of organophosphate hydrolase (OPH) in E. coli. Molecular Biology Reports 36(3): 449-454

Mahen, E.M.; Watson, P.Y.; Cottrell, J.W.; Fedor, M.J. 2010: MRNA secondary structures fold sequentially but exchange rapidly in vivo. Plos Biology 8(2): E1000307

Benetti, E.; Caridi, G.; Centi, S.; Vella, M.D.; Ghiggeri, G.M.; Artifoni, L.; Murer, L. 2014: MRNA sequencing of a novel NPHS2 intronic mutation in a child with focal and segmental glomerulosclerosis. Saudi Journal of Kidney Diseases and Transplantation: An Official Publication of the Saudi Center for Organ Transplantation Saudi Arabia 25(4): 854-857

Bryant, D.; Onions, T.; Raybould, R.; Flynn, Ái.; Tristram, A.; Meyrick, S.; Giles, P.; Ashelford, K.; Hibbitts, S.; Fiander, A.; Powell, N. 2014: MRNA sequencing of novel cell lines from human papillomavirus type-16 related vulval intraepithelial neoplasia: consequences of expression of HPV16 E4 and E5. Journal of Medical Virology 86(9): 1534-1541

Dehm, S.M. 2013: MRNA splicing variants: exploiting modularity to outwit cancer therapy. Cancer Research 73(17): 5309-5314

Hung, F.; Deng, L.; Ravnikar, P.; Condon, R.; Li, B.; Do, L.; Saha, D.; Tsao, Y.-S.; Merchant, A.; Liu, Z.; Shi, S. 2010: MRNA stability and antibody production in CHO cells: improvement through gene optimization. Biotechnology Journal 5(4): 393-401

Benjamin, D.; Moroni, C. 2007: MRNA stability and cancer: an emerging link?. Expert Opinion on Biological Therapy 7(10): 1515-1529

Mazzoni, C.; Falcone, C. 2011: MRNA stability and control of cell proliferation. Biochemical Society Transactions 39(5): 1461-1465

Soranzo, N.; Zampieri, M.; Farina, L.; Altafini, C. 2009: MRNA stability and the unfolding of gene expression in the long-period yeast metabolic cycle. Bmc Systems Biology 3: 18

Molin, C.; Jauhiainen, A.; Warringer, J.; Nerman, O.; Sunnerhagen, P. 2009: MRNA stability changes precede changes in steady-state mRNA amounts during hyperosmotic stress. Rna 15(4): 600-614

Liu, H.; Luo, M.; Wen, J.-k. 2014: MRNA stability in the nucleus. Journal of Zhejiang University. Science. B 15(5): 444-454

Macdonald, R.L.; Kang, J.-Q. 2012: MRNA surveillance and endoplasmic reticulum quality control processes alter biogenesis of mutant GABAA receptor subunits associated with genetic epilepsies. Epilepsia 53(Suppl 9): 59-70

Weissman, D. 2015: MRNA transcript therapy. Expert Review of Vaccines 14(2): 265-281

Szóstek, A.Z.; Siemieniuch, M.J.; Lukasik, K.; Galvão, A.M.; Ferreira-Dias, G.M.; Skarzynski, D.J. 2012: MRNA transcription of prostaglandin synthases and their products in the equine endometrium in the course of fibrosis. Theriogenology 78(4): 768-776

Wang, Z-Rong.; Bo, X-Wen.; Zhao, W-Juan.; Kang, L-Chao. 2012: MRNA transcription of translation elongation factor and primase in different segments of Moniezia expansa. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 30(3): 250-252

Sunde, R.A. 2010: MRNA transcripts as molecular biomarkers in medicine and nutrition. Journal of Nutritional Biochemistry 21(8): 665-670

Ryser, M.F.; Ugarte, F.; Thieme, S.; Bornhäuser, M.; Roesen-Wolff, A.; Brenner, S. 2008: MRNA transfection of CXCR4-GFP fusion--simply generated by PCR-results in efficient migration of primary human mesenchymal stem cells. Tissue Engineering. Part C Methods 14(3): 179-184

Rejman, J.; Tavernier, G.; Bavarsad, N.; Demeester, J.; De Smedt, S.C. 2010: MRNA transfection of cervical carcinoma and mesenchymal stem cells mediated by cationic carriers. Journal of Controlled Release: Official Journal of the Controlled Release Society 147(3): 385-391

McLenachan, S.; Zhang, D.; Palomo, A.B.én.A.; Edel, M.J.; Chen, F.K. 2013: MRNA transfection of mouse and human neural stem cell cultures. Plos one 8(12): E83596

Heng, B.C.; Heinimann, K.; Miny, P.; Iezzi, G.; Glatz, K.; Scherberich, A.; Zulewski, H.; Fussenegger, M. 2013: MRNA transfection-based, feeder-free, induced pluripotent stem cells derived from adipose tissue of a 50-year-old patient. Metabolic Engineering 18: 9-24

Topisirovic, I.; Sonenberg, N. 2011: MRNA translation and energy metabolism in cancer: the role of the MAPK and mTORC1 pathways. Cold Spring Harbor Symposia on Quantitative Biology 76: 355-367

Zhao, Y-Bo.; Krishnan, J. 2014: MRNA translation and protein synthesis: an analysis of different modelling methodologies and a new PBN based approach. Bmc Systems Biology 8: 25

Apcher, S.; Komarova, A.; Daskalogianni, C.; Yin, Y.; Malbert-Colas, L.; Fåhraeus, R. 2009: MRNA translation regulation by the Gly-Ala repeat of Epstein-Barr virus nuclear antigen 1. Journal of Virology 83(3): 1289-1298

Jansen, R.-P.; Niessing, D.; Baumann, S.; Feldbrügge, M. 2014: MRNA transport meets membrane traffic. Trends in Genetics: Tig 30(9): 408-417

Weiss, R.; Scheiblhofer, S.; Roesler, E.; Weinberger, E.; Thalhamer, J. 2012: MRNA vaccination as a safe approach for specific protection from type i allergy. Expert Review of Vaccines 11(1): 55-67

De Temmerman, M.-L.; Dewitte, H.; Vandenbroucke, R.E.; Lucas, B.; Libert, C.; Demeester, J.; De Smedt, S.C.; Lentacker, I.; Rejman, J. 2011: MRNA-Lipoplex loaded microbubble contrast agents for ultrasound-assisted transfection of dendritic cells. Biomaterials 32(34): 9128-9135

Savory, E.A.; Adhikari, B.N.; Hamilton, J.P.; Vaillancourt, B.; Buell, C.R.; Day, B. 2012: MRNA-Seq analysis of the Pseudoperonospora cubensis transcriptome during cucumber (Cucumis sativus L.) infection. Plos one 7(4): E35796

Zhao, Y.; Ji, S.; Wang, J.; Huang, J.; Zheng, P. 2014: MRNA-Seq and microRNA-Seq whole-transcriptome analyses of rhesus monkey embryonic stem cell neural differentiation revealed the potential regulators of rosette neural stem cells. Dna Research: An International Journal for Rapid Publication of Reports on Genes and Genomes 21(5): 541-554

Leite, R.B.; Milan, M.; Coppe, A.; Bortoluzzi, S.; dos Anjos, A.ón.; Reinhardt, R.; Saavedra, C.; Patarnello, T.; Cancela, M.L.; Bargelloni, L. 2013: MRNA-Seq and microarray development for the Grooved Carpet shell clam, Ruditapes decussatus: a functional approach to unravel host-parasite interaction. Bmc Genomics 14: 741

Cann, G.M.; Gulzar, Z.G.; Cooper, S.; Li, R.; Luo, S.; Tat, M.; Stuart, S.; Schroth, G.; Srinivas, S.; Ronaghi, M.; Brooks, J.D.; Talasaz, A.H. 2012: MRNA-Seq of single prostate cancer circulating tumor cells reveals recapitulation of gene expression and pathways found in prostate cancer. Plos one 7(11): E49144

Yin, X.; Sachidanandam, R.; Morshed, S.; Latif, R.; Shi, R.; Davies, T.F. 2014: MRNA-Seq reveals novel molecular mechanisms and a robust fingerprint in Graves' disease. Journal of Clinical Endocrinology and Metabolism 99(10): E2076-E2083

Turrel-Davin, F.; Venet, F.; Monnin, C.éc.; Barbalat, V.ér.; Cerrato, E.; Pachot, A.; Lepape, A.; Alberti-Segui, C.; Monneret, G. 2011: MRNA-based approach to monitor recombinant gamma-interferon restoration of LPS-induced endotoxin tolerance. Critical Care 15(5): R252

Van Gulck, E.; Vlieghe, E.; Vekemans, M.; Van Tendeloo, V.F.I.; Van De Velde, A.; Smits, E.; Anguille, S.éb.; Cools, N.; Goossens, H.; Mertens, L.; De Haes, W.; Wong, J.; Florence, E.; Vanham, G.; Berneman, Z.N. 2012: MRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. Aids 26(4): F1-12

Benteyn, D.é; Heirman, C.; Bonehill, A.; Thielemans, K.; Breckpot, K. 2015: MRNA-based dendritic cell vaccines. Expert Review of Vaccines 14(2): 161-176

Van Tendeloo, V.F.I.; Ponsaerts, P.; Berneman, Z.N. 2007: MRNA-based gene transfer as a tool for gene and cell therapy. Current Opinion in Molecular Therapeutics 9(5): 423-431

Tian, L.; Okita, T.W. 2014: MRNA-based protein targeting to the endoplasmic reticulum and chloroplasts in plant cells. Current Opinion in Plant Biology 22: 77-85

Visser, M.; Zubakov, D.; Ballantyne, K.N.; Kayser, M. 2011: MRNA-based skin identification for forensic applications. International Journal of Legal Medicine 125(2): 253-263

Fotin-Mleczek, M.; Zanzinger, K.; Heidenreich, R.; Lorenz, C.; Kowalczyk, A.; Kallen, K.-J.; Huber, S.M. 2014: MRNA-based vaccines synergize with radiation therapy to eradicate established tumors. Radiation Oncology 9: 180

Karalok, H.M.; Aydin, E.; Saglam, O.; Torun, A.; Guzeloglu-Kayisli, O.; Lalioti, M.D.; Kristiansson, H.; Duke, C.M.P.; Choe, G.; Flannery, C.; Kallen, C.B.; Seli, E. 2014: MRNA-binding protein TIA-1 reduces cytokine expression in human endometrial stromal cells and is down-regulated in ectopic endometrium. Journal of Clinical Endocrinology and Metabolism 99(12): E2610-E2619

Levy, O.; Zhao, W.; Mortensen, L.J.; Leblanc, S.; Tsang, K.; Fu, M.; Phillips, J.A.; Sagar, V.; Anandakumaran, P.; Ngai, J.; Cui, C.H.; Eimon, P.; Angel, M.; Lin, C.P.; Yanik, M.F.; Karp, J.M. 2013: MRNA-engineered mesenchymal stem cells for targeted delivery of interleukin-10 to sites of inflammation. Blood 122(14): E23-E32

Schüring, A.N.; Braun, J.; Wüllner, S.; Kiesel, L.; Götte, M. 2011: MRNA-expression of ERα, ERβ, and PR in clonal stem cell cultures obtained from human endometrial biopsies. Thescientificworldjournal 11: 1762-1769

Fluman, N.; Navon, S.; Bibi, E.; Pilpel, Y. 2014: MRNA-programmed translation pauses in the targeting of E. coli membrane proteins. Elife 3

Zhang, X.; Yao, D.; Wang, Q.; Xu, W.; Wei, Q.; Wang, C.; Liu, C.; Zhang, C.; Yan, H.; Ling, Y.; Su, Z.; Li, F. 2013: MRNA-seq analysis of the Gossypium arboreum transcriptome reveals tissue selective signaling in response to water stress during seedling stage. Plos one 8(1): E54762

Hammer, P.; Banck, M.S.; Amberg, R.; Wang, C.; Petznick, G.; Luo, S.; Khrebtukova, I.; Schroth, G.P.; Beyerlein, P.; Beutler, A.S. 2010: MRNA-seq with agnostic splice site discovery for nervous system transcriptomics tested in chronic pain. Genome Research 20(6): 847-860

Lao, K.Q.; Tang, F.; Barbacioru, C.; Wang, Y.; Nordman, E.; Lee, C.; Xu, N.; Wang, X.; Tuch, B.; Bodeau, J.; Siddiqui, A.; Surani, M.A. 2009: MRNA-sequencing whole transcriptome analysis of a single cell on the SOLiD system. Journal of Biomolecular Techniques: Jbt 20(5): 266-271

Burgess, H.M.; Gray, N.K. 2010: MRNA-specific regulation of translation by poly(A)-binding proteins. Biochemical Society Transactions 38(6): 1517-1522

Kheirelseid, E.A.H.; Miller, N.; Chang, K.H.; Nowell, J.; Kerin, M.J. 2013: MRNA/miRNA correlations in colorectal cancer: novel mechanisms in cancer initiation and progression. International Journal of Colorectal Disease 28(7): 1031-1034

Xie, C.; Xu, S.; Yang, L.; Ke, Z.; Xing, J.; Gai, J.; Gong, X.; Xu, L.; Bao, B. 2011: MRNA/microRNA Profile at the Metamorphic Stage of Olive Flounder (Paralichthys olivaceus). Comparative and Functional Genomics 2011: 256038

Van Lint, S.; Heirman, C.; Thielemans, K.; Breckpot, K. 2013: MRNA: from a chemical blueprint for protein production to an off-the-shelf therapeutic. Human Vaccines and Immunotherapeutics 9(2): 265-274

Müller, M.; Neugebauer, K.M.; Eckmann, C. 2010: MRNA: a complex(ed) life. Genome Biology 11(5): 304

Van Lint, S.; Thielemans, K.; Breckpot, K. 2011: MRNA: delivering an antitumor message?. ImmunoTherapy 3(5): 605-607

Alic, A.; Pérez-Ortín, Jé.E.; Moreno, Jín.; Arnau, V. 2013: mRNAStab--a web application for mRNA stability analysis. Bioinformatics 29(6): 813-814

Lazzarini, R.; Olivieri, F.; Ferretti, C.; Mattioli-Belmonte, M.; Di Primio, R.; Orciani, M. 2014: MRNAs and mi RNAs profiling of mesenchymal stem cells derived from amniotic fluid and skin: the double face of the coin. Cell and Tissue Research 355(1): 121-130

Träger, C.; Vernby, A.; Kullman, A.; Ora, I.; Kogner, P.; Kågedal, B. 2008: MRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis. International Journal of Cancer 123(12): 2849-2855

Voronina, A.S.; Pshennikova, E.S. 2010: MRNPs: from informosomes to stress-granules. Molekuliarnaia Biologiia 44(4): 591-600

Liu, L.; Chowdhury, S.; Uppal, S.; Fang, X.; Liu, J.-L.; Srikant, C.B. 2015: MReg2 inhibits nuclear entry of apoptosis-inducing factor in mouse insulinoma cells. Growth Factors 33(1): 1-7

Kredel, S.; Oswald, F.; Nienhaus, K.; Deuschle, K.; Röcker, C.; Wolff, M.; Heilker, R.; Nienhaus, G.U.; Wiedenmann, J.ör. 2009: MRuby, a bright monomeric red fluorescent protein for labeling of subcellular structures. Plos one 4(2): E4391

Cardano, M.; Diaferia, G.R.; Cattaneo, M.; Dessì, S.S.; Long, Q.; Conti, L.; Deblasio, P.; Cattaneo, E.; Biunno, I. 2011: MSEL-1L (Suppressor/enhancer Lin12-like) protein levels influence murine neural stem cell self-renewal and lineage commitment. Journal of Biological Chemistry 286(21): 18708-18719

Lu, M.; Wang, J.; Ives, H.E.; Pearce, D. 2011: MSIN1 protein mediates SGK1 protein interaction with mTORC2 protein complex and is required for selective activation of the epithelial sodium channel. Journal of Biological Chemistry 286(35): 30647-30654

Cabrera Mendoza, N.és.I.án.; Castro Enriquez, P.P.; Demeneghi Marini, V.ón.P.; Fernández Luque, L.; Morales Romero, J.; Sainz Vazquez, L.; Ortiz León, M.ía.C. 2014: MSalUV: a new mobile messaging system for diabetes control in Mexico. Revista Panamericana de Salud Publica 35(5-6): 371-377

Yun, E.J.; Vu, T.H. 2012: MSmile is necessary for bronchial smooth muscle and alveolar myofibroblast development. Anatomical Record 295(1): 167-176

Thielen, B.; Heinen, S.; Schomburg, D. 2009: MSpecs: a software tool for the administration and editing of mass spectral libraries in the field of metabolomics. Bmc Bioinformatics 10: 229

Eskenazi, B.; Quirós-Alcalá, L.; Lipsitt, J.M.; Wu, L.D.; Kruger, P.; Ntimbane, T.; Nawn, J.B.; Bornman, M.S.R.; Seto, E. 2014: MSpray: a mobile phone technology to improve malaria control efforts and monitor human exposure to malaria control pesticides in Limpopo, South Africa. Environment International 68: 219-226

Shringarpure, S.; Xing, E.P. 2009: MStruct: inference of population structure in light of both genetic admixing and allele mutations. Genetics 182(2): 575-593

Wenz, T.; Luca, C.; Torraco, A.; Moraes, C.T. 2009: MTERF2 regulates oxidative phosphorylation by modulating mtDNA transcription. Cell Metabolism 9(6): 499-511

Senge, M.O. 2012: MTHPC--a drug on its way from second to third generation photosensitizer?. Photodiagnosis and Photodynamic Therapy 9(2): 170-179

François, A.él.; Marchal, S.; Guillemin, F.ço.; Bezdetnaya, L. 2011: MTHPC-based photodynamic therapy induction of autophagy and apoptosis in cultured cells in relation to mitochondria and endoplasmic reticulum stress. International Journal of Oncology 39(6): 1537-1543

De Visscher, S.A.H.J.; Melchers, L.J.; Dijkstra, P.U.; Karakullukcu, B.; Tan, I.B.; Hopper, C.; Roodenburg, J.L.N.; Witjes, M.J.H. 2013: MTHPC-mediated photodynamic therapy of early stage oral squamous cell carcinoma: a comparison to surgical treatment. Annals of Surgical Oncology 20(9): 3076-3082

Dabkeviciene, D.; Stankevicius, V.; Grazeliene, G.; Markuckas, A.; Didziapetriene, J.; Kirveliene, V. 2010: MTHPC-mediated photodynamic treatment of Lewis lung carcinoma in vitro and in vivo. Medicina 46(5): 345-350

Derer, S.; Till, A.; Haesler, R.; Sina, C.; Grabe, N.; Jung, S.; Nikolaus, S.; Kuehbacher, T.; Groetzinger, J.; Rose-John, S.; Rosenstiel, P.C.; Schreiber, S. 2013: MTNF reverse signalling induced by TNFα antagonists involves a GDF-1 dependent pathway: implications for Crohn's disease. Gut 62(3): 376-386

Zhang, H.; Dou, J.; Yu, Y.; Zhao, Y.; Fan, Y.; Cheng, J.; Xu, X.; Liu, W.; Guan, S.; Chen, Z.; shi, Y.; Patel, R.; Vasudevan, S.A.; Zage, P.E.; Zhang, H.; Nuchtern, J.G.; Kim, E.S.; Fu, S.; Yang, J. 2015: MTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling. Apoptosis: An International Journal on Programmed Cell Death 20(1): 50-62

Iyer, A.M.; van Scheppingen, J.; Milenkovic, I.; Anink, J.J.; Adle-Biassette, H.; Kovacs, G.G.; Aronica, E. 2014: MTOR Hyperactivation in down syndrome hippocampus appears early during development. Journal of Neuropathology and Experimental Neurology 73(7): 671-683

Plantinga, T.S.; Heinhuis, B.; Gerrits, D.; Netea, M.G.; Joosten, L.A.B.; Hermus, A.R.M.M.; Oyen, W.J.G.; Schweppe, R.E.; Haugen, B.R.; Boerman, O.C.; Smit, J.W.A.; Netea-Maier, R.T. 2014: MTOR Inhibition promotes TTF1-dependent redifferentiation and restores iodine uptake in thyroid carcinoma cell lines. Journal of Clinical Endocrinology and Metabolism 99(7): E1368-E1375

Cau, S.B.A.; Tostes, R.C. 2012: MTOR Inhibition: a Promise for a Young Heart. Frontiers in Physiology 3: 31

Kaeberlein, M. 2013: MTOR Inhibition: from Aging to Autism and Beyond. Scientifica 2013: 849186

Liu, Q.; Thoreen, C.; Wang, J.; Sabatini, D.; Gray, N.S. 2009: MTOR Mediated Anti-Cancer Drug Discovery. Drug Discovery Today. Therapeutic Strategies 6(2): 47-55

Soliman, G.A.; Acosta-Jaquez, H.A.; Dunlop, E.A.; Ekim, B.; Maj, N.E.; Tee, A.R.; Fingar, D.C. 2010: MTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. Journal of Biological Chemistry 285(11): 7866-7879

Laplante, M.; Sabatini, D.M. 2012: MTOR Signaling. Cold Spring Harbor Perspectives in Biology 4(2)

Raychaudhuri, S.K.; Raychaudhuri, S.P. 2014: MTOR Signaling Cascade in Psoriatic Disease: Double Kinase mTOR Inhibitor a Novel Therapeutic Target. Indian Journal of Dermatology 59(1): 67-70

Cao, R.; Obrietan, K. 2010: MTOR Signaling and Entrainment of the Mammalian Circadian Clock. Molecular and Cellular Pharmacology 2(4): 125-130

Xu, S.; Cai, Y.; Wei, Y. 2014: MTOR Signaling from Cellular Senescence to Organismal Aging. Aging and Disease 5(4): 263-273

Proud, C.G. 2011: MTOR Signalling in Health and Disease. Biochemical Society Transactions 39(2): 431-436

Wong, M. 2014: MTOR Strikes Again: mTORC1 Activation Causes Epilepsy Independent of Overt Pathological Changes. Epilepsy Currents 14(1): 41-43

Yang, C.; Peng, J.; Jiang, W.; Zhang, Y.; Chen, X.; Wu, X.; Zhu, Y.; Zhang, H.; Chen, J.; Wang, J.; Cho, W.C.S.; Jin, K. 2013: MTOR activation in immature cells of primary nasopharyngeal carcinoma and anti-tumor effect of rapamycin in vitro and in vivo. Cancer Letters 341(2): 186-194

Lyra, J.; Vinagre, J.ão.; Batista, R.; Pinto, V.; Prazeres, H.; Rodrigues, F.; Eloy, C.; Sobrinho-Simões, M.; Soares, P. 2014: MTOR activation in medullary thyroid carcinoma with RAS mutation. European Journal of Endocrinology 171(5): 633-640

Zhou, C-Fei.; Ji, J.; Yuan, F.; Shi, M.; Zhang, J.; Liu, B-Ya.; Zhu, Z-Gang. 2011: MTOR activation in well differentiated pancreatic neuroendocrine tumors: a retrospective study on 34 cases. Hepato-Gastroenterology 58(112): 2140-2143

Lee, J.Y.; Nakada, D.; Yilmaz, O.H.; Tothova, Z.; Joseph, N.M.; Lim, M.S.; Gilliland, D.G.; Morrison, S.J. 2010: MTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion. Cell Stem Cell 7(5): 593-605

Dwyer, J.M.; Lepack, A.E.; Duman, R.S. 2012: MTOR activation is required for the antidepressant effects of mGluR₂/₃ blockade. International Journal of Neuropsychopharmacology 15(4): 429-434

Benhamron, S.; Pattanayak, S.P.; Berger, M.; Tirosh, B. 2015: MTOR activation promotes plasma cell differentiation and bypasses XBP-1 for immunoglobulin secretion. Molecular and Cellular Biology 35(1): 153-166

Yu, J.; Henske, E.P. 2010: MTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the "perfect storm" of pro-metastatic factors in LAM pathogenesis. Lymphatic Research and Biology 8(1): 43-49

Vadysirisack, D.D.; Ellisen, L.W. 2012: MTOR activity under hypoxia. Methods in Molecular Biology 821: 45-58

Toker, A. 2008: MTOR and Akt signaling in cancer: SGK cycles in. Molecular Cell 31(1): 6-8

Turnquist, H.R.; Cardinal, J.; Macedo, C.; Rosborough, B.R.; Sumpter, T.L.; Geller, D.A.; Metes, D.; Thomson, A.W. 2010: MTOR and GSK-3 shape the CD4+ T-cell stimulatory and differentiation capacity of myeloid DCs after exposure to LPS. Blood 115(23): 4758-4769

Shackelford, D.B.; Vasquez, D.S.; Corbeil, J.; Wu, S.; Leblanc, M.; Wu, C.-L.; Vera, D.R.; Shaw, R.J. 2009: MTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proceedings of the National Academy of Sciences of the United States of America 106(27): 11137-11142

Yang, F.; Chu, X.; Yin, M.; Liu, X.; Yuan, H.; Niu, Y.; Fu, L. 2014: MTOR and autophagy in normal brain aging and caloric restriction ameliorating age-related cognition deficits. Behavioural Brain Research 264: 82-90

Hu, Y.; Liu, J.; Wu, Y.-F.; Lou, J.; Mao, Y.-Y.; Shen, H.-H.; Chen, Z.-H. 2014: MTOR and autophagy in regulation of acute lung injury: a review and perspective. Microbes and Infection 16(9): 727-734

Dunlop, E.A.; Tee, A.R. 2014: MTOR and autophagy: a dynamic relationship governed by nutrients and energy. Seminars in Cell and Developmental Biology 36: 121-129

Efeyan, A.; Sabatini, D.M. 2010: MTOR and cancer: many loops in one pathway. Current Opinion in Cell Biology 22(2): 169-176

Wesierska-Gadek, J.óz. 2010: MTOR and its link to the picture of Dorian Gray - re-activation of mTOR promotes aging. Aging 2(12): 892-893

Puertollano, R. 2014: MTOR and lysosome regulation. F1000prime Reports 6: 52

Wang, L.; Xu, S.; Yue, W. 2010: MTOR and non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 13(1): 69-72

Ma, Y.-Q.; Wu, D.-K.; Liu, J.-K. 2013: MTOR and tau phosphorylated proteins in the hippocampal tissue of rats with type 2 diabetes and Alzheimer's disease. Molecular Medicine Reports 7(2): 623-627

Watson, K.; Baar, K. 2014: MTOR and the health benefits of exercise. Seminars in Cell and Developmental Biology 36: 130-139

Goncharova, E.A. 2013: MTOR and vascular remodeling in lung diseases: current challenges and therapeutic prospects. Faseb Journal: Official Publication of the Federation of American Societies for Experimental Biology 27(5): 1796-1807

Molinolo, A.A.; Marsh, C.; El Dinali, M.; Gangane, N.; Jennison, K.; Hewitt, S.; Patel, V.; Seiwert, T.Y.; Gutkind, J.S. 2012: MTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 18(9): 2558-2568

Ong, C.T.; Khoo, Y.T.; Mukhopadhyay, A.; Do, D.V.; Lim, I.J.; Aalami, O.; Phan, T.T. 2007: MTOR as a potential therapeutic target for treatment of keloids and excessive scars. Experimental Dermatology 16(5): 394-404

Wong, M. 2012: MTOR as a potential treatment target for epilepsy. Future Neurology 7(5): 537-545

Hudes, G.R. 2007: MTOR as a target for therapy of renal cancer. Clinical Advances in Hematology and Oncology: H&o 5(10): 772-774

Al-Batran, S.-E.; Ducreux, M.; Ohtsu, A. 2012: MTOR as a therapeutic target in patients with gastric cancer. International Journal of Cancer 130(3): 491-496

Kantidakis, T.; Ramsbottom, B.A.; Birch, J.L.; Dowding, S.N.; White, R.J. 2010: MTOR associates with TFIIIC, is found at tRNA and 5S rRNA genes, and targets their repressor Maf1. Proceedings of the National Academy of Sciences of the United States of America 107(26): 11823-11828

Mondino, A.; Mueller, D.L. 2007: MTOR at the crossroads of T cell proliferation and tolerance. Seminars in Immunology 19(3): 162-172

Song, X.; Kusakari, Y.; Xiao, C-Yang.; Kinsella, S.D.; Rosenberg, M.A.; Scherrer-Crosbie, M.; Hara, K.; Rosenzweig, A.; Matsui, T. 2010: MTOR attenuates the inflammatory response in cardiomyocytes and prevents cardiac dysfunction in pathological hypertrophy. American Journal of Physiology. Cell Physiology 299(6): C1256-C1266

Tsang, C.K.; Liu, H.; Zheng, X.F.S. 2010: MTOR binds to the promoters of RNA polymerase I- and III-transcribed genes. Cell Cycle 9(5): 953-957

Wang, Z.; Martin, D.; Molinolo, A.A.; Patel, V.; Iglesias-Bartolome, R.; Degese, M.S.; Vitale-Cross, L.; Chen, Q.; Gutkind, J.S. 2014: MTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations. Journal of the National Cancer Institute 106(9)

Neasta, J.; Barak, S.; Hamida, S.B.; Ron, D. 2014: MTOR complex 1: a key player in neuroadaptations induced by drugs of abuse. Journal of Neurochemistry 130(2): 172-184

García-Martínez, J.M.; Alessi, D.R. 2008: MTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochemical Journal 416(3): 375-385

Masui, K.; Tanaka, K.; Akhavan, D.; Babic, I.; Gini, B.; Matsutani, T.; Iwanami, A.; Liu, F.; Villa, G.R.; Gu, Y.; Campos, C.; Zhu, S.; Yang, H.; Yong, W.H.; Cloughesy, T.F.; Mellinghoff, I.K.; Cavenee, W.K.; Shaw, R.J.; Mischel, P.S. 2013: MTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metabolism 18(5): 726-739

Cybulski, N.; Polak, P.; Auwerx, J.; Rüegg, M.A.; Hall, M.N. 2009: MTOR complex 2 in adipose tissue negatively controls whole-body growth. Proceedings of the National Academy of Sciences of the United States of America 106(24): 9902-9907

Zhao, L.; Yue, P.; Khuri, F.R.; Sun, S.-Y. 2013: MTOR complex 2 is involved in regulation of Cbl-dependent c-FLIP degradation and sensitivity of TRAIL-induced apoptosis. Cancer Research 73(6): 1946-1957

Dai, N.; Christiansen, J.; Nielsen, F.C.; Avruch, J. 2013: MTOR complex 2 phosphorylates IMP1 cotranslationally to promote IGF2 production and the proliferation of mouse embryonic fibroblasts. Genes and Development 27(3): 301-312

Kim, S.J.; DeStefano, M.A.; Oh, W.J.; Wu, C.-c.; Vega-Cotto, N.M.; Finlan, M.; Liu, D.; Su, B.; Jacinto, E. 2012: MTOR complex 2 regulates proper turnover of insulin receptor substrate-1 via the ubiquitin ligase subunit Fbw8. Molecular Cell 48(6): 875-887

Oh, W.J.; Jacinto, E. 2011: MTOR complex 2 signaling and functions. Cell Cycle 10(14): 2305-2316

Wu, Y.-T.; Ouyang, W.; Lazorchak, A.S.; Liu, D.; Shen, H.-M.; Su, B. 2011: MTOR complex 2 targets Akt for proteasomal degradation via phosphorylation at the hydrophobic motif. Journal of Biological Chemistry 286(16): 14190-14198

Zhang, F.; Zhang, X.; Li, M.; Chen, P.; Zhang, B.; Guo, H.; Cao, W.; Wei, X.; Cao, X.; Hao, X.; Zhang, N. 2010: MTOR complex component Rictor interacts with PKCzeta and regulates cancer cell metastasis. Cancer Research 70(22): 9360-9370

Lu, M.; Wang, J.; Jones, K.T.; Ives, H.E.; Feldman, M.E.; Yao, L.-j.; Shokat, K.M.; Ashrafi, K.; Pearce, D. 2010: MTOR complex-2 activates ENaC by phosphorylating SGK1. Journal of the American Society of Nephrology: Jasn 21(5): 811-818

Kopper, L.ás.ó; Tímár, J.óz. 2011: MTOR complexes -- molecular spiders in molecular networks. Magyar Onkologia 55(4): 287-294

Grahammer, F.; Wanner, N.; Huber, T.B. 2014: MTOR controls kidney epithelia in health and disease. Nephrology Dialysis Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association 29(Suppl 1): I9

Yu, J.; Yaba, A.; Kasiman, C.; Thomson, T.; Johnson, J. 2011: MTOR controls ovarian follicle growth by regulating granulosa cell proliferation. Plos one 6(7): E21415

Howell, J.J.; Manning, B.D. 2011: MTOR couples cellular nutrient sensing to organismal metabolic homeostasis. Trends in Endocrinology and Metabolism: Tem 22(3): 94-102

Gao, D.; Inuzuka, H.; Tan, M.-K.M.; Fukushima, H.; Locasale, J.W.; Liu, P.; Wan, L.; Zhai, B.; Chin, Y.R.; Shaik, S.; Lyssiotis, C.A.; Gygi, S.P.; Toker, A.; Cantley, L.C.; Asara, J.M.; Harper, J.W.; Wei, W. 2011: MTOR drives its own activation via SCF(βTrCP)-dependent degradation of the mTOR inhibitor DEPTOR. Molecular Cell 44(2): 290-303

Ching, J.K.; Elizabeth, S.V.; Ju, J-Sun.; Lusk, C.; Pittman, S.K.; Weihl, C.C. 2013: MTOR dysfunction contributes to vacuolar pathology and weakness in valosin-containing protein associated inclusion body myopathy. Human Molecular Genetics 22(6): 1167-1179

Wang, X.; Li, L.; Niu, X.; Dang, X.; Li, P.; Qu, L.; Bi, X.; Gao, Y.; Hu, Y.; Li, M.; Qiao, W.; Peng, Z.; Pan, L. 2014: MTOR enhances foam cell formation by suppressing the autophagy pathway. Dna and Cell Biology 33(4): 198-204

Lambert, I.H.; Jensen, J.V.; Pedersen, P.A. 2014: MTOR ensures increased release and reduced uptake of the organic osmolyte taurine under hypoosmotic conditions in mouse fibroblasts. American Journal of Physiology. Cell Physiology 306(11): C1028-C1040

Kasajima, A.; Pavel, M.; Darb-Esfahani, S.; Noske, A.; Stenzinger, A.; Sasano, H.; Dietel, M.; Denkert, C.; Röcken, C.; Wiedenmann, B.; Weichert, W. 2011: MTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours. Endocrine-Related Cancer 18(1): 181-192

Handra-Luca, A. 2014: MTOR expression in colorectal adenoma. Human Pathology 45(4): 895-897

Schug, T.T. 2010: MTOR favors senescence over quiescence in p53-arrested cells. Aging 2(6): 327-328

Rivas, D.A.; Lessard, S.J.; Coffey, V.G. 2009: MTOR function in skeletal muscle: a focal point for overnutrition and exercise. Applied Physiology Nutrition and Metabolism 34(5): 807-816

Jiang, Y. 2010: MTOR goes to the nucleus. Cell Cycle 9(5): 868

Baccarani, U.; Adani, G.Luigi.; Tavio, M.; Grossi, P.; Viale, P. 2010: MTOR immunosuppression in HIV-positive liver transplant recipients. Transplantation 90(9): 1039-40; author reply 1040

Walsh, S.; Flanagan, L.; Quinn, C.; Evoy, D.; McDermott, E.W.; Pierce, A.; Duffy, M.J. 2012: MTOR in breast cancer: differential expression in triple-negative and non-triple-negative tumors. Breast 21(2): 178-182

Lu, M.-K.; Gong, X.-G.; Guan, K.-L. 2011: MTOR in podocyte function: is rapamycin good for diabetic nephropathy?. Cell Cycle 10(20): 3415-3416

Wysocki, P.J. 2009: MTOR in renal cell cancer: modulator of tumor biology and therapeutic target. Expert Review of Molecular Diagnostics 9(3): 231-241

Wang, Z.; Jin, W.; Jin, H.; Wang, X. 2014: MTOR in viral hepatitis and hepatocellular carcinoma: function and treatment. Biomed Research International 2014: 735672

Decressac, M.; Björklund, A. 2013: MTOR inhibition alleviates L-DOPA-induced dyskinesia in parkinsonian rats. Journal of Parkinson's Disease 3(1): 13-17

Johnson, S.C.; Yanos, M.E.; Kayser, E.-B.; Quintana, A.; Sangesland, M.; Castanza, A.; Uhde, L.; Hui, J.; Wall, V.Z.; Gagnidze, A.; Oh, K.; Wasko, B.M.; Ramos, F.J.; Palmiter, R.D.; Rabinovitch, P.S.; Morgan, P.G.; Sedensky, M.M.; Kaeberlein, M. 2013: MTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome. Science 342(6165): 1524-1528

Hirase, C.; Maeda, Y.; Yamaguchi, T.; Miyatake, J-Ichi.; Kanamaru, A. 2009: MTOR inhibition and adult T-cell leukemia. Leukemia and Lymphoma 50(4): 645-647

Smalley, S.; Chalmers, A.J.; Morley, S.J. 2014: MTOR inhibition and levels of the DNA repair protein MGMT in T98G glioblastoma cells. Molecular Cancer 13: 144

Fuereder, T.; Jaeger-Lansky, A.; Hoeflmayer, D.; Preusser, M.; Strommer, S.; Cejka, D.; Koehrer, S.; Crevenna, R.; Wacheck, V. 2010: MTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo. Cancer Letters 296(2): 249-256

Baraz, R.; Cisterne, A.; Saunders, P.O.; Hewson, J.; Thien, M.; Weiss, J.; Basnett, J.; Bradstock, K.F.; Bendall, L.J. 2014: MTOR inhibition by everolimus in childhood acute lymphoblastic leukemia induces caspase-independent cell death. Plos one 9(7): E102494

Deming, D.A.; Leystra, A.A.; Farhoud, M.; Nettekoven, L.; Clipson, L.; Albrecht, D.; Washington, M.K.; Sullivan, R.; Weichert, J.P.; Halberg, R.B. 2013: MTOR inhibition elicits a dramatic response in PI3K-dependent colon cancers. Plos one 8(4): E60709

Diken, M.; Kreiter, S.; Vascotto, F.; Selmi, A.; Attig, S.; Diekmann, J.; Huber, C.; Türeci, Öz.; Sahin, U. 2013: MTOR inhibition improves antitumor effects of vaccination with antigen-encoding RNA. Cancer Immunology Research 1(6): 386-392

Eimer, C.; Gerullis, H.; Heuck, C.; Otto, T. 2011: MTOR inhibition in advanced renal cell carcinoma: which criteria should be used to evaluate therapeutic outcome?. Anti-Cancer Drugs 22(1): 18-23

Jardine, M.J.; Liyanage, T.; Buxton, E.; Perkovic, V. 2013: MTOR inhibition in autosomal-dominant polycystic kidney disease (ADPKD): the question remains open. Nephrology Dialysis Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association 28(2): 242-244

O'Regan, R.; Hawk, N.N. 2011: MTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy. Expert Opinion on Therapeutic Targets 15(7): 859-872

Junge, G.; Dumortier, T.; Schwende, H.; Fung, J. 2013: MTOR inhibition in liver transplantation: how to dose for effective/safe CNi reduction?. Transplantation Proceedings 45(5): 1979-1980

Nag, S. 2012: MTOR inhibition in management of advanced breast cancer. Indian Journal of Medical and Paediatric Oncology: Official Journal of Indian Society of Medical and Paediatric Oncology 33(2): 89-94

Kapuy, O.; Vinod, P.K.; Bánhegyi, G.áb. 2014: MTOR inhibition increases cell viability via autophagy induction during endoplasmic reticulum stress - An experimental and modeling study. Febs Open Bio 4: 704-713

Bailey, S.T.; Zhou, B.; Damrauer, J.S.; Krishnan, B.; Wilson, H.L.; Smith, A.M.; Li, M.; Yeh, J.J.; Kim, W.Y. 2014: MTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma. Plos one 9(9): E104413

Tang, Y.; Fang, Q.; Shi, D.; Niu, P.; Chen, Y.; Deng, J. 2014: MTOR inhibition of cardamonin on antiproliferation of A549 cells is involved in a FKBP12 independent fashion. Life Sciences 99(1-2): 44-51

Acquaviva, J.; He, S.; Sang, J.; Smith, D.L.; Sequeira, M.; Zhang, C.; Bates, R.C.; Proia, D.A. 2014: MTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis. Molecular Cancer Research: Mcr 12(5): 703-713

Iglesias-Bartolome, R.; Patel, V.; Cotrim, A.; Leelahavanichkul, K.; Molinolo, A.A.; Mitchell, J.B.; Gutkind, J.Silvio. 2012: MTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis. Cell Stem Cell 11(3): 401-414

Sukumari-Ramesh, S.; Singh, N.; Dhandapani, K.M.; Vender, J.R. 2011: MTOR inhibition reduces cellular proliferation and sensitizes pituitary adenoma cells to ionizing radiation. Surgical Neurology International 2: 22

Ghayad, S.E.; Bieche, I.; Vendrell, J.A.; Keime, C.; Lidereau, R.; Dumontet, C.; Cohen, P.A. 2008: MTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Science 99(10): 1992-2003

Cejka, D.; Preusser, M.; Fuereder, T.; Sieghart, W.; Werzowa, J.; Strommer, S.; Wacheck, V. 2008: MTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo. Anticancer Research 28(6a): 3801-3808

Faber, A.C.; Coffee, E.M.; Costa, C.; Dastur, A.; Ebi, H.; Hata, A.N.; Yeo, A.T.; Edelman, E.J.; Song, Y.; Tam, A.T.; Boisvert, J.L.; Milano, R.J.; Roper, J.; Kodack, D.P.; Jain, R.K.; Corcoran, R.B.; Rivera, M.N.; Ramaswamy, S.; Hung, K.E.; Benes, C.H.; Engelman, J.A. 2014: MTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Cancer Discovery 4(1): 42-52

Márquez, E.; Pascual, J. 2014: MTOR inhibition, AKT proteins and chronic kidney disease. Nefrologia: Publicacion Oficial de la Sociedad Espanola Nefrologia 34(4): 425-427

Keniry, M.; Parsons, R. 2011: MTOR inhibition, the second generation: ATP-competitive mTOR inhibitor initiates unexpected receptor tyrosine kinase-driven feedback loop. Cancer Discovery 1(3): 203-204

Martinet, W.; De Loof, H.; De Meyer, G.R.Y. 2014: MTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques. Atherosclerosis 233(2): 601-607

Weir, M.R.; Diekmann, F.; Flechner, S.M.; Lebranchu, Y.; Mandelbrot, D.A.; Oberbauer, R.; Kahan, B.D. 2010: MTOR inhibition: the learning curve in kidney transplantation. Transplant International: Official Journal of the European Society for Organ Transplantation 23(5): 447-460

Muro, K. 2011: MTOR inhibitor. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(1): 7-11

Zhao, L.; Teng, B.; Wen, L.; Feng, Q.; Wang, H.; Li, N.; Wang, Y.; Liang, Z. 2014: MTOR inhibitor AZD8055 inhibits proliferation and induces apoptosis in laryngeal carcinoma. International Journal of Clinical and Experimental Medicine 7(2): 337-347

Mancini, M.; Corradi, V.; Petta, S.; Martinelli, G.; Barbieri, E.; Santucci, M.A. 2010: MTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein. Leukemia Research 34(5): 641-648

Lane, H.A.; Wood, J.M.; McSheehy, P.M.J.; Allegrini, P.R.; Boulay, A.; Brueggen, J.; Littlewood-Evans, A.; Maira, S.-M.; Martiny-Baron, G.; Schnell, C.R.; Sini, P.; O'Reilly, T. 2009: MTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 15(5): 1612-1622

Cai, Y.; Xia, Q.; Su, Q.; Luo, R.; Sun, Y.; Shi, Y.; Jiang, W. 2013: MTOR inhibitor RAD001 (everolimus) induces apoptotic, not autophagic cell death, in human nasopharyngeal carcinoma cells. International Journal of Molecular Medicine 31(4): 904-912

Pool, S.E.; Bison, S.; Koelewijn, S.J.; van der Graaf, L.M.; Melis, M.; Krenning, E.P.; de Jong, M. 2013: MTOR inhibitor RAD001 promotes metastasis in a rat model of pancreatic neuroendocrine cancer. Cancer Research 73(1): 12-18

Alain, T.; Sonenberg, N.; Topisirovic, I. 2012: MTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio. Oncotarget 3(12): 1491-1492

Nakagawa, S.; Masuda, S.; Nishihara, K.; Inui, K.-I. 2010: MTOR inhibitor everolimus ameliorates progressive tubular dysfunction in chronic renal failure rats. Biochemical Pharmacology 79(1): 67-76

Kudo, M. 2011: MTOR inhibitor for the treatment of hepatocellular carcinoma. Digestive Diseases 29(3): 310-315

Holtan, S.G.; Porrata, L.F.; Colgan, J.P.; Zent, C.S.; Habermann, T.M.; Markovic, S.N. 2008: MTOR inhibitor monotherapy is insufficient to suppress viremia and disease progression in Epstein-Barr virus-driven lymphoproliferative disorders (EBV-LPD). American Journal of Hematology 83(8): 688-689

Franco-Esteve, A.; Tordera, D.; de la Sen, M.L.; Jiménez, L.; Mas, P.; Muñoz, C.; Olivares, J.ús. 2012: MTOR inhibitor monotherapy. a good treatment choice in renal transplantation?. Nefrologia: Publicacion Oficial de la Sociedad Espanola Nefrologia 32(5): 631-638

Hou, G.; Zhang, Q.; Wang, L.; Liu, M.; Wang, J.; Xue, L. 2010: MTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice. Cancer Letters 290(2): 248-254

Ghiglieri, V.; Pendolino, V.; Bagetta, V.; Sgobio, C.; Calabresi, P.; Picconi, B. 2010: MTOR inhibitor rapamycin suppresses striatal post-ischemic LTP. Experimental Neurology 226(2): 328-331

Rindi, G.; Caplin, M. 2011: MTOR inhibitor therapy for patients with carcinoid. Lancet 378(9808): 1978-1980

Klümpen, H.-J.; Queiroz, K.C.S.; Spek, C.A.; van Noesel, C.J.M.; Brink, H.C.; de Leng, W.W.J.; de Wilde, R.F.; Mathus-Vliegen, E.M.H.; Offerhaus, G.J.A.; Alleman, M.A.; Westermann, A.M.; Richel, D.J. 2011: MTOR inhibitor treatment of pancreatic cancer in a patient with Peutz-Jeghers syndrome. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 29(6): E150-E153

Campistol, J.M.; de Fijter, J.W.; Flechner, S.M.; Langone, A.; Morelon, E.; Stockfleth, E. 2010: MTOR inhibitor-associated dermatologic and mucosal problems. Clinical Transplantation 24(2): 149-156

Willemsen, A.E.C.A.B.; van Herpen, C.M.L. 2013: MTOR inhibitor-related pulmonary toxicity; incidence even higher. Acta Oncologica 52(6): 1234

Rostaing, L.; Kamar, N. 2010: MTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?. Journal of Nephrology 23(2): 133-142

Bogani, C.; Bartalucci, N.ò; Martinelli, S.; Tozzi, L.; Guglielmelli, P.; Bosi, A.; Vannucchi, A.M. 2013: MTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms. Plos one 8(1): E54826

Levey, A.S.; Stevens, L.A. 2011: MTOR inhibitors and autosomal dominant polycystic kidney disease. New England Journal of Medicine 364(3): 287; Author Reply 287-289

Grantham, J.J.; Bennett, W.M.; Perrone, R.D. 2011: MTOR inhibitors and autosomal dominant polycystic kidney disease. New England Journal of Medicine 364(3): 286-287; Author Reply 287-289

Holdaas, H.; Potena, L.; Saliba, F. 2015: MTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern?. Transplantation Reviews 29(2): 93-102

Zaza, G.; Granata, S.; Tomei, P.; Masola, V.; Gambaro, G.; Lupo, A. 2014: MTOR inhibitors and renal allograft: Yin and Yang. Journal of Nephrology 27(5): 495-506

Waidmann, O.; Hofmann, W.-P.; Zeuzem, S.; Trojan, J. 2011: MTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation. Journal of Hepatology 54(2): 396-398

Vázquez-Martín, A.; Oliveras-Ferraros, C.; del Barco, S.; Martín-Castillo, B.ña.; Menéndez, J.A. 2009: MTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb). Clinical and Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 11(7): 455-459

Husseinzadeh, N.; Husseinzadeh, H.D. 2014: MTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review. Gynecologic Oncology 133(2): 375-381

Nashan, B.ör. 2014: MTOR inhibitors and their role in modern concepts of immunosuppression. World Journal of Surgery 38(12): 3199-3201

Moro, J.; Almenar, L.; Martínez-Dolz, L.; Izquierdo, M.; Rueda, J.; Arnau, M.A.; Agüero, J.; Sánchez-Lázaro, I.; Ortiz, V.; Salvador, A. 2007: mTOR inhibitors and their secondary effects in cardiac transplant recipients: a descriptive study. Transplantation Proceedings 39(7): 2365-2367

Moro, J.é A.; Almenar, L.; Martínez-Dolz, L.; Salvador, A. 2008: MTOR inhibitors and unilateral edema. Revista Espanola de Cardiologia 61(9): 987-988

Teachey, D.T.; Sheen, C.; Hall, J.; Ryan, T.; Brown, V.I.; Fish, J.; Reid, G.S.D.; Seif, A.E.; Norris, R.; Chang, Y.J.; Carroll, M.; Grupp, S.A. 2008: MTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood 112(5): 2020-2023

Curatolo, P.; Moavero, R. 2013: MTOR inhibitors as a new therapeutic option for epilepsy. Expert Review of Neurotherapeutics 13(6): 627-638

Kushwaha, S.S. 2014: MTOR inhibitors as primary immunosuppression after heart transplant: confounding factors in clinical trials. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 14(9): 1958-1959

Roy, D.; Sin, S.-H.; Lucas, A.; Venkataramanan, R.; Wang, L.; Eason, A.; Chavakula, V.; Hilton, I.B.; Tamburro, K.M.; Damania, B.; Dittmer, D.P. 2013: MTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis. Cancer Research 73(7): 2235-2246

Ishikawa, D.; Takeuchi, S.; Nakagawa, T.; Sano, T.; Nakade, J.; Nanjo, S.; Yamada, T.; Ebi, H.; Zhao, L.; Yasumoto, K.; Nakamura, T.; Matsumoto, K.; Kagamu, H.; Yoshizawa, H.; Yano, S. 2013: MTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF. Plos one 8(5): E62104

Treiber, G. 2009: MTOR inhibitors for hepatocellular cancer: a forward-moving target. Expert Review of Anticancer Therapy 9(2): 247-261

Voss, M.H.; Molina, A.M.; Motzer, R.J. 2011: mTOR inhibitors in advanced renal cell carcinoma. Hematology/Oncology Clinics of North America 25(4): 835-852

Pape, L.; Ahlenstiel, T. 2014: MTOR inhibitors in pediatric kidney transplantation. Pediatric Nephrology 29(7): 1119-1129

Watnick, T.; Germino, G.G. 2010: MTOR inhibitors in polycystic kidney disease. New England Journal of Medicine 363(9): 879-881

Battelli, C.; Cho, D.C. 2011: MTOR inhibitors in renal cell carcinoma. Therapy 8(4): 359-367

Demetri, G.D. 2011: MTOR inhibitors in sarcoma. Clinical Advances in Hematology and Oncology: H&o 9(2): 145-147

Vinayak, S.; Carlson, R.W. 2013: MTOR inhibitors in the treatment of breast cancer. Oncology 27(1): 38-44; 46 48 Passim

Fasolo, A.; Sessa, C. 2008: MTOR inhibitors in the treatment of cancer. Expert Opinion on Investigational Drugs 17(11): 1717-1734

Komotar, R.J.; Starke, R.M.; Connolly, E.S.; Sisti, M.B. 2011: MTOR inhibitors in the treatment of subependymal giant-cell astrocytomas associated with tuberous sclerosis. Neurosurgery 68(4): N24-N25

Kawada, J.-i.; Ito, Y.; Iwata, S.; Suzuki, M.; Kawano, Y.; Kanazawa, T.; Siddiquey, M.N.A.; Kimura, H. 2014: MTOR inhibitors induce cell-cycle arrest and inhibit tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 20(21): 5412-5422

Schedel, F.; Pries, R.; Thode, B.; Wollmann, B.; Wulff, S.; Jocham, D.; Wollenberg, B.; Kausch, I. 2011: MTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma. Oncology Reports 25(3): 763-768

Riaz, H.; Riaz, T.; Hussain, S.A. 2012: MTOR inhibitors: a novel class of anti-cancer agents. Infectious Agents and Cancer 7(1): 1

Wong, G.; Chapman, J.R.; Craig, J.C. 2012: MTOR inhibitors: a myth, a cure for cancer or something in between?. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 12(5): 1075-1076

Chumsri, S.; Sabnis, G.; Tkaczuk, K.; Brodie, A. 2014: MTOR inhibitors: changing landscape of endocrine-resistant breast cancer. Future Oncology 10(3): 443-456

Mavrommati, I.; Maffucci, T. 2011: MTOR inhibitors: facing new challenges ahead. Current Medicinal Chemistry 18(18): 2743-2762

Ravaud, A.; Bernhard, J.-C.; Gross-Goupil, M.; Digue, L.; Ferriere, J.-M. 2010: MTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma. Bulletin du Cancer 97: 45-51

Mabuchi, S.; Kawase, C.; Altomare, D.A.; Morishige, K.; Sawada, K.; Hayashi, M.; Tsujimoto, M.; Yamoto, M.; Klein-Szanto, A.J.; Schilder, R.J.; Ohmichi, M.; Testa, J.R.; Kimura, T. 2009: MTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 15(17): 5404-5413

Utomo, W.K.; Narayanan, V.; Biermann, K.; van Eijck, C.H.J.; Bruno, M.J.; Peppelenbosch, M.P.; Braat, H. 2014: MTOR is a promising therapeutical target in a subpopulation of pancreatic adenocarcinoma. Cancer Letters 346(2): 309-317

Schiewer, M.J.; Den, R.; Hoang, D.T.; Augello, M.A.; Lawrence, Y.R.; Dicker, A.P.; Knudsen, K.E. 2012: MTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer. Endocrine-Related Cancer 19(1): 1-12

Chou, S.-D.; Prince, T.; Gong, J.; Calderwood, S.K. 2012: MTOR is essential for the proteotoxic stress response, HSF1 activation and heat shock protein synthesis. Plos one 7(6): E39679

Krymskaya, V.P.; Snow, J.; Cesarone, G.; Khavin, I.; Goncharov, D.A.; Lim, P.N.; Veasey, S.C.; Ihida-Stansbury, K.; Jones, P.L.; Goncharova, E.A. 2011: MTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia. Faseb Journal: Official Publication of the Federation of American Societies for Experimental Biology 25(6): 1922-1933

Rodrik-Outmezguine, V.S.; Chandarlapaty, S.; Pagano, N.C.; Poulikakos, P.I.; Scaltriti, M.; Moskatel, E.; Baselga, Jé.; Guichard, S.; Rosen, N. 2011: MTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discovery 1(3): 248-259

Jiang, Q.; Weiss, J.M.; Back, T.; Chan, T.; Ortaldo, J.R.; Guichard, S.; Wiltrout, R.H. 2011: mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment. Cancer Research 71(12): 4074-4084

Grzybowska-Izydorczyk, O.; Smolewski, P. 2012: MTOR kinase inhibitors as a treatment strategy in hematological malignancies. Future Medicinal Chemistry 4(4): 487-504

Sun, S.-Y. 2013: MTOR kinase inhibitors as potential cancer therapeutic drugs. Cancer Letters 340(1): 1-8

Limon, J.J.; So, L.; Jellbauer, S.; Chiu, H.; Corado, J.; Sykes, S.M.; Raffatellu, M.; Fruman, D.A. 2014: MTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition. Proceedings of the National Academy of Sciences of the United States of America 111(47): E5076-E5085

Zhang, Y.; Bi, Y.; Yang, H.; Chen, X.; Liu, H.; Lu, Y.; Zhang, Z.; Liao, J.; Yang, S.; Chu, Y.; Yang, R.; Liu, G. 2014: MTOR limits the recruitment of CD11b+Gr1+Ly6Chigh myeloid-derived suppressor cells in protecting against murine immunological hepatic injury. Journal of Leukocyte Biology 95(6): 961-970

Yecies, J.L.; Manning, B.D. 2011: MTOR links oncogenic signaling to tumor cell metabolism. Journal of Molecular Medicine 89(3): 221-228

Zeidan, A.; Hunter, J.C.; Javadov, S.; Karmazyn, M. 2011: MTOR mediates RhoA-dependent leptin-induced cardiomyocyte hypertrophy. Molecular and Cellular Biochemistry 352(1-2): 99-108

Castilho, R.M.; Squarize, C.H.; Chodosh, L.A.; Williams, B.O.; Gutkind, J.S. 2009: MTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. Cell Stem Cell 5(3): 279-289

Wilson, S.M.; Barbone, D.; Yang, T.-M.; Jablons, D.M.; Bueno, R.; Sugarbaker, D.J.; Nishimura, S.L.; Gordon, G.J.; Broaddus, V.C. 2008: MTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids. American Journal of Respiratory Cell and Molecular Biology 39(5): 576-583

Xin-Long, C.; Zhao-Fan, X.; Dao-Feng, B.; Wei, D. 2011: MTOR partly mediates insulin resistance by phosphorylation of insulin receptor substrate-1 on serine(307) residues after burn. Burns: Journal of the International Society for Burn Injuries 37(1): 86-93

Zhao, C.; Vollrath, D. 2011: MTOR pathway activation in age-related retinal disease. Aging 3(4): 346-347

Pópulo, H.; Soares, P.; Faustino, A.; Rocha, A.S.; Silva, P.; Azevedo, F.; Lopes, J.M. 2011: MTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics. Pigment Cell and Melanoma Research 24(1): 254-257

Martín-Cano, F.E.; Camello-Almaraz, C.; Hernandez, D.; Pozo, M.J.; Camello, P.J. 2013: MTOR pathway and Ca²⁺ stores mobilization in aged smooth muscle cells. Aging 5(5): 339-346

Pócza, T.ím.; Sebestyén, A.; Turányi, E.; Krenács, T.; Márk, A.; Sticz, T.ás.B.él.; Jakab, Z.; Hauser, P.ét. 2014: MTOR pathway as a potential target in a subset of human medulloblastoma. Pathology Oncology Research: Por 20(4): 893-900

Francipane, M.Giovanna.; Lagasse, E. 2014: MTOR pathway in colorectal cancer: an update. Oncotarget 5(1): 49-66

Hanna, S.C.; Heathcote, S.A.; Kim, W.Y. 2008: MTOR pathway in renal cell carcinoma. Expert Review of Anticancer Therapy 8(2): 283-292

Pinto Marín, A.; Redondo Sánchez, A.és.; Espinosa Arranz, E.; Zamora Auñón, P.; Castelo Fernández, B.; González Barón, M. 2012: MTOR pathway inhibition in renal cell carcinoma. Urologic Oncology 30(4): 356-361

Wacheck, V. 2010: MTOR pathway inhibitors in cancer therapy: moving past rapamycin. Pharmacogenomics 11(9): 1189-1191

De Joussineau, C.; Sahut-Barnola, I.; Tissier, F.éd.ér.; Dumontet, T.; Drelon, C.; Batisse-Lignier, M.; Tauveron, I.; Pointud, J.-C.; Lefrançois-Martinez, A.-M.; Stratakis, C.A.; Bertherat, J.ér.ôm.; Val, P.; Martinez, A. 2014: MTOR pathway is activated by PKA in adrenocortical cells and participates in vivo to apoptosis resistance in primary pigmented nodular adrenocortical disease (PPNAD). Human Molecular Genetics 23(20): 5418-5428

Cui, J.; He, W.; Yi, B.; Zhao, H.; Lu, K.; Ruan, H.; Ma, D. 2014: MTOR pathway is involved in ADP-evoked astrocyte activation and ATP release in the spinal dorsal horn in a rat neuropathic pain model. Neuroscience 275: 395-403

Zarogoulidis, P.; Lampaki, S.; Turner, J.F.; Huang, H.; Kakolyris, S.; Syrigos, K.; Zarogoulidis, K. 2014: MTOR pathway: a current, up-to-date mini-review (Review). Oncology Letters 8(6): 2367-2370

Rosner, M.; Hengstschläger, M. 2011: MTOR protein localization is cell cycle-regulated. Cell Cycle 10(20): 3608-3610

Chen, X.; Cheng, H.; Pan, T.; Liu, Y.; Su, Y.; Ren, C.; Huang, D.; Zha, X.; Liang, C. 2015: MTOR regulate EMT through RhoA and Rac1 pathway in prostate cancer. Molecular Carcinogenesis 54(10): 1086-1095

Bi, Y.; Liu, G.; Yang, R. 2011: MTOR regulates T-cell differentiation and activation in immunity and autoimmunity. Critical Reviews in Eukaryotic Gene Expression 21(4): 313-322

Meng, Q.; Guo, H.; Xiao, L.; Cui, Y.; Guo, R.; Xiao, D.; Huang, Y. 2013: MTOR regulates TGF-β₂-induced epithelial-mesenchymal transition in cultured human lens epithelial cells. Graefe's Archive for Clinical and Experimental Ophthalmology 251(10): 2363-2370

Rosenbluth, J.M.; Pietenpol, J.A. 2009: MTOR regulates autophagy-associated genes downstream of p73. Autophagy 5(1): 114-116

Ka, M.; Condorelli, G.; Woodgett, J.R.; Kim, W.-Y. 2014: MTOR regulates brain morphogenesis by mediating GSK3 signaling. Development 141(21): 4076-4086

Vollenbröker, B.; George, B.; Wolfgart, M.; Saleem, M.A.; Pavenstädt, H.; Weide, T. 2009: MTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes. American Journal of Physiology. Renal Physiology 296(2): F418-F426

Cang, C.; Zhou, Y.; Navarro, B.; Seo, Y.-J.; Aranda, K.; Shi, L.; Battaglia-Hsu, S.; Nissim, I.; Clapham, D.E.; Ren, D. 2013: MTOR regulates lysosomal ATP-sensitive two-pore Na(+) channels to adapt to metabolic state. Cell 152(4): 778-790

Krajcovic, M.; Krishna, S.; Akkari, L.; Joyce, J.A.; Overholtzer, M. 2013: MTOR regulates phagosome and entotic vacuole fission. Molecular Biology of the Cell 24(23): 3736-3745

Ge, Y.; Wu, A.-L.; Warnes, C.; Liu, J.; Zhang, C.; Kawasome, H.; Terada, N.; Boppart, M.D.; Schoenherr, C.J.; Chen, J. 2009: MTOR regulates skeletal muscle regeneration in vivo through kinase-dependent and kinase-independent mechanisms. American Journal of Physiology. Cell Physiology 297(6): C1434-C1444

Laragione, T.; Gulko, P.ér.S. 2010: MTOR regulates the invasive properties of synovial fibroblasts in rheumatoid arthritis. Molecular Medicine 16(9-10): 352-358

Watanabe, K.; Ijiri, K.; Ohtsuki, T. 2014: MTOR regulates the nucleoplasmic diffusion of Xrn2 under conditions of heat stress. Febs Letters 588(18): 3454-3460

Hegner, B.ör.; Lange, M.; Kusch, A.; Essin, K.; Sezer, O.; Schulze-Lohoff, E.; Luft, F.C.; Gollasch, M.; Dragun, D. 2009: MTOR regulates vascular smooth muscle cell differentiation from human bone marrow-derived mesenchymal progenitors. Arteriosclerosis Thrombosis and Vascular Biology 29(2): 232-238

Chen, C.; Liu, Y.; Liu, Y.; Zheng, P. 2009: MTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Science Signaling 2(98): Ra75

March, H.N.; Winton, D.J. 2011: MTOR regulation by JNK: rescuing the starving intestinal cancer cell?. Gastroenterology 140(5): 1387-1391

Jung, C.H.; Ro, S.-H.; Cao, J.; Otto, N.M.; Kim, D.-H. 2010: MTOR regulation of autophagy. Febs Letters 584(7): 1287-1295

Matsumoto, K.; Arao, T.; Tanaka, K.; Kaneda, H.; Kudo, K.; Fujita, Y.; Tamura, D.; Aomatsu, K.; Tamura, T.; Yamada, Y.; Saijo, N.; Nishio, K. 2009: MTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. Cancer Research 69(18): 7160-7164

Huang, J.-J.; Lin, T.-Y. 2007: MTOR signal pathway and its inhibitors in antitumor therapy: a review. Ai Zheng 26(12): 1397-1403

Zheng, L.; Zhang, D.; Zhang, Y.; Wen, Y.; Wang, Y. 2014: MTOR signal transduction pathways contribute to TN-C FNIII A1 overexpression by mechanical stress in osteosarcoma cells. Molecules and Cells 37(2): 118-125

Takei, N.; Nawa, H. 2014: MTOR signaling and its roles in normal and abnormal brain development. Frontiers in Molecular Neuroscience 7: 28

Zhang, X.-Z.; Li, Z.-R.; Li, Y. 2013: MTOR signaling as a fuel sensor and its role in the regulation of energy homeostasis. Sheng Li Ke Xue Jin Zhan 44(5): 390-394

D'Antona, G.; Nisoli, E. 2010: MTOR signaling as a target of amino acid treatment of the age-related sarcopenia. Interdisciplinary Topics in Gerontology 37: 115-141

Laplante, M.; Sabatini, D.M. 2009: MTOR signaling at a glance. Journal of Cell Science 122(Part 20): 3589-3594

Phornphutkul, C.; Wu, K-Ying.; Auyeung, V.; Chen, Q.; Gruppuso, P.A. 2008: MTOR signaling contributes to chondrocyte differentiation. Developmental Dynamics: An Official Publication of the American Association of Anatomists 237(3): 702-712

Bergeron, Y.; Chagniel, L.; Bureau, Gève.; Massicotte, G.; Cyr, M. 2014: MTOR signaling contributes to motor skill learning in mice. Frontiers in Molecular Neuroscience 7: 26

Kim, J.G.; Horvath, T.L. 2012: MTOR signaling fades POMC neurons during aging. Neuron 75(3): 356-357

Ghosh, S.; Varela, L.; Sood, A.; Park, B.Ho.; Lotan, T.L. 2013: MTOR signaling feedback modulates mammary epithelial differentiation and restrains invasion downstream of PTEN loss. Cancer Research 73(16): 5218-5231

Liu, Y.; Zhang, D.-t.; Liu, X.-g. 2015: MTOR signaling in T cell immunity and autoimmunity. International Reviews of Immunology 34(1): 50-66

Inoki, K. 2014: MTOR signaling in autophagy regulation in the kidney. Seminars in Nephrology 34(1): 2-8

Zhou, H.; Huang, S. 2010: MTOR signaling in cancer cell motility and tumor metastasis. Critical Reviews in Eukaryotic Gene Expression 20(1): 1-16

Cao, R.; Li, A.; Cho, H.-Y. 2009: MTOR signaling in epileptogenesis: too much of a good thing?. Journal of Neuroscience: the Official Journal of the Society for Neuroscience 29(40): 12372-12373

Akhavan, D.; Cloughesy, T.F.; Mischel, P.S. 2010: MTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro-Oncology 12(8): 882-889

Fouraschen, S.M.; de Ruiter, P.E.; Kwekkeboom, J.; de Bruin, R.W.; Kazemier, G.; Metselaar, H.J.; Tilanus, H.W.; van der Laan, L.J.; de Jonge, J. 2013: MTOR signaling in liver regeneration: Rapamycin combined with growth factor treatment. World Journal of Transplantation 3(3): 36-47

Kristof, A.S. 2010: MTOR signaling in lymphangioleiomyomatosis. Lymphatic Research and Biology 8(1): 33-42

Conn, C.S.; Qian, S.-B. 2011: MTOR signaling in protein homeostasis: less is more?. Cell Cycle 10(12): 1940-1947

Adhikari, D.; Liu, K. 2010: MTOR signaling in the control of activation of primordial follicles. Cell Cycle 9(9): 1673-1674

Xie, L.; Sun, F.; Wang, J.; Mao, X.; Xie, L.; Yang, S.-H.; Su, D.-M.; Simpkins, J.W.; Greenberg, D.A.; Jin, K. 2014: MTOR signaling inhibition modulates macrophage/microglia-mediated neuroinflammation and secondary injury via regulatory T cells after focal ischemia. Journal of Immunology 192(12): 6009-6019

Chen, W.; Drakos, E.; Grammatikakis, I.; Schlette, E.J.; Li, J.; Leventaki, V.; Staikou-Drakopoulou, E.; Patsouris, E.; Panayiotidis, P.; Medeiros, L.J.; Rassidakis, G.Z. 2010: MTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells. Molecular Cancer 9: 292

Zhang, Y.-J.; Bao, Y.-J.; Dai, Q.; Yang, W.-Y.; Cheng, P.; Zhu, L.-M.; Wang, B.-J.; Jiang, F.-H. 2011: MTOR signaling is involved in indomethacin and nimesulide suppression of colorectal cancer cell growth via a COX-2 independent pathway. Annals of Surgical Oncology 18(2): 580-588

Gomez-Pinillos, A.; Ferrari, A.C. 2012: MTOR signaling pathway and mTOR inhibitors in cancer therapy. Hematology/Oncology Clinics of North America 26(3): 483-505 Vii

Ferrandiz-Pulido, C.; Masferrer, E.; Toll, A.; Hernandez-Losa, J.; Mojal, S.; Pujol, R.M.; Ramon y Cajal, S.; de Torres, I.; Garcia-Patos, V. 2013: MTOR signaling pathway in penile squamous cell carcinoma: pmTOR and peIF4E over expression correlate with aggressive tumor behavior. Journal of Urology 190(6): 2288-2295

Zhang, Y.-J.; Dai, Q.; Sun, D.-F.; Xiong, H.; Tian, X.-Q.; Gao, F.-H.; Xu, M.-H.; Chen, G.-Q.; Han, Z.-G.; Fang, J.-Y. 2009: MTOR signaling pathway is a target for the treatment of colorectal cancer. Annals of Surgical Oncology 16(9): 2617-2628

Cheekatla, S.S.; Aggarwal, A.; Naik, S. 2012: MTOR signaling pathway regulates the IL-12/IL-10 axis in Leishmania donovani infection. Medical Microbiology and Immunology 201(1): 37-46

Raman, N.; Nayak, A.; Muller, S. 2014: MTOR signaling regulates nucleolar targeting of the SUMO-specific isopeptidase SENP3. Molecular and Cellular Biology 34(24): 4474-4484

Ogasawara, R.; Kobayashi, K.; Tsutaki, A.; Lee, K.; Abe, T.; Fujita, S.; Nakazato, K.; Ishii, N. 2013: MTOR signaling response to resistance exercise is altered by chronic resistance training and detraining in skeletal muscle. Journal of Applied Physiology 114(7): 934-940

Watanabe, R.; Wei, L.; Huang, J. 2011: MTOR signaling, function, novel inhibitors, and therapeutic targets. Journal of Nuclear Medicine: Official Publication Society of Nuclear Medicine 52(4): 497-500

Sun, Y.; Chen, J. 2008: MTOR signaling: PLD takes center stage. Cell Cycle 7(20): 3118-3123

Fernandez, D.; Perl, A. 2010: MTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus?. Discovery Medicine 9(46): 173-178

Hoeffer, C.A.; Klann, E. 2010: MTOR signaling: at the crossroads of plasticity, memory and disease. Trends in Neurosciences 33(2): 67-75

Petroulakis, E.; Mamane, Y.; Le Bacquer, O.; Shahbazian, D.; Sonenberg, N. 2007: MTOR signaling: implications for cancer and anticancer therapy. British Journal of Cancer 96 Suppl: R11-R15

Peter, C.; Waldmann, H.; Cobbold, S.P. 2010: MTOR signalling and metabolic regulation of T cell differentiation. Current Opinion in Immunology 22(5): 655-661

Albanell, J.; Dalmases, A.; Rovira, A.; Rojo, F. 2007: MTOR signalling in human cancer. Clinical and Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 9(8): 484-493

Land, S.C.; Scott, C.L.; Walker, D. 2014: MTOR signalling, embryogenesis and the control of lung development. Seminars in Cell and Developmental Biology 36: 68-78

Yang, Z.; Ming, X.-F. 2012: MTOR signalling: the molecular interface connecting metabolic stress, aging and cardiovascular diseases. Obesity Reviews: An Official Journal of the International Association for the Study of Obesity 13(Suppl 2): 58-68

Zhou, J.; Su, P.; Wang, L.; Chen, J.; Zimmermann, M.; Genbacev, O.; Afonja, O.; Horne, M.C.; Tanaka, T.; Duan, E.; Fisher, S.J.; Liao, J.; Chen, J.; Wang, F. 2009: MTOR supports long-term self-renewal and suppresses mesoderm and endoderm activities of human embryonic stem cells. Proceedings of the National Academy of Sciences of the United States of America 106(19): 7840-7845

Weiler, M.; Blaes, J.; Pusch, S.; Sahm, F.; Czabanka, M.; Luger, S.; Bunse, L.; Solecki, G.; Eichwald, V.; Jugold, M.; Hodecker, S.; Osswald, M.; Meisner, C.; Hielscher, T.; Rübmann, P.; Pfenning, P.-N.; Ronellenfitsch, M.; Kempf, T.; Schnölzer, M.; Abdollahi, A.; Lang, F.; Bendszus, M.; von Deimling, A.; Winkler, F.; Weller, M.; Vajkoczy, P.; Platten, M.; Wick, W. 2014: MTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proceedings of the National Academy of Sciences of the United States of America 111(1): 409-414

Zha, X.; Sun, Q.; Zhang, H. 2011: MTOR upregulation of glycolytic enzymes promotes tumor development. Cell Cycle 10(7): 1015-1016

Hands, S.L.; Proud, C.G.; Wyttenbach, A. 2009: MTOR's role in ageing: protein synthesis or autophagy?. Aging 1(7): 586-597

Nazio, F.; Cecconi, F. 2013: MTOR, AMBRA1, and autophagy: an intricate relationship. Cell Cycle 12(16): 2524-2525

Chotechuang, N.; Azzout-Marniche, D.; Bos, C.éc.; Chaumontet, C.; Gausserès, N.; Steiler, T.; Gaudichon, C.; Tomé, D. 2009: MTOR, AMPK, and GCN2 coordinate the adaptation of hepatic energy metabolic pathways in response to protein intake in the rat. American Journal of Physiology. Endocrinology and Metabolism 297(6): E1313-E1323

Annovazzi, L.; Mellai, M.; Caldera, V.; Valente, G.; Tessitore, L.; Schiffer, D. 2009: MTOR, S6 and AKT expression in relation to proliferation and apoptosis/autophagy in glioma. Anticancer Research 29(8): 3087-3094

Tang, B.Luen. 2013: MTOR, autophagy, and reprogramming. Frontiers in Cell and Developmental Biology 1: 4

Geissler, E.K.; Schlitt, H.J.; Thomas, G. 2008: MTOR, cancer and transplantation. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 8(11): 2212-2218

Julien, L.-A.é; Roux, P.P. 2010: MTOR, the mammalian target of rapamycin. Medecine Sciences: M/S 26(12): 1056-1060

Cheng, S.-C.; Quintin, J.; Cramer, R.A.; Shepardson, K.M.; Saeed, S.; Kumar, V.; Giamarellos-Bourboulis, E.J.; Martens, J.H.A.; Rao, N.A.; Aghajanirefah, A.; Manjeri, G.R.; Li, Y.; Ifrim, D.C.; Arts, R.J.W.; van der Veer, B.M.J.W.; van der Meer, B.M.J.W.; Deen, P.M.T.; Logie, C.; O'Neill, L.A.; Willems, P.; van de Veerdonk, F.L.; van der Meer, J.W.M.; Ng, A.; Joosten, L.A.B.; Wijmenga, C.; Stunnenberg, H.G.; Xavier, R.J.; Netea, M.G. 2014: MTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science 345(6204): 1250684

Decuypere, J.-P.; Kindt, D.; Luyten, T.; Welkenhuyzen, K.; Missiaen, L.; De Smedt, H.; Bultynck, G.; Parys, J.B. 2013: MTOR-Controlled Autophagy Requires Intracellular Ca(2+) Signaling. Plos one 8(4): E61020

Evren, S.; Dermen, A.; Lockwood, G.; Fleshner, N.; Sweet, J. 2011: MTOR-RAPTOR and 14-3-3σ immunohistochemical expression in high grade prostatic intraepithelial neoplasia and prostatic adenocarcinomas: a tissue microarray study. Journal of Clinical Pathology 64(8): 683-688

Ge, W.; Ren, J. 2012: MTOR-STAT3-notch signalling contributes to ALDH2-induced protection against cardiac contractile dysfunction and autophagy under alcoholism. Journal of Cellular and Molecular Medicine 16(3): 616-626

Dasanu, C.A.; Clark, B.A.; Alexandrescu, D.T. 2009: MTOR-blocking agents in advanced renal cancer: an emerging therapeutic option. Expert Opinion on Investigational Drugs 18(2): 175-187

Hung, C.-M.; Garcia-Haro, L.; Sparks, C.A.; Guertin, D.A. 2012: MTOR-dependent cell survival mechanisms. Cold Spring Harbor Perspectives in Biology 4(12)

Li, Z.; Xu, G.; Li, Y.; Zhao, J.; Mulholland, M.W.; Zhang, W. 2012: MTOR-dependent modulation of gastric nesfatin-1/NUCB2. Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology Biochemistry and Pharmacology 29(3-4): 493-500

Denis, J.ér.ôm.A.; Gauthier, M.; Rachdi, L.; Aubert, S.; Giraud-Triboult, K.; Poydenot, P.; Benchoua, A.; Champon, B.; Maury, Y.; Baldeschi, C.; Scharfmann, R.; Piétu, G.èv.; Peschanski, M.; Martinat, C.éc. 2013: MTOR-dependent proliferation defect in human ES-derived neural stem cells affected by myotonic dystrophy type 1. Journal of Cell Science 126(Part 8): 1763-1772

Liu, J.; Stevens, P.D.; Gao, T. 2011: MTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells. Journal of Biological Chemistry 286(8): 6510-6520

Li, N.; Lee, B.; Liu, R.-J.; Banasr, M.; Dwyer, J.M.; Iwata, M.; Li, X.-Y.; Aghajanian, G.; Duman, R.S. 2010: MTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329(5994): 959-964

Vikhreva, P.N.; Shepelev, M.V.; Korobko, I.V. 2014: MTOR-dependent transcriptional repression of Pdcd4 tumor suppressor in lung cancer cells. Biochimica et Biophysica Acta 1839(1): 43-49

Zhang, Y.; Zheng, X.F.S. 2012: MTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. Cell Cycle 11(3): 594-603

Gerullis, H.; Ecke, T.H.; Eimer, C.; Heuck, C.J.; Otto, T. 2010: MTOR-inhibition in metastatic renal cell carcinoma. Focus on temsirolimus: a review. Minerva Urologica e Nefrologica 62(4): 411-423

Debing, Y.; Neyts, J. 2014: MTOR-inhibitors may aggravate chronic hepatitis E. Journal of Hepatology 61(4): 720-722

Easley, C.A.; Ben-Yehudah, A.; Redinger, C.J.; Oliver, S.L.; Varum, S.T.; Eisinger, V.M.; Carlisle, D.L.; Donovan, P.J.; Schatten, G.P. 2010: MTOR-mediated activation of p70 S6K induces differentiation of pluripotent human embryonic stem cells. Cellular Reprogramming 12(3): 263-273

Zhao, C.; Yasumura, D.; Li, X.; Matthes, M.; Lloyd, M.; Nielsen, G.; Ahern, K.; Snyder, M.; Bok, D.; Dunaief, J.L.; LaVail, M.M.; Vollrath, D. 2011: MTOR-mediated dedifferentiation of the retinal pigment epithelium initiates photoreceptor degeneration in mice. Journal of Clinical Investigation 121(1): 369-383

Wang, S.; Zhou, S.-l.; Min, F.-y.; Ma, J.-j.; Shi, X.-j.; Bereczki, E.; Wu, J. 2014: MTOR-mediated hyperphosphorylation of tau in the hippocampus is involved in cognitive deficits in streptozotocin-induced diabetic mice. Metabolic Brain Disease 29(3): 729-736

Menendez, J.A.; Vellon, L.; Oliveras-Ferraros, C.; Cufí, Sílvia.; Vazquez-Martin, A. 2011: MTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: a roadmap from energy metabolism to stem cell renewal and aging. Cell Cycle 10(21): 3658-3677

Zhang, Z.; Zhang, G.; Xu, X.; Su, W.; Yu, B. 2012: MTOR-rictor is the Ser473 kinase for AKT1 in mouse one-cell stage embryos. Molecular and Cellular Biochemistry 361(1-2): 249-257

Kim, J.Eun.; He, Q.; Chen, Y.; Shi, C.; Yu, K. 2014: MTOR-targeted therapy: differential perturbation to mitochondrial membrane potential and permeability transition pore plays a role in therapeutic response. Biochemical and Biophysical Research Communications 447(1): 184-191

Contreras, A.G.; Dormond, O.; Edelbauer, M.; Calzadilla, K.; Hoerning, A.; Pal, S.; Briscoe, D.M. 2008: MTOR-understanding the clinical effects. Transplantation Proceedings 40(10 Suppl): S9

Hall, M.N. 2008: MTOR-what does it do?. Transplantation Proceedings 40(10 Suppl): S5-S8

Völkers, M.; Sussman, M. 2013: MTOR/PRAS40 interaction: hypertrophy or proliferation. Cell Cycle 12(23): 3579-3580

Pastor, Mía.Dolores.; García-Yébenes, I.; Fradejas, N.; Pérez-Ortiz, Jé.Manuel.; Mora-Lee, S.; Tranque, P.; Moro, Mía.Angeles.; Pende, M.; Calvo, S. 2009: MTOR/S6 kinase pathway contributes to astrocyte survival during ischemia. Journal of Biological Chemistry 284(33): 22067-22078

Yamnik, R.L.; Holz, M.K. 2010: MTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor alpha serine 167 phosphorylation. Febs Letters 584(1): 124-128

Rossi, G.; Cavazza, A.; Graziano, P.; Papotti, M. 2012: MTOR/p70S6K in diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. American Journal of Respiratory and Critical Care Medicine 185(3): 341; Author Reply 341-2

Zhou, Q.; Deng, Z.; Zhu, Y.; Long, H.; Zhang, S.; Zhao, J. 2010: MTOR/p70S6K signal transduction pathway contributes to osteosarcoma progression and patients' prognosis. Medical Oncology 27(4): 1239-1245

Datan, E.; Shirazian, A.; Benjamin, S.; Matassov, D.; Tinari, A.; Malorni, W.; Lockshin, R.A.; Garcia-Sastre, A.; Zakeri, Z. 2014: MTOR/p70S6K signaling distinguishes routine, maintenance-level autophagy from autophagic cell death during influenza a infection. Virology 452-453: 175-190

Yu, H.-y.; Ma, D.-c.; Lin, D.; Sun, Y.-h.; Tao, S.-y. 2012: MTOR/p70s6k signaling pathway is involved in megakaryocyte polyploidization. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 28(1): 21-24

Wood, T.L.; Bercury, K.K.; Cifelli, S.E.; Mursch, L.E.; Min, J.; Dai, J.; Macklin, W.B. 2013: MTOR: a link from the extracellular milieu to transcriptional regulation of oligodendrocyte development. Asn Neuro 5(1): E00108

Rodriguez, F.J.; Raabe, E.H. 2014: MTOR: a new therapeutic target for pediatric low-grade glioma?. Cns Oncology 3(2): 89-91

Gouras, G.K. 2013: MTOR: at the crossroads of aging, chaperones, and Alzheimer's disease. Journal of Neurochemistry 124(6): 747-748

Goberdhan, D.C.I.; Boyd, C.A.R. 2009: MTOR: dissecting regulation and mechanism of action to understand human disease. Biochemical Society Transactions 37(Part 1): 213-216

Zhang, Y.; Zhang, T.; Cao, C.-M.; Xiao, R.-P. 2012: MTOR: good, bad, or ugly?. Cardiovascular Research 95(3): 261-262

Child, N.D.; Benarroch, E.E. 2014: MTOR: its role in the nervous system and involvement in neurologic disease. Neurology 83(17): 1562-1572

Widlund, A.L.; Baur, J.A.; Vang, O. 2013: MTOR: more targets of resveratrol?. Expert Reviews in Molecular Medicine 15: E10

Delgoffe, G.M.; Powell, J.D. 2009: MTOR: taking cues from the immune microenvironment. Immunology 127(4): 459-465

Cohen, E.E.W. 2008: MTOR: the mammalian target of replication. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 26(3): 348-349

Wick, W.; Blaes, J.; Weiler, M. 2011: MTORC 2:1 for chemotherapy sensitization in glioblastoma. Cancer Discovery 1(6): 475-476

Gorre, N.; Adhikari, D.; Lindkvist, R.; Brännström, M.; Liu, K.; Shen, Y. 2014: MTORC1 Signaling in oocytes is dispensable for the survival of primordial follicles and for female fertility. Plos one 9(10): E110491

Laplante, M.; Sabatini, D.M. 2010: MTORC1 activates SREBP-1c and uncouples lipogenesis from gluconeogenesis. Proceedings of the National Academy of Sciences of the United States of America 107(8): 3281-3282

Bowers, D.C.; Kucejova, B.; Margraf, L.; Gargan, L.; Brugarolas, J. 2011: MTORC1 activation in childhood ependymoma and response to sirolimus. Journal of Neuro-Oncology 103(3): 797-801

Inoki, K.; Mori, H.; Wang, J.; Suzuki, T.; Hong, S.; Yoshida, S.; Blattner, S.M.; Ikenoue, T.; Rüegg, M.A.; Hall, M.N.; Kwiatkowski, D.J.; Rastaldi, M.P.; Huber, T.B.; Kretzler, M.; Holzman, L.B.; Wiggins, R.C.; Guan, K.-L. 2011: MTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. Journal of Clinical Investigation 121(6): 2181-2196

Balcazar, N.; Sathyamurthy, A.; Elghazi, L.; Gould, A.; Weiss, A.; Shiojima, I.; Walsh, K.; Bernal-Mizrachi, E. 2009: MTORC1 activation regulates beta-cell mass and proliferation by modulation of cyclin D2 synthesis and stability. Journal of Biological Chemistry 284(12): 7832-7842

McCarty, M.F. 2011: mTORC1 activity as a determinant of cancer risk--rationalizing the cancer-preventive effects of adiponectin, metformin, rapamycin, and low-protein vegan diets. Medical Hypotheses 77(4): 642-648

Martin, T.D.; Dennis, M.D.; Gordon, B.S.; Kimball, S.R.; Jefferson, L.S. 2014: MTORC1 and JNK coordinate phosphorylation of the p70S6K1 autoinhibitory domain in skeletal muscle following functional overloading. American Journal of Physiology. Endocrinology and Metabolism 306(12): E1397-E1405

Fan, W.; Cheng, K.; Qin, X.; Narsinh, K.H.; Wang, S.; Hu, S.; Wang, Y.; Chen, Y.; Wu, J.C.; Xiong, L.; Cao, F. 2013: MTORC1 and mTORC2 play different roles in the functional survival of transplanted adipose-derived stromal cells in hind limb ischemic mice via regulating inflammation in vivo. Stem Cells 31(1): 203-214

Hasty, P.; Sharp, Z.D.; Curiel, T.J.; Campisi, J. 2013: MTORC1 and p53: clash of the gods?. Cell Cycle 12(1): 20-25

Tartarin, P.; Froment, P. 2013: MTORC1 and sirolimus: a link with fertility. Medecine Sciences: M/S 29(2): 200-205

Adegoke, O.A.J.; Abdullahi, A.; Tavajohi-Fini, P. 2012: MTORC1 and the regulation of skeletal muscle anabolism and mass. Applied Physiology Nutrition and Metabolism 37(3): 395-406

Norrmén, C.; Figlia, G.; Lebrun-Julien, F.éd.ér.; Pereira, J.A.; Trötzmüller, M.; Köfeler, H.C.; Rantanen, V.; Wessig, C.; van Deijk, A.-L.F.; Smit, A.B.; Verheijen, M.H.G.; Rüegg, M.A.; Hall, M.N.; Suter, U. 2014: MTORC1 controls PNS myelination along the mTORC1-RXRγ-SREBP-lipid biosynthesis axis in Schwann cells. Cell Reports 9(2): 646-660

Morita, M.; Gravel, S-Pierre.; Chénard, Vérie.; Sikström, K.; Zheng, L.; Alain, T.; Gandin, V.; Avizonis, D.; Arguello, M.; Zakaria, C.; McLaughlan, S.; Nouet, Y.; Pause, A.; Pollak, M.; Gottlieb, E.; Larsson, O.; St-Pierre, J.; Topisirovic, I.; Sonenberg, N. 2013: MTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metabolism 18(5): 698-711

Tan, C.Y.; Hagen, T. 2013: MTORC1 dependent regulation of REDD1 protein stability. Plos one 8(5): E63970

Michels, A.A.; Robitaille, A.M.; Buczynski-Ruchonnet, D.; Hodroj, W.; Reina, J.H.; Hall, M.N.; Hernandez, N. 2010: MTORC1 directly phosphorylates and regulates human MAF1. Molecular and Cellular Biology 30(15): 3749-3757

Bhaskar, P.T.; Nogueira, V.; Patra, K.C.; Jeon, S.-M.; Park, Y.; Robey, R.B.; Hay, N. 2009: MTORC1 hyperactivity inhibits serum deprivation-induced apoptosis via increased hexokinase Ii and GLUT1 expression, sustained Mcl-1 expression, and glycogen synthase kinase 3beta inhibition. Molecular and Cellular Biology 29(18): 5136-5147

Giovannini, M.; Bonne, N.-X.; Vitte, J.; Chareyre, F.; Tanaka, K.; Adams, R.; Fisher, L.M.; Valeyrie-Allanore, L.; Wolkenstein, P.; Goutagny, S.; Kalamarides, M. 2014: MTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma. Neuro-Oncology 16(4): 493-504

Elkabets, M.; Vora, S.; Juric, D.; Morse, N.; Mino-Kenudson, M.; Muranen, T.; Tao, J.; Campos, A.B.; Rodon, J.; Ibrahim, Y.H.; Serra, V.; Rodrik-Outmezguine, V.; Hazra, S.; Singh, S.; Kim, P.; Quadt, C.; Liu, M.; Huang, A.; Rosen, N.; Engelman, J.A.; Scaltriti, M.; Baselga, J.é 2013: MTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. Science Translational Medicine 5(196): 196ra99

Thiem, S.; Pierce, T.P.; Palmieri, M.; Putoczki, T.L.; Buchert, M.; Preaudet, A.; Farid, R.O.; Love, C.; Catimel, B.; Lei, Z.; Rozen, S.; Gopalakrishnan, V.; Schaper, F.; Hallek, M.; Boussioutas, A.; Tan, P.; Jarnicki, A.; Ernst, M. 2013: MTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice. Journal of Clinical Investigation 123(2): 767-781

Soliman, G.A.; Acosta-Jaquez, H.A.; Fingar, D.C. 2010: MTORC1 inhibition via rapamycin promotes triacylglycerol lipolysis and release of free fatty acids in 3T3-L1 adipocytes. Lipids 45(12): 1089-1100

Pachow, D.; Andrae, N.; Kliese, N.; Angenstein, F.; Stork, O.; Wilisch-Neumann, A.; Kirches, E.; Mawrin, C. 2013: MTORC1 inhibitors suppress meningioma growth in mouse models. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 19(5): 1180-1189

Preitschopf, A.; Li, K.; Schörghofer, D.; Kinslechner, K.; Schütz, B.; Thi Thanh Pham, H.; Rosner, M.; Joo, G.J.; Röhrl, C.; Weichhart, T.; Stangl, H.; Lubec, G.; Hengstschläger, M.; Mikula, M. 2014: MTORC1 is essential for early steps during Schwann cell differentiation of amniotic fluid stem cells and regulates lipogenic gene expression. Plos one 9(9): E107004

Hoshii, T.; Tadokoro, Y.; Naka, K.; Ooshio, T.; Muraguchi, T.; Sugiyama, N.; Soga, T.; Araki, K.; Yamamura, K.-I.; Hirao, A. 2012: MTORC1 is essential for leukemia propagation but not stem cell self-renewal. Journal of Clinical Investigation 122(6): 2114-2129

Wang, W.; Liu, J.; Ma, A.; Miao, R.; Jin, Y.; Zhang, H.; Xu, K.; Wang, C.; Wang, J. 2014: MTORC1 is involved in hypoxia-induced pulmonary hypertension through the activation of Notch3. Journal of Cellular Physiology 229(12): 2117-2125

Qian, S.-B.; Zhang, X.; Sun, J.; Bennink, J.R.; Yewdell, J.W.; Patterson, C. 2010: MTORC1 links protein quality and quantity control by sensing chaperone availability. Journal of Biological Chemistry 285(35): 27385-27395

Grahammer, F.; Haenisch, N.; Steinhardt, F.; Sandner, L.; Sander, L.; Roerden, M.; Arnold, F.; Cordts, T.; Wanner, N.; Reichardt, W.; Kerjaschki, D.; Ruegg, M.A.; Hall, M.N.; Moulin, P.; Busch, H.; Boerries, M.; Walz, G.; Artunc, F.; Huber, T.B. 2014: MTORC1 maintains renal tubular homeostasis and is essential in response to ischemic stress. Proceedings of the National Academy of Sciences of the United States of America 111(27): E2817-E2826

Chan, E.Y. 2009: MTORC1 phosphorylates the ULK1-mAtg13-FIP200 autophagy regulatory complex. Science Signaling 2(84): Pe51

Tang, H.; Inoki, K.; Lee, M.; Wright, E.; Khuong, A.; Khuong, A.; Sugiarto, S.; Garner, M.; Paik, J.; DePinho, R.A.; Goldman, D.; Guan, K.-L.; Shrager, J.B. 2014: MTORC1 promotes denervation-induced muscle atrophy through a mechanism involving the activation of FoxO and E3 ubiquitin ligases. Science Signaling 7(314): Ra18

Mills, J.R.; Hippo, Y.; Robert, F.; Chen, S.M.H.; Malina, A.; Lin, C-Ju.; Trojahn, U.; Wendel, H-Guido.; Charest, A.; Bronson, R.T.; Kogan, S.C.; Nadon, R.; Housman, D.E.; Lowe, S.W.; Pelletier, J. 2008: MTORC1 promotes survival through translational control of Mcl-1. Proceedings of the National Academy of Sciences of the United States of America 105(31): 10853-10858

Finlay, D.K. 2013: MTORC1 regulates CD8+ T-cell glucose metabolism and function independently of PI3K and PKB. Biochemical Society Transactions 41(2): 681-686

Anonymous 2013: MTORC1 regulates glutamine metabolism. Cancer discovery 3(7): OF25

Proud, C.G. 2013: MTORC1 regulates the efficiency and cellular capacity for protein synthesis. Biochemical Society Transactions 41(4): 923-926

Zoncu, R.; Bar-Peled, L.; Efeyan, A.; Wang, S.; Sancak, Y.; Sabatini, D.M. 2011: MTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase. Science 334(6056): 678-683

Buel, G.R.; Kim, S.G.; Blenis, J. 2013: MTORC1 signaling aids in CADalyzing pyrimidine biosynthesis. Cell Metabolism 17(5): 633-635

Blandino-Rosano, M.; Chen, A.Y.; Scheys, J.O.; Alejandro, E.U.; Gould, A.P.; Taranukha, T.; Elghazi, L.; Cras-Méneur, C.; Bernal-Mizrachi, E. 2012: MTORC1 signaling and regulation of pancreatic β-cell mass. Cell Cycle 11(10): 1892-1902

Chen, J.; Long, F. 2014: MTORC1 signaling controls mammalian skeletal growth through stimulation of protein synthesis. Development 141(14): 2848-2854

Iadevaia, V.; Liu, R.; Proud, C.G. 2014: MTORC1 signaling controls multiple steps in ribosome biogenesis. Seminars in Cell and Developmental Biology 36: 113-120

Gan, B.; DePinho, R.A. 2009: MTORC1 signaling governs hematopoietic stem cell quiescence. Cell Cycle 8(7): 1003-1006

Santini, E.; Valjent, E.; Fisone, G. 2010: MTORC1 signaling in Parkinson's disease and L-DOPA-induced dyskinesia: a sensitized matter. Cell Cycle 9(14): 2713-2718

Cam, H.; Easton, J.B.; High, A.; Houghton, P.J. 2010: MTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1α. Molecular Cell 40(4): 509-520

Proud, C.G. 2009: MTORC1 signalling and mRNA translation. Biochemical Society Transactions 37(Pt 1): 227-231

Flinn, R.J.; Backer, J.M. 2010: MTORC1 signals from late endosomes: taking a TOR of the endocytic system. Cell Cycle 9(10): 1869-1870

Kelsey, I.; Manning, B.D. 2013: MTORC1 status dictates tumor response to targeted therapeutics. Science Signaling 6(294): Pe31

Hartman, N.W.; Lin, T.V.; Zhang, L.; Paquelet, G.E.; Feliciano, D.M.; Bordey, Aélique. 2013: MTORC1 targets the translational repressor 4E-BP2, but not S6 kinase 1/2, to regulate neural stem cell self-renewal in vivo. Cell Reports 5(2): 433-444

Lee, P-Shun.; Wilhelmson, A.S.K.; Hubner, A.P.; Reynolds, S.B.; Gallacchi, D.A.; Chiou, T.T.; Kwiatkowski, D.J. 2010: MTORC1-S6K activation by endotoxin contributes to cytokine up-regulation and early lethality in animals. Plos one 5(12): E14399

Julien, L.-A.; Carriere, A.; Moreau, J.; Roux, P.P. 2010: MTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Molecular and Cellular Biology 30(4): 908-921

Gan, B.; Sahin, E.ün.; Jiang, S.; Sanchez-Aguilera, A.; Scott, K.L.; Chin, L.; Williams, D.A.; Kwiatkowski, D.J.; DePinho, R.A. 2008: MTORC1-dependent and -independent regulation of stem cell renewal, differentiation, and mobilization. Proceedings of the National Academy of Sciences of the United States of America 105(49): 19384-19389

Donnelly, R.P.; Loftus, Róisín.M.; Keating, Séad.E.; Liou, K.T.; Biron, C.A.; Gardiner, C.M.; Finlay, D.K. 2014: MTORC1-dependent metabolic reprogramming is a prerequisite for NK cell effector function. Journal of Immunology 193(9): 4477-4484

Workman, E.R.; Niere, F.; Raab-Graham, K.F. 2013: MTORC1-dependent protein synthesis underlying rapid antidepressant effect requires GABABR signaling. Neuropharmacology 73: 192-203

Fort, P.E.; Losiewicz, M.K.; Pennathur, S.; Jefferson, L.S.; Kimball, S.R.; Abcouwer, S.F.; Gardner, T.W. 2014: MTORC1-independent reduction of retinal protein synthesis in type 1 diabetes. Diabetes 63(9): 3077-3090

Dowling, R.J.O.; Topisirovic, I.; Alain, T.; Bidinosti, M.; Fonseca, B.D.; Petroulakis, E.; Wang, X.; Larsson, O.; Selvaraj, A.; Liu, Y.; Kozma, S.C.; Thomas, G.; Sonenberg, N. 2010: MTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 328(5982): 1172-1176

Belibi, F.; Ravichandran, K.; Zafar, I.; He, Z.; Edelstein, C.L. 2011: MTORC1/2 and rapamycin in female Han:SPRD rats with polycystic kidney disease. American Journal of Physiology. Renal Physiology 300(1): F236-F244

Wilson-Edell, K.A.; Yevtushenko, M.A.; Rothschild, D.E.; Rogers, A.N.; Benz, C.C. 2014: MTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms. Breast Cancer Research and Treatment 144(2): 287-298

Benjamin, D.; Hall, M.N. 2014: MTORC1: turning off is just as important as turning on. Cell 156(4): 627-628

Masui, K.; Cavenee, W.K.; Mischel, P.S. 2014: MTORC2 dictates Warburg effect and drug resistance. Cell Cycle 13(7): 1053-1054

Masui, K.; Cavenee, W.K.; Mischel, P.S. 2014: MTORC2 in the center of cancer metabolic reprogramming. Trends in Endocrinology and Metabolism: Tem 25(7): 364-373

Yan, L.; Mieulet, V.; Lamb, R.F. 2008: MTORC2 is the hydrophobic motif kinase for SGK1. Biochemical Journal 416(3): E19-E21

Li, X.; Gao, T. 2014: MTORC2 phosphorylates protein kinase Cζ to regulate its stability and activity. Embo Reports 15(2): 191-198

Zhou, Y.; Wang, D.; Gao, X.; Lew, K.; Richards, A.M.; Wang, P. 2014: MTORC2 phosphorylation of Akt1: a possible mechanism for hydrogen sulfide-induced cardioprotection. Plos one 9(6): E99665

Moore, S.F.; Hunter, R.W.; Hers, I. 2011: MTORC2 protein complex-mediated Akt (Protein Kinase B) Serine 473 Phosphorylation is not required for Akt1 activity in human platelets [corrected. Journal of Biological Chemistry 286(28): 24553-24560

Dada, S.; Demartines, N.; Dormond, O. 2008: MTORC2 regulates PGE2-mediated endothelial cell survival and migration. Biochemical and Biophysical Research Communications 372(4): 875-879

Sen, B.; Xie, Z.; Case, N.; Thompson, W.R.; Uzer, G.; Styner, M.; Rubin, J. 2014: MTORC2 regulates mechanically induced cytoskeletal reorganization and lineage selection in marrow-derived mesenchymal stem cells. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 29(1): 78-89

Liu, L.; Das, S.; Losert, W.; Parent, C.A. 2010: MTORC2 regulates neutrophil chemotaxis in a cAMP- and RhoA-dependent fashion. Developmental Cell 19(6): 845-857

Gleason, C.E.; Frindt, G.; Cheng, C.-J.; Ng, M.; Kidwai, A.; Rashmi, P.; Lang, F.; Baum, M.; Palmer, L.G.; Pearce, D. 2015: MTORC2 regulates renal tubule sodium uptake by promoting ENaC activity. Journal of Clinical Investigation 125(1): 117-128

Chen, J.; Holguin, N.; Shi, Y.; Silva, M.J.; Long, F. 2015: MTORC2 signaling promotes skeletal growth and bone formation in mice. Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research 30(2): 369-378

Lamming, D.W. 2014: MTORC2 takes the longevity stAGE. Oncotarget 5(17): 7214-7215

Cameron, A.J.M.; Linch, M.D.; Saurin, A.T.; Escribano, C.; Parker, P.J. 2011: MTORC2 targets AGC kinases through Sin1-dependent recruitment. Biochemical Journal 439(2): 287-297

Cota, D. 2014: MTORC2, the "other" mTOR, is a new player in energy balance regulation. Molecular Metabolism 3(4): 349-350

Mizunuma, M.; Neumann-Haefelin, E.; Moroz, N.; Li, Y.; Blackwell, T.K. 2014: MTORC2-SGK-1 acts in two environmentally responsive pathways with opposing effects on longevity. Aging Cell 13(5): 869-878

Panasyuk, G.; Nemazanyy, I.; Zhyvoloup, A.; Filonenko, V.; Davies, D.; Robson, M.; Pedley, R.B.; Waterfield, M.; Gout, I. 2009: MTORbeta splicing isoform promotes cell proliferation and tumorigenesis. Journal of Biological Chemistry 284(45): 30807-30814

DeSouza, L.V.; Krakovska, O.; Darfler, M.M.; Krizman, D.B.; Romaschin, A.D.; Colgan, T.J.; Siu, K.W.M. 2010: MTRAQ-based quantification of potential endometrial carcinoma biomarkers from archived formalin-fixed paraffin-embedded tissues. Proteomics 10(17): 3108-3116

Letavernier, E.; Legendre, C. 2008: MToR inhibitors-induced proteinuria: mechanisms, significance, and management. Transplantation Reviews 22(2): 125-130

Tang, Z.; Baykal, A.T.; Gao, H.; Quezada, H.C.; Zhang, H.; Bereczki, E.; Serhatli, M.; Baykal, B.; Acioglu, C.; Wang, S.; Ioja, E.; Ji, X.; Zhang, Y.; Guan, Z.; Winblad, B.; Pei, J.-J. 2014: MTor is a signaling hub in cell survival: a mass-spectrometry-based proteomics investigation. Journal of Proteome Research 13(5): 2433-2444

Frost, R.A.; Lang, C.H. 2011: MTor signaling in skeletal muscle during sepsis and inflammation: where does it all go wrong?. Physiology 26(2): 83-96

Guerra, E.; Lattanzio, R.; La Sorda, R.; Dini, F.; Tiboni, G.M.; Piantelli, M.; Alberti, S. 2012: MTrop1/Epcam knockout mice develop congenital tufting enteropathy through dysregulation of intestinal E-cadherin/β-catenin. Plos one 7(11): E49302

Yamasaki, A.; Menon, S.; Yu, S.; Barrowman, J.; Meerloo, T.; Oorschot, V.; Klumperman, J.; Satoh, A.; Ferro-Novick, S. 2009: MTrs130 is a component of a mammalian TRAPPIi complex, a Rab1 GEF that binds to COPI-coated vesicles. Molecular Biology of the Cell 20(19): 4205-4215

Chen, T.; Zhou, T.; He, B.; Yu, H.; Guo, X.; Song, X.; Sha, J. 2014: MUbiSiDa: a comprehensive database for protein ubiquitination sites in mammals. Plos one 9(1): E85744

Lemfack, M.C.; Nickel, J.; Dunkel, M.; Preissner, R.; Piechulla, B. 2014: MVOC: a database of microbial volatiles. Nucleic Acids Research 42(Database Issue): D744-D748

Wong, Y.-F.; Sheng, Q.; Chung, J.W.L.; Chan, J.K.F.; Chow, K.L. 2010: Mab-31 and the TGF-beta pathway act in the ray lineage to pattern C. elegans male sensory rays. Bmc Developmental Biology 10: 82

Cederlund, M.L.; Vendrell, V.; Morrissey, M.E.; Yin, J.; Gaora, P.Ó; Smyth, V.A.; Higgins, D.G.; Kennedy, B.án.N. 2011: Mab21l2 transgenics reveal novel expression patterns of mab21l1 and mab21l2, and conserved promoter regulation without sequence conservation. Developmental Dynamics: An Official Publication of the American Association of Anatomists 240(4): 745-754

Cong, R.; Das, S.; Douet, J.; Wong, J.; Buschbeck, M.; Mongelard, F.; Bouvet, P. 2014: MacroH2A1 histone variant represses rDNA transcription. Nucleic Acids Research 42(1): 181-192

Matsuda, M.; Fishman, R.S.; Hong, T.; Lee, C.H.; Ushiyama, T.; Yanagisawa, Y.; Tomioka, Y.; Ito, T. 2012: Magnetic dispersion and anisotropy in multiferroic BiFeO3. Physical Review Letters 109(6): 067205

Lone, A.G.; Deslandes, V.; Nash, J.H.E.; Jacques, M.; MacInnes, J.I. 2009: MalT knockout mutation invokes a stringent type gene-expression profile in Actinobacillus pleuropneumoniae in bronchoalveolar fluid. Bmc Microbiology 9: 195

Ogura, M. 2008: Malignant lymphoma. Physiopathology and treatment. 1. Hodgkin's lymphoma. Nihon Naika Gakkai Zasshi. Journal of the Japanese Society of Internal Medicine 97(7): 1568-1580

Yang, W.; Li, R.; Peng, T.; Zhang, Y.; Jiang, W.; Li, Y.; Li, J. 2010: MamO and mamE genes are essential for magnetosome crystal biomineralization in Magnetospirillum gryphiswaldense MSR-1. Research in Microbiology 161(8): 701-705

Passaro, A.; Di Maio, M.; Del Signore, E.; Gori, B.; de Marinis, F. 2014: Management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis. Clinical Lung Cancer 15(4): 307-312

Garcia Ruiz, M.; Garcia Chaves, A.; Ruiz Ibañez, C.; Gutierrez Mazo, J.Mario.; Ramirez Giraldo, J.Carlos.; Pelaez Echavarria, A.; Valencia Diaz, E.; Pelaez Restrepo, G.; Montoya Munera, E.Nelson.; Garcia Loaiza, B.; Gomez Gonzalez, S. 2011: MantisGRID: a grid platform for DICOM medical images management in Colombia and Latin America. Journal of Digital Imaging 24(2): 271-283

Ginolhac, A.; Rasmussen, M.; Gilbert, M.T.P.; Willerslev, E.; Orlando, L. 2011: MapDamage: testing for damage patterns in ancient DNA sequences. Bioinformatics 27(15): 2153-2155

Pante, E.; Simon-Bouhet, B. 2013: Marmap: a package for importing, plotting and analyzing bathymetric and topographic data in R. Plos one 8(9): E73051

Li, H.-H.; Chiang, C.-S.; Huang, H.-Y.; Liaw, G.-J. 2009: Mars and tousled-like kinase act in parallel to ensure chromosome fidelity in Drosophila. Journal of Biomedical Science 16: 51

Rusconi, F. 2009: MassXpert 2: a cross-platform software environment for polymer chemistry modelling and simulation/analysis of mass spectrometric data. Bioinformatics 25(20): 2741-2742

Buckberry, S.; Bent, S.J.; Bianco-Miotto, T.; Roberts, C.T. 2014: MassiR: a method for predicting the sex of samples in gene expression microarray datasets. Bioinformatics 30(14): 2084-2085

Van Beek, J.D. 2007: MatNMR: a flexible toolbox for processing, analyzing and visualizing magnetic resonance data in Matlab. Journal of Magnetic Resonance 187(1): 19-26

Yilmaz, L.S.; Parnerkar, S.; Noguera, D.R. 2011: MathFISH, a web tool that uses thermodynamics-based mathematical models for in silico evaluation of oligonucleotide probes for fluorescence in situ hybridization. Applied and Environmental Microbiology 77(3): 1118-1122

Menzel, P.; Stadler, P.F.; Gorodkin, J. 2011: MaxAlike: maximum likelihood-based sequence reconstruction with application to improved primer design for unknown sequences. Bioinformatics 27(3): 317-325

Ramisetty, B.Chandra.Mohan.; Natarajan, B.; Santhosh, R.Sarojini. 2015: MazEF-mediated programmed cell death in bacteria: "what is this?". Critical Reviews in Microbiology 41(1): 89-100

Calle, M.L.; Urrea, V.íc.; Malats, N.úr.; Van Steen, K. 2010: Mbmdr: an R package for exploring gene-gene interactions associated with binary or quantitative traits. Bioinformatics 26(17): 2198-2199

Teshima, K.M.; Innan, H. 2009: Mbs: modifying Hudson's ms software to generate samples of DNA sequences with a biallelic site under selection. Bmc Bioinformatics 10: 166

Richardson, J.; Lundegaard, P.R.; Reynolds, N.L.; Dorin, J.R.; Porteous, D.J.; Jackson, I.J.; Patton, E.E. 2008: Mc1r Pathway regulation of zebrafish melanosome dispersion. Zebrafish 5(4): 289-295

Copeland, W.K.; Krishnan, V.; Beck, D.; Settles, M.; Foster, J.A.; Cho, K.-C.; Day, M.; Hickey, R.; Schütte, U.M.E.; Zhou, X.; Williams, C.J.; Forney, L.J.; Abdo, Z. 2012: McaGUI: microbial community analysis R-Graphical User Interface (GUI). Bioinformatics 28(16): 2198-2199

Steinberg, L.M.; Regan, J.M. 2009: McrA-targeted real-time quantitative PCR method to examine methanogen communities. Applied and Environmental Microbiology 75(13): 4435-4442

Bhutia, S.K.; Das, S.K.; Kegelman, T.P.; Azab, B.; Dash, R.; Su, Z.-Z.; Wang, X.-Y.; Rizzi, F.; Bettuzzi, S.; Lee, S.-G.; Dent, P.; Grant, S.; Curiel, D.T.; Sarkar, D.; Fisher, P.B. 2012: Mda-7/IL-24 differentially regulates soluble and nuclear clusterin in prostate cancer. Journal of Cellular Physiology 227(5): 1805-1813

Li, Y.-J.; Liu, G.; Li, Y.; Vecchiarelli-Federico, L.M.; Liu, J.C.; Zacksenhaus, E.; Shan, S.W.; Yang, B.B.; Li, Q.; Dash, R.; Fisher, P.B.; Archer, M.C.; Ben-David, Y. 2013: Mda-7/IL-24 expression inhibits breast cancer through upregulation of growth arrest-specific gene 3 (gas3) and disruption of β1 integrin function. Molecular Cancer Research: Mcr 11(6): 593-603

Jia, J.; Li, S.; Gong, W.; Ding, J.; Fang, C.; Quan, Z. 2011: Mda-7/IL-24 induces apoptosis in human GBC-SD gallbladder carcinoma cells via mitochondrial apoptotic pathway. Oncology Reports 25(1): 195-201

Zhang, X.; Kang, X.; Shi, L.; Li, J.; Xu, W.; Qian, H.; Wu, M.; Yin, Z. 2008: Mda-7/IL-24 induces apoptosis in human HepG2 hepatoma cells by endoplasmic reticulum stress. Oncology Reports 20(2): 437-442

Dong, C.-Y.; Zhang, F.; Duan, Y.-J.; Yang, B.-X.; Lin, Y.-M.; Ma, X.-T. 2008: Mda-7/IL-24 inhibits the proliferation of hematopoietic malignancies in vitro and in vivo. Experimental Hematology 36(8): 938-946

Dash, R.; Bhutia, S.K.; Azab, B.; Su, Z-zhong.; Quinn, B.A.; Kegelmen, T.P.; Das, S.K.; Kim, K.; Lee, S-Geun.; Park, M.A.; Yacoub, A.; Rahmani, M.; Emdad, L.; Dmitriev, I.P.; Wang, X-Yang.; Sarkar, D.; Grant, S.; Dent, P.; Curiel, D.T.; Fisher, P.B. 2010: Mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity. Cytokine and Growth Factor Reviews 21(5): 381-391

Boukerche, H.; Su, Z.-z.; Prévot, C.él.; Sarkar, D.; Fisher, P.B. 2008: Mda-9/Syntenin promotes metastasis in human melanoma cells by activating c-Src. Proceedings of the National Academy of Sciences of the United States of America 105(41): 15914-15919

Hwangbo, C.; Park, J.; Lee, J.-H. 2011: Mda-9/Syntenin protein positively regulates the activation of Akt protein by facilitating integrin-linked kinase adaptor function during adhesion to type i collagen. Journal of Biological Chemistry 286(38): 33601-33612

Beastrom, N.; Lu, H.; Macke, A.; Canan, B.D.; Johnson, E.K.; Penton, C.M.; Kaspar, B.K.; Rodino-Klapac, L.R.; Zhou, L.; Janssen, P.M.L.; Montanaro, F. 2011: Mdx(⁵cv) mice manifest more severe muscle dysfunction and diaphragm force deficits than do mdx Mice. American Journal of Pathology 179(5): 2464-2474

Bounoutas, A.; Zheng, Q.; Nonet, M.L.; Chalfie, M. 2009: Mec-15 encodes an F-box protein required for touch receptor neuron mechanosensation, synapse formation and development. Genetics 183(2): 607

Rajabiani, A.; Kamrani, F.; Boroumand, M.A.; Saffar, H. 2014: Mec-A-mediated Resistance in Staphylococcus aureus in a Referral Hospital, Tehran, Iran. Jundishapur Journal of Microbiology 7(4): E9181

Youn, J.-H.; Hwang, S.Y.; Kim, S.H.; Koo, H.C.; Shin, S.; Lim, S.-K.; Park, Y.H. 2010: MecA gene transferrability and antibiogram of zoonotic Staphylococcus intermedius from animals, staff and the environment in animal hospitals in Korea. Journal of Microbiology and Biotechnology 20(2): 425-432

Kamberović, F.; Ibrahimagić, A.; Uzunović, S.; Budimir, A.; Rijnders, M.I.A.; Stobberingh, E.E. 2015: MecA-positive methicillin-sensitive Staphylococcus aureus clinical isolates in Zenica-Doboj Canton, Bosnia and Herzegovina. Journal of ChemoTherapy 27(6): 330-336

Loncaric, I.; Kübber-Heiss, A.; Posautz, A.; Stalder, G.L.; Hoffmann, D.; Rosengarten, R.; Walzer, C. 2014: MecC- and mecA-positive meticillin-resistant Staphylococcus aureus (MRSA) isolated from livestock sharing habitat with wildlife previously tested positive for mecC-positive MRSA. Veterinary Dermatology 25(2): 147-148

Gaval-Cruz, M.; Weinshenker, D. 2009: Mechanisms of disulfiram-induced cocaine abstinence: antabuse and cocaine relapse. Molecular Interventions 9(4): 175-187

Bessone, M.; Rathelot, P.; Agopian, R.; Pracchia, S.; Schmitt, E.; Pascual, P.; Roche, M.; Rasamison, R.; Curti, C.; Montana, M.; Vanelle, P.; Pelissier, V.ér.; Mousnier, A. 2014: MediEVAL: a new evaluating tool for the medication-use system. Therapie 69(3): 195-206

Benton, A.; Holmes, J.H.; Hill, S.; Chung, A.; Ungar, L. 2012: Medpie: an information extraction package for medical message board posts. Bioinformatics 28(5): 743-744

Bley, C.; van der Linden, M.; Reinert, R.R.é 2011: Mef(A) is the predominant macrolide resistance determinant in Streptococcus pneumoniae and Streptococcus pyogenes in Germany. International Journal of Antimicrobial Agents 37(5): 425-431

Boissel, S.; Jarjour, J.; Astrakhan, A.; Adey, A.; Gouble, A.ès.; Duchateau, P.; Shendure, J.; Stoddard, B.L.; Certo, M.T.; Baker, D.; Scharenberg, A.M. 2014: MegaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering. Nucleic Acids Research 42(4): 2591-2601

Wu, C.; Singaram, V.; McKim, K.S. 2008: Mei-38 is required for chromosome segregation during meiosis in Drosophila females. Genetics 180(1): 61-72

Gao, J.Y.; Liu, Z.; Wang, Y. 2009: Mer-(3,5-Dichloro-2-oxidobenzaldehyde thio-semicarbazonato-κS,N,O)(methanol-κO)(1,10-phenanthroline-κN,N')nickel(II). Acta Crystallographica. Section E Structure Reports Online 65(Part 5): M523-M524

Ke, Y.Z.; Zheng, L.F.; Luo, J.H.; Huang, X.H.; Huang, C.C. 2007: Mer-Bis(1,4-dibenzoylthiosemicarbazidato-kappa3O,N,O')cobalt(II). Acta Crystallographica. Section C Crystal Structure Communications 63(Part 8): M343-M345

Jones, P.G.; Freund, A.; Weinkauf, A.; Kowalsky, W.; Johannes, H.-H. 2010: Mer-Bis[2-(1,3-benzothiazol-2-yl)phenyl-κC,N][3-phenyl-5-(2-pyridyl)-1,2,4-triazol-1-ido-κN,N]iridium(III) deuterochloro-form 3.5-solvate. Acta Crystallographica. Section e Structure Reports Online 66(Part 9): M1088-M1089

Jones, P.G.; Debeaux, M.; Weinkauf, A.; Hopf, H.; Kowalsky, W.; Johannes, H-Hermann. 2009: Mer-Bis[3,5-difluoro-2-(2-pyrid-yl)phenyl-κC,N]{5-(2-pyridyl-κN)-3-[3-(4-vinyl-benz-yloxy)phen-yl]-1,2,4-triazol-1-ido}iridium(III) methanol solvate. Acta Crystallographica. Section E Structure Reports Online 66(Pt 1): M66-M67

Yeşilel, O.Z.; Olmez, H.; Arici, C. 2007: Mer-Diaquabis(1H-imidazole-kappaN3)[orotato(2-)]cobalt(II). Acta Crystallographica. Section C Crystal Structure Communications 63(Part 6): M240-M242

Merola, J.S.; Slebodnick, C.; Berg, M.; Ritchie, M.K. 2014: Mer-Hydridotris(tri-methyl-phosphane-κP)(d-valinato-κ(2) N,O)iridium hexa-fluorido-phosphate di-chloro-methane 0.675-solvate. Acta Crystallographica. Section E Structure Reports Online 70(Part 3): M82

Zhu, L.; Huang, J.; Han, S.-Y.; An, Z. 2008: Mer-Triaqua-(1,10-phenanthroline-κN,N')(sulfato-κO)magnesium(II). Acta Crystallographica. Section e Structure Reports Online 64(Part 5): M683

Jones, P.G.; Freund, A.; Debeaux, M.; Kowalsky, W.; Johannes, H.-H. 2010: Mer-[3-Phenyl-5-(2-pyridyl-κN)-1,2,4-triazol-1-ido-κN]bis-(2-quinolylphenyl-κC,N)iridium(III) deuterochloro-form disolvate. Acta Crystallographica. Section e Structure Reports Online 66(Part 11): M1408-M1409

Jameson, E. 2012: Merging art and neuroscience. Annals of Neurosciences 19(2): 60

Maeda, C.; Shinokubo, H.; Osuka, A. 2009: Meso,meso'-Bis(5-azaindol-2-yl)-appended meso-meso-linked Zn(II) diporphyrin: a discrete fluorescent assembly. Organic Letters 11(22): 5322-5325

Hieu, T.H.; Anh, L.T.; Soldatenkov, A.T.; Kurilkin, V.V.; Khrustalev, V.N. 2012: Meso-(1S*,21R*)-25-Methyl-8,11,14-trioxa-22,24,25-triaza-tetra-cyclo-[19.3.1.0(2,7).0(15,20)]penta-cosa-2,4,6,15(20),16,18-hexa-ene-23-thione chloro-form monosolvate. Acta Crystallographica. Section e Structure Reports Online 68(Part 10): O2848-O2849

Inokuma, Y.; Easwaramoorthi, S.; Yoon, Z.Seok.; Kim, D.; Osuka, A. 2008: Meso-(4-(N,N-dialkylamino)phenyl)-substituted subporphyrins: remarkably perturbed absorption spectra and enhanced fluorescence by intramolecular charge transfer interactions. Journal of the American Chemical Society 130(37): 12234-12235

Wardell, S.M.S.V.; Wardell, J.L.; de Lima, G.M.; Tiekink, E.R.T. 2010: Meso-1-{[2-(Propyl-1-sulfin-yl)eth-yl]sulfin-yl}propane. Acta Crystallographica. Section E Structure Reports Online 66(Pt 3): O647-O648

Kang, S.; Hayashi, H.; Umeyama, T.; Matano, Y.; Tkachenko, N.V.; Lemmetyinen, H.; Imahori, H. 2008: Meso-3,5-Bis(trifluoromethyl)phenyl-substituted expanded porphyrins: synthesis, characterization, and optical, electrochemical, and photophysical properties. Chemistry An Asian Journal 3(12): 2065-2074

Li, P.; Zhang, C.; Xu, W. 2011: Meso-3,6-Dioxopiperazine-2,5-diacet-amide. Acta Crystallographica. Section E Structure Reports Online 67(Part 11): O3041

Rivera, A.; Quiroga, D.; Ríos-Motta, J.; Kučeraková, M.; Dušek, M. 2013: Meso-4,4'-Difluoro-2,2'-{[(3aR,7aS)-2,3,3a,4,5,6,7,7a-octa-hydro-1H-1,3-benzimidazole-1,3-di-yl]bis-(methyl-ene)}diphenol. Acta Crystallographica. Section E Structure Reports Online 69(Pt 2): O217

Rivera, A.; Quiroga, D.; Ríos-Motta, J.; Kučeraková, M.; Dušek, M. 2013: Meso-4,4'-Dimeth-oxy-2,2'-{[(3aR,7aS)-2,3,3a,4,5,6,7,7a-octa-hydro-1H-benz-imidazole-1,3-di-yl]bis-(methyl-ene)}diphenol. Acta Crystallographica. Section E Structure Reports Online 69(Pt 7): O1057-O1058

Galas, H.; Viirre, R.D.; Lough, A.J. 2009: Meso-4,5-Diphenyl-imidazolidin-2-one. Acta Crystallographica. Section E Structure Reports Online 65(Part 12): O3087

Prasath, R.; Bhavana, P.; Gupta, S.K.; Butcher, R.J. 2013: Meso-5,10,15,20-Tetra-kis(3-methyl-thio-phen-2-yl)porphyrinato-κ(4) N,N',N'',N''']nickel(II) benzene hemisolvate. Acta Crystallographica. Section E Structure Reports Online 69(Part 12): M652-M653

Leonarska, A.; Zubko, M.; Kuś, P.; Kusz, J.; Ratuszna, A. 2012: Meso-5,10,15,20-Tetra-kis(4-hy-droxy-3-meth-oxy-phen-yl)porphyrin propionic acid monosolvate. Acta Crystallographica. Section E Structure Reports Online 68(Part 9): O2797-O2798

Prasath, R.; Bhavana, P.; Ng, S.W.; Tiekink, E.R.T. 2012: Meso-5,10,15,20-Tetra-kis(5-bromo-thio-phen-2-yl)porphyrinato-κ(4)N,N',N'',N''']nickel(II). Acta Crystallographica. Section e Structure Reports Online 68(Part 4): M471-M472

Li, B.; Zhang, G.; Sun, S.; Yin, Z. 2011: Meso-5,5'-Bis[(4-fluoro-phen-yl)diazen-yl]-2,2'-(pentane-3,3-di-yl)di-1H-pyrrole. Acta Crystallographica. Section E Structure Reports Online 67(Part 2): O247

Jeong, S.-D.; Nowak-Król, A.; Kim, Y.; Kim, S.-J.; Gryko, D.T.; Lee, C.-H. 2010: Meso-Alkylidene (m-benzi)pentaphyrin: a modified pentaphyrin bearing exocyclic double bonds at meso-positions. Chemical Communications 46(46): 8737-8739

Kusaka, S.; Sakamoto, R.; Kitagawa, Y.; Okumura, M.; Nishihara, H. 2013: Meso-Alkynyl BODIPYs: structure, photoproperties, π-extension, and manipulation of frontier orbitals. Chemistry An Asian Journal 8(4): 723-727

Karthik, G.; Srinivasan, A.; Chandrashekar, T.K. 2014: Meso-Aryl core-modified fused sapphyrins: syntheses and structural diversity. Organic Letters 16(13): 3472-3475

Xu, H.-J.; Mack, J.; Descalzo, A.B.; Shen, Z.; Kobayashi, N.; You, X.-Z.; Rurack, K. 2011: Meso-Aryl phenanthroporphyrins: synthesis and spectroscopic properties. Chemistry 17(32): 8965-8983

Shimizu, S.; Cho, W.-S.; Sessler, J.L.; Shinokubo, H.; Osuka, A. 2008: Meso-Aryl substituted rubyrin and its higher homologues: structural characterization and chemical properties. Chemistry 14(9): 2668-2678

Makarova, E.A.; Shimizu, S.; Matsuda, A.; Luk'yanets, E.A.; Kobayashi, N. 2008: Meso-Aryl tribenzosubporphyrin--a totally substituted subporphyrin species. Chemical Communications 18: 2109-2111

Anju, K.S.; Ramakrishnan, S.; Srinivasan, A. 2011: Meso-Aryl triphyrin(2.1.1). Organic Letters 13(9): 2498-2501

Ogikubo, J.; Meehan, E.; Engle, J.T.; Ziegler, C.J.; Brückner, C. 2012: Meso-Aryl-3-alkyl-2-oxachlorins. Journal of Organic Chemistry 77(14): 6199-6207

Inokuma, Y.; Yoon, Z.S.; Kim, D.; Osuka, A. 2007: Meso-Aryl-substituted subporphyrins: synthesis, structures, and large substituent effects on their electronic properties. Journal of the American Chemical Society 129(15): 4747-4761

Duan, X-E.; Tong, H-Bo.; Bai, S-Di.; Wei, X-Hong.; Liu, D-Sheng. 2012: Meso-Bis{η(5)-1-[1-(dimethylamino)ethenyl]-3-(trimethylsilyl)cyclopentadienyl}iron(II) and the cobalt(II) analogue. Acta Crystallographica. Section C Crystal Structure Communications 68(Pt 6): M139-M142

Lee, M.-S.; Kim, K.J.; Kim, D.; Lee, K.-E.; Hwang, J.-K. 2011: Meso-Dihydroguaiaretic acid inhibits hepatic lipid accumulation by activating AMP-activated protein kinase in human HepG2 cells. Biological and Pharmaceutical Bulletin 34(10): 1628-1630

Feng, Z.-Q.; Ye, Y.-F.; Yang, X.-L.; Dong, T.; Wang, H.-Q. 2010: Meso-Dimethyl 2,5-dibromo-hexa-ne-dioate. Acta Crystallographica. Section e Structure Reports Online 66(Part 12): O3163

Ni, Y.; Zeng, L.; Kang, N.-Y.; Huang, K.-W.; Wang, L.; Zeng, Z.; Chang, Y.-T.; Wu, J. 2014: Meso-Ester and carboxylic acid substituted BODIPYs with far-red and near-infrared emission for bioimaging applications. Chemistry 20(8): 2301-2310

Kato, K.; Teraguchi, R.; Motodate, S.; Uchida, A.; Mochida, T.; Peganova, T.'y.A.; Vologdin, N.V.; Akita, H. 2008: Meso-Phbox-Pd(II) catalyzed tandem carbonylative cyclization of 1-ethynyl-1-propargyl acetate. Chemical Communications 31: 3687-3689

Ngo, T.H.; Nastasi, F.; Puntoriero, F.; Campagna, S.; Dehaen, W.; Maes, W. 2010: Meso-Pyrimidinyl-substituted A2B- and A3-corroles. Journal of Organic Chemistry 75(6): 2127-2130

Li, J.; Zhang, K.; Zhang, X.; Huang, K.-W.; Chi, C.; Wu, J. 2010: Meso-Substituted bisanthenes as soluble and stable near-infrared dyes. Journal of Organic Chemistry 75(3): 856-863

Chen, L.; Zhao, H.-B.; Xie, Y.-J.; Yang, D.-L.; Wang, B.-Y. 2010: Meso-Tetra-kis(4-heptyl-oxyphen-yl)porphyrinato]nickel(II). Acta Crystallographica. Section e Structure Reports Online 66(Part 11): M1455

Khalil, G.E.; Daddario, P.; Lau, K.S.F.; Imtiaz, S.; King, M.; Gouterman, M.; Sidelev, A.; Puran, N.; Ghandehari, M.; Brückner, C. 2010: Meso-Tetraarylporpholactones as high pH sensors. Analyst 135(8): 2125-2131

Hyland, M.A.; Morton, M.D.; Brückner, C. 2012: Meso-Tetrakis(pentafluorophenyl)porphyrin-derived chromene-annulated chlorins. Journal of Organic Chemistry 77(7): 3038-3048

Zhao, H.-B.; Chen, L.; Wang, B.-Y.; Liao, J.-X.; Xu, Y.-J. 2013: Meso-Tetrakis[4-(heptyloxy)phenyl]porphyrin. Acta Crystallographica. Section C Crystal Structure Communications 69(Part 6): 651-653

Carvalho, C.M.B.; Santos, S.ér.M.; Neves, M.G.P.M.S.; Tomé, A.C.; Silva, A.M.S.; Rocha, J.ão.; Cavaleiro, J.é A.S. 2013: Meso-Tetraphenylbenzoporphyrin-2(2),2(3)-dicarboxylic anhydride: a platform to benzoporphyrin derivatives. Journal of Organic Chemistry 78(13): 6622-6631

Kamiya, H.; Kondo, T.; Sakida, T.; Yamaguchi, S.; Shinokubo, H. 2012: Meso-Thiaporphyrinoids revisited: missing of sulfur by small metals. Chemistry 18(50): 16129-16135

Horton, D.B.; Siripurapu, K.B.; Norrholm, S.D.; Culver, J.P.; Hojahmat, M.; Beckmann, J.S.; Harrod, S.B.; Deaciuc, A.G.; Bardo, M.T.; Crooks, P.A.; Dwoskin, L.P. 2011: Meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release. Journal of Pharmacology and Experimental Therapeutics 336(3): 940-951

Hayashi, S.-y.; Inokuma, Y.; Osuka, A. 2010: Meso-Tris(oligo-2,5-thienylene)-substituted subporphyrins. Organic Letters 12(18): 4148-4151

Dong, S.; Jiang, J. 2011: Meso-[5,10,15,20-Tetra-kis(4-cyano-phen-yl)porphyrinato]zinc. Acta Crystallographica. Section E Structure Reports Online 67(Part 4): M431

Shi, F.; Chen, X.; Rong, R.; Bao, Q. 2010: Meso-[5,5,7,12,12,14-Hexamethyl-1,4,8,11-tetra-azacyclo-tetra-deca-1(14),7-diene]nickel(II) dibromide dihydrate. Acta Crystallographica. Section E Structure Reports Online 66(Part 6): M665-M666

Brückner, C.; Ogikubo, J.; McCarthy, J.R.; Akhigbe, J.; Hyland, M.A.; Daddario, P.; Worlinsky, J.L.; Zeller, M.; Engle, J.T.; Ziegler, C.J.; Ranaghan, M.J.; Sandberg, M.N.; Birge, R.R. 2012: Meso-arylporpholactones and their reduction products. Journal of Organic Chemistry 77(15): 6480-6494

Kitano, M.; Sung, J.; Park, K.H.; Yorimitsu, H.; Kim, D.; Osuka, A. 2013: Meso-meso-linked subporphyrin dimer. Chemistry 19(49): 16523-16527

Tong, C.C.; Quesada, R.; Sessler, J.L.; Gale, P.A. 2008: Meso-octamethylcalix[4]pyrrole: an old yet new transmembrane ion-pair transporter. Chemical Communications 47: 6321-6323

Maes, W.; Ngo, T.H.; Vanderhaeghen, J.; Dehaen, W. 2007: Meso-pyrimidinyl-substituted A2B-corroles. Organic Letters 9(16): 3165-3168

Ota, K.; Tanaka, T.; Osuka, A. 2014: Meso-β dibenzo[a,g]corannulene-fused porphyrins. Organic Letters 16(11): 2974-2977

De Maria, R.; Miretti, S.; Iussich, S.; Olivero, M.; Morello, E.; Bertotti, A.; Christensen, J.G.; Biolatti, B.; Levine, R.A.; Buracco, P.; Di Renzo, M.Flavia. 2009: Met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma. Journal of Pathology 218(3): 399-408

Lommen, A.; van der Kamp, H.J.; Kools, H.J.; van der Lee, M.K.; van der Weg, G.; Mol, H.G.J. 2012: MetAlignID: a high-throughput software tool set for automated detection of trace level contaminants in comprehensive LECO two-dimensional gas chromatography time-of-flight mass spectrometry data. Journal of Chromatography. a 1263: 169-178

Ma, J.; Su, T.; Li, M.-D.; Zhang, X.; Huang, J.; Phillips, D.L. 2013: Meta versus para substitution: how does C-H activation in a methyl group occur in 3-methylbenzophenone but does not take place in 4-methylbenzophenone?. Journal of Organic Chemistry 78(10): 4867-4878

Flídrová, K.ín.; Slavík, P.; Eigner, V.ác.; Dvořáková, H.; Lhoták, P. 2013: Meta-Bridged calix[4]arenes: a straightforward synthesis via organomercurial chemistry. Chemical Communications 49(60): 6749-6751

Reuter, R.; Wegner, H.A. 2012: Meta-Oligoazobiphenyls - synthesis via site-selective Mills reaction and photochemical properties. Beilstein Journal of Organic Chemistry 8: 877-883

Hofmann, N.; Ackermann, L. 2013: Meta-Selective C-H bond alkylation with secondary alkyl halides. Journal of the American Chemical Society 135(15): 5877-5884

Shi, Z.-M.; Chen, S.-G.; Zhao, X.; Jiang, X.-K.; Li, Z.-T. 2011: Meta-Substituted benzamide oligomers that complex mono-, di- and tricarboxylates: folding-induced selectivity and chirality. Organic and Biomolecular Chemistry 9(23): 8122-8129

Huang, T.; Rehak, L.; Jander, G. 2012: Meta-Tyrosine in Festuca rubra ssp. commutata (Chewings fescue) is synthesized by hydroxylation of phenylalanine. Phytochemistry 75: 60-66

Lu, X.; Yang, X.; Zhang, Z.; Wang, D. 2010: Meta-analysis of serum tumor markers in lung cancer. Zhongguo Fei Ai Za Zhi 13(12): 1136-1140

Ander, C.; Schulz-Trieglaff, O.B.; Stoye, J.; Cox, A.J. 2013: MetaBEETL: high-throughput analysis of heterogeneous microbial populations from shotgun DNA sequences. Bmc Bioinformatics 14(Suppl 5): S2

Wehrens, R.; Weingart, G.; Mattivi, F. 2014: MetaMS: an open-source pipeline for GC-MS-based untargeted metabolomics. Journal of Chromatography. B Analytical Technologies in the Biomedical and Life Sciences 966: 109-116

Kastenmüller, G.; Römisch-Margl, W.; Wägele, B.; Altmaier, E.; Suhre, K. 2011: MetaP-server: a web-based metabolomics data analysis tool. Journal of Biomedicine and Biotechnology 2011

Whitaker, J.W.; Letunic, I.; McConkey, G.A.; Westhead, D.R. 2009: MetaTIGER: a metabolic evolution resource. Nucleic Acids Research 37(Database Issue): D531-D538

Tautenhahn, R.; Patti, G.J.; Kalisiak, E.; Miyamoto, T.; Schmidt, M.; Lo, F.Y.; McBee, J.; Baliga, N.S.; Siuzdak, G. 2011: MetaXCMS: second-order analysis of untargeted metabolomics data. Analytical Chemistry 83(3): 696-700

Lyne, M.; Smith, R.N.; Lyne, R.; Aleksic, J.; Hu, F.; Kalderimis, A.; Stepan, R.; Micklem, G. 2013: MetabolicMine: an integrated genomics, genetics and proteomics data warehouse for common metabolic disease research. Database: the Journal of Biological Databases and Curation 2013: Bat060

Stevens, J.R.; Nicholas, G. 2009: Metahdep: meta-analysis of hierarchically dependent gene expression studies. Bioinformatics 25(19): 2619-2620

Leggett, D.J.; McBryde, W.A. 1975: Metal ion interactions of picoline-2-aldehyde thiosemicarbazone. Talanta 22(10-11): 781-789

Dale, R.K.; Matzat, L.H.; Lei, E.P. 2014: Metaseq: a Python package for integrative genome-wide analysis reveals relationships between chromatin insulators and associated nuclear mRNA. Nucleic Acids Research 42(14): 9158-9170

Lefever, S.; Hoebeeck, J.; Pattyn, F.; Tusnády, G.áb.; De Paepe, A.; Speleman, F.; Arányi, T.ás.; Vandesompele, J. 2010: MethGraph: a genome visualization tool for PCR-based methylation assays. Epigenetics 5(2): 159-163

Zhou, X.; Li, D.; Lowdon, R.F.; Costello, J.F.; Wang, T. 2014: MethylC Track: visual integration of single-base resolution DNA methylation data on the WashU EpiGenome Browser. Bioinformatics 30(15): 2206-2207

Tatsunami, R.; Takahashi, K.; Oba, T.; Tampo, Y. 2009: Methylglyoxal-induced superoxide anion production in endothelial cells. Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan 129(1): 147-153

Anonymous 1983: mettler. Analytical Chemistry 55(13): 1327A

Anonymous 1983: mettler. Analytical Chemistry 55(13): 1329A

Fetar, H.; Gilmour, C.; Klinoski, R.; Daigle, D.M.; Dean, C.R.; Poole, K. 2011: MexEF-oprN multidrug efflux operon of Pseudomonas aeruginosa: regulation by the MexT activator in response to nitrosative stress and chloramphenicol. Antimicrobial Agents and ChemoTherapy 55(2): 508-514

Miguel, J.M.; Boquete, L.; Ortega, S.; Cordero, C.A.én.; Barea, R.; Blanco, R. 2012: MfERG_LAB: Software for processing multifocal electroretinography signals. Computer Methods and Programs in Biomedicine 108(1): 377-387

Saravia, L.A. 2014: MfSBA: Multifractal analysis of spatial patterns in ecological communities. F1000research 3: 14

Singh, S.; Kaushal, A.; Khare, S.; Kumar, A. 2014: Mga genosensor for early detection of human rheumatic heart disease. Applied Biochemistry and Biotechnology 173(1): 228-238

Barchiesi, J.; Castelli, M.ía.E.; Soncini, F.C.; Véscovi, E.G.ía. 2008: MgtA Expression is induced by rob overexpression and mediates a Salmonella enterica resistance phenotype. Journal of Bacteriology 190(14): 4951-4958

Schlachter, S.; Elder, A.D.; Esposito, A.; Kaminski, G.S.; Frank, J.H.; van Geest, L.K.; Kaminski, C.F. 2009: MhFLIM: resolution of heterogeneous fluorescence decays in widefield lifetime microscopy. Optics Express 17(3): 1557-1570

Xu, Y.; Chen, B.; Chao, H.; Zhou, N-Yi. 2013: MhpT encodes an active transporter involved in 3-(3-hydroxyphenyl)propionate catabolism by Escherichia coli K-12. Applied and Environmental Microbiology 79(20): 6362-6368

Nguyen, D.T.; Nguyen, C.D.; Hargraves, R.; Kurgan, L.A.; Cios, K.J. 2013: Mi-DS: Multiple-Instance Learning Algorithm. IEEE Transactions on Cybernetics 43(1): 143-154

Feldhahn, M.; Dönnes, P.; Schubert, B.; Schilbach, K.; Rammensee, H.-G.; Kohlbacher, O. 2012: MiHA-Match: computational detection of tissue-specific minor histocompatibility antigens. Journal of Immunological Methods 386(1-2): 94-100

Sikand, K.; Slaibi, J.E.; Singh, R.; Slane, S.D.; Shukla, G.C. 2011: MiR 488* inhibits androgen receptor expression in prostate carcinoma cells. International Journal of Cancer 129(4): 810-819

Balatti, V.; Pekarky, Y.; Rizzotto, L.; Croce, C.M. 2013: MiR deregulation in CLL. Advances in Experimental Medicine and Biology 792: 309-325

Kater, A.P.; Eldering, E. 2014: MiR in CLL: more than mere markers of prognosis?. Blood 124(1): 2-4

Bennett, P.E.; Bemis, L.; Norris, D.A.; Shellman, Y.G. 2013: MiR in melanoma development: mi RNAs and acquired hallmarks of cancer in melanoma. Physiological Genomics 45(22): 1049-1059

Kuphal, S.; Bosserhoff, A. 2013: MiR networks in melanoma - more to come!. Pigment Cell and Melanoma Research 2013

Seca, H.; Almeida, G.M.; Guimarães, J.é E.; Vasconcelos, M.H. 2010: MiR signatures and the role of mi Rs in acute myeloid leukaemia. European Journal of Cancer 46(9): 1520-1527

Müller, D.W.; Bosserhoff, A.K. 2009: MiR(acle)s - new players in the regulation of known suspects. Pigment Cell and Melanoma Research 22(5): 525-526

Karatas, O.F.; Guzel, E.; Suer, I.; Ekici, I.D.; Caskurlu, T.; Creighton, C.J.; Ittmann, M.; Ozen, M. 2014: MiR-1 and miR-133b are differentially expressed in patients with recurrent prostate cancer. Plos one 9(6): E98675

Letelier, P.; García, P.; Leal, P.; Álvarez, H.éc.; Ili, C.; López, J.; Castillo, J.; Brebi, P.; Roa, J.C. 2014: MiR-1 and miR-145 act as tumor suppressor micro RNAs in gallbladder cancer. International Journal of Clinical and Experimental Pathology 7(5): 1849-1867

Stahlhut, C.; Suárez, Y.; Lu, J.; Mishima, Y.; Giraldez, A.J. 2012: MiR-1 and miR-206 regulate angiogenesis by modulating VegfA expression in zebrafish. Development 139(23): 4356-4364

Nohata, N.; Sone, Y.; Hanazawa, T.; Fuse, M.; Kikkawa, N.; Yoshino, H.; Chiyomaru, T.; Kawakami, K.; Enokida, H.; Nakagawa, M.; Shozu, M.; Okamoto, Y.; Seki, N. 2011: MiR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. Oncotarget 2(1-2): 29-42

Pan, Z.; Sun, X.; Ren, J.; Li, X.; Gao, X.; Lu, C.; Zhang, Y.; Sun, H.; Wang, Y.; Wang, H.; Wang, J.; Xie, L.; Lu, Y.; Yang, B. 2012: MiR-1 exacerbates cardiac ischemia-reperfusion injury in mouse models. Plos one 7(11): E50515

Xu, Y.; Zheng, M.; Merritt, R.E.; Shrager, J.B.; Wakelee, H.A.; Kratzke, R.A.; Hoang, C.D. 2013: MiR-1 induces growth arrest and apoptosis in malignant mesothelioma. Chest 144(5): 1632-1643

Terentyev, D.; Belevych, A.E.; Terentyeva, R.; Martin, M.M.; Malana, G.E.; Kuhn, D.E.; Abdellatif, M.; Feldman, D.S.; Elton, T.S.; Györke, S. 2009: MiR-1 overexpression enhances Ca(2+) release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B56alpha and causing CaMKII-dependent hyperphosphorylation of RyR2. Circulation research 104(4): 514-521

Varendi, K.är.; Kumar, A.; Härma, M.-A.; Andressoo, J.-O. 2014: MiR-1, miR-10b, miR-155, and miR-191 are novel regulators of BDNF. Cellular and Molecular Life Sciences: Cmls 71(22): 4443-4456

Boštjančič, E.; Jerše, M.; Glavač, D.; Zidar, N. 2015: MiR-1, miR-133a/b, and miR-208a in human fetal hearts correlate to the apoptotic and proliferation markers. Experimental Biology and Medicine 240(2): 211-219

Huang, F.; Tang, L.; Fang, Z.-f.; Hu, X.-q.; Pan, J.-y.; Zhou, S.-h. 2013: MiR-1-mediated induction of cardiogenesis in mesenchymal stem cells via downregulation of Hes-1. Biomed Research International 2013: 216286

Wystub, K.; Besser, J.; Bachmann, A.; Boettger, T.; Braun, T. 2013: MiR-1/133a clusters cooperatively specify the cardiomyogenic lineage by adjustment of myocardin levels during embryonic heart development. Plos Genetics 9(9): E1003793

Shan, Z.-X.; Lin, Q.-X.; Deng, C.-Y.; Zhu, J.-N.; Mai, L.-P.; Liu, J.-L.; Fu, Y.-H.; Liu, X.-Y.; Li, Y.-X.; Zhang, Y.-Y.; Lin, S.-G.; Yu, X.-Y. 2010: MiR-1/miR-206 regulate Hsp60 expression contributing to glucose-mediated apoptosis in cardiomyocytes. Febs Letters 584(16): 3592-3600

Chen, D.; Sun, Y.; Yuan, Y.; Han, Z.; Zhang, P.; Zhang, J.; You, M.J.; Teruya-Feldstein, J.; Wang, M.; Gupta, S.; Hung, M.-C.; Liang, H.; Ma, L. 2014: MiR-100 induces epithelial-mesenchymal transition but suppresses tumorigenesis, migration and invasion. Plos Genetics 10(2): E1004177

Thu, K.L.; Chari, R.; Lockwood, W.W.; Lam, S.; Lam, W.L. 2011: MiR-101 DNA copy loss is a prominent subtype specific event in lung cancer. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 6(9): 1594-1598

Yao, Y.-L.; Ma, J.; Wang, P.; Xue, Y.-X.; Li, Z.; Zhao, L.-N.; Li, Z.-Q.; Feng, T.-D.; Liu, Y.-H. 2015: MiR-101 acts as a tumor suppressor by targeting Kruppel-like factor 6 in glioblastoma stem cells. Cns Neuroscience and Therapeutics 21(1): 40-51

Xu, Y.; An, Y.; Wang, Y.; Zhang, C.; Zhang, H.; Huang, C.; Jiang, H.; Wang, X.; Li, X. 2013: MiR-101 inhibits autophagy and enhances cisplatin-induced apoptosis in hepatocellular carcinoma cells. Oncology Reports 29(5): 2019-2024

Lin, X.; Guan, H.; Li, H.; Liu, L.; Liu, J.; Wei, G.; Huang, Z.; Liao, Z.; Li, Y. 2014: MiR-101 inhibits cell proliferation by targeting Rac1 in papillary thyroid carcinoma. Biomedical Reports 2(1): 122-126

Liang, X.; Liu, Y.; Zeng, L.; Yu, C.; Hu, Z.; Zhou, Q.; Yang, Z. 2014: MiR-101 inhibits the G1-to-S phase transition of cervical cancer cells by targeting Fos. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society 24(7): 1165-1172

Smits, M.; Nilsson, J.; Mir, S.E.; van der Stoop, P.M.; Hulleman, E.; Niers, J.M.; de Witt Hamer, P.C.; Marquez, V.E.; Cloos, J.; Krichevsky, A.M.; Noske, D.P.; Tannous, B.A.; Würdinger, T. 2010: MiR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget 1(8): 710-720

Wang, L.; Li, L.; Guo, R.; Li, X.; Lu, Y.; Guan, X.; Gitau, S.C.; Wang, L.; Xu, C.; Yang, B.; Shan, H. 2014: MiR-101 promotes breast cancer cell apoptosis by targeting Janus kinase 2. Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology Biochemistry and Pharmacology 34(2): 413-422

Liu, L.; Guo, J.; Yu, L.; Cai, J.; Gui, T.; Tang, H.; Song, L.; Wang, J.; Han, F.; Yang, C.; Chen, C.; Marks, A.; Wang, Z. 2014: MiR-101 regulates expression of EZH2 and contributes to progression of and cisplatin resistance in epithelial ovarian cancer. Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine 35(12): 12619-12626

Yin, J.; Wang, M.; Jin, C.; Qi, Q. 2014: MiR-101 sensitizes A549 NSCLC cell line to CDDP by activating caspase 3-dependent apoptosis. Oncology Letters 7(2): 461-465

Lin, C.; Huang, F.; Li, Q.-Z.; Zhang, Y.-J. 2014: MiR-101 suppresses tumor proliferation and migration, and induces apoptosis by targeting EZH2 in esophageal cancer cells. International Journal of Clinical and Experimental Pathology 7(10): 6543-6550

Li, M.; Liu, Z.; Zhang, Z.; Liu, G.; Sun, S.; Sun, C. 2015: MiR-103 promotes 3T3-L1 cell adipogenesis through AKT/mTOR signal pathway with its target being MEF2D. Biological Chemistry 396(3): 235-244

Zhang, Y.; Qu, X.; Li, C.; Fan, Y.; Che, X.; Wang, X.; Cai, Y.; Hu, X.; Liu, Y. 2015: MiR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1. Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine 36(4): 2277-2285

Chen, H.-Y.; Lin, Y.-M.; Chung, H.-C.; Lang, Y.-D.; Lin, C.-J.; Huang, J.; Wang, W.-C.; Lin, F.-M.; Chen, Z.; Huang, H.-D.; Shyy, J.Y.-J.; Liang, J.-T.; Chen, R.-H. 2012: MiR-103/107 promote metastasis of colorectal cancer by targeting the metastasis suppressors DAPK and KLF4. Cancer Research 72(14): 3631-3641

Honeywell, D.R.; Cabrita, M.A.; Zhao, H.; Dimitroulakos, J.; Addison, C.L. 2013: MiR-105 inhibits prostate tumour growth by suppressing CDK6 levels. Plos one 8(8): E70515

Fang, Y.; Shen, H.; Li, H.; Cao, Y.; Qin, R.; Long, L.; Zhu, X.; Xie, C.; Xu, W. 2013: MiR-106a confers cisplatin resistance by regulating PTEN/Akt pathway in gastric cancer cells. Acta Biochimica et Biophysica Sinica 45(11): 963-972

Wang, Z.; Liu, M.; Zhu, H.; Zhang, W.; He, S.; Hu, C.; Quan, L.; Bai, J.; Xu, N. 2013: MiR-106a is frequently upregulated in gastric cancer and inhibits the extrinsic apoptotic pathway by targeting FAS. Molecular Carcinogenesis 52(8): 634-646

Liu, Z.; Gersbach, E.; Zhang, X.; Xu, X.; Dong, R.; Lee, P.; Liu, J.; Kong, B.; Shao, C.; Wei, J.-J. 2013: MiR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma. Molecular Cancer Research: Mcr 11(11): 1314-1325

Zhi, F.; Zhou, G.; Shao, N.; Xia, X.; Shi, Y.; Wang, Q.; Zhang, Y.; Wang, R.; Xue, L.; Wang, S.; Wu, S.; Peng, Y.; Yang, Y. 2013: MiR-106a-5p inhibits the proliferation and migration of astrocytoma cells and promotes apoptosis by targeting FASTK. Plos one 8(8): E72390

Jiang, Y.; Wu, Y.; Greenlee, A.R.; Wu, J.; Han, Z.; Li, X.; Zhao, Y. 2011: MiR-106a-mediated malignant transformation of cells induced by anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide. Toxicological Sciences: An Official Journal of the Society of Toxicology 119(1): 50-60

Wang, H.; Liu, J.; Zong, Y.; Xu, Y.; Deng, W.; Zhu, H.; Liu, Y.; Ma, C.; Huang, L.; Zhang, L.; Qin, C. 2010: MiR-106b aberrantly expressed in a double transgenic mouse model for Alzheimer's disease targets TGF-β type Ii receptor. Brain Research 1357: 166-174

Shen, G.; Jia, H.; Tai, Q.; Li, Y.; Chen, D. 2013: MiR-106b downregulates adenomatous polyposis coli and promotes cell proliferation in human hepatocellular carcinoma. Carcinogenesis 34(1): 211-219

Zhai, Z.; Wu, F.; Chuang, A.Y.; Kwon, J.H. 2013: MiR-106b fine tunes ATG16L1 expression and autophagic activity in intestinal epithelial HCT116 cells. Inflammatory Bowel Diseases 19(11): 2295-2301

Li, K.K.-W.; Xia, T.; Ma, F.M.T.; Zhang, R.; Mao, Y.; Wang, Y.; Zhou, L.; Lau, K.-M.; Ng, H.-K. 2015: MiR-106b is overexpressed in medulloblastomas and interacts directly with PTEN. Neuropathology and Applied Neurobiology 41(2): 145-164

Tan, W.; Li, Y.; Lim, S.-G.; Tan, T.M.C. 2014: MiR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma. World Journal of Gastroenterology 20(20): 5962-5972

Zhou, C.; Li, G.; Zhou, J.; Han, N.; Liu, Z.; Yin, J. 2014: MiR-107 activates ATR/Chk1 pathway and suppress cervical cancer invasion by targeting MCL1. Plos one 9(11): E111860

Bhatia, H.; Verma, G.; Datta, M. 2014: MiR-107 orchestrates ER stress induction and lipid accumulation by post-transcriptional regulation of fatty acid synthase in hepatocytes. Biochimica et Biophysica Acta 1839(4): 334-343

Chen, P.-S.; Su, J.-L.; Cha, S.-T.; Tarn, W.-Y.; Wang, M.-Y.; Hsu, H.-C.; Lin, M.-T.; Chu, C.-Y.; Hua, K.-T.; Chen, C.-N.; Kuo, T.-C.; Chang, K.-J.; Hsiao, M.; Chang, Y.-W.; Chen, J.-S.; Yang, P.-C.; Kuo, M.-L. 2011: MiR-107 promotes tumor progression by targeting the let-7 microRNA in mice and humans. Journal of Clinical Investigation 121(9): 3442-3455

Zhang, Z.; Zhang, L.; Yin, Z.-Y.; Fan, X.-L.; Hu, B.; Wang, L.-Q.; Zhang, D. 2014: MiR-107 regulates cisplatin chemosensitivity of A549 non small cell lung cancer cell line by targeting cyclin dependent kinase 8. International Journal of Clinical and Experimental Pathology 7(10): 7236-7241

Wang, W.-X.; Wilfred, B.R.; Madathil, S.K.; Tang, G.; Hu, Y.; Dimayuga, J.; Stromberg, A.J.; Huang, Q.; Saatman, K.E.; Nelson, P.T. 2010: MiR-107 regulates granulin/progranulin with implications for traumatic brain injury and neurodegenerative disease. American Journal of Pathology 177(1): 334-345

Feng, L.; Xie, Y.; Zhang, H.; Wu, Y. 2012: MiR-107 targets cyclin-dependent kinase 6 expression, induces cell cycle G1 arrest and inhibits invasion in gastric cancer cells. Medical Oncology 29(2): 856-863

Foley, N.H.; O'Neill, L.A. 2012: MiR-107: a toll-like receptor-regulated miRNA dysregulated in obesity and type Ii diabetes. Journal of Leukocyte Biology 92(3): 521-527

Wang, F.; Yang, X-Yan.; Zhao, J-Yuan.; Yu, L-Wei.; Zhang, P.; Duan, W-Yuan.; Chong, M.; Gui, Y-Hao. 2014: MiR-10a and miR-10b target the 3'-untranslated region of TBX5 to repress its expression. Pediatric Cardiology 35(6): 1072-1079

Huang, H.; Xie, C.; Sun, X.; Ritchie, R.P.; Zhang, J.; Chen, Y.Eugene. 2010: MiR-10a contributes to retinoid acid-induced smooth muscle cell differentiation. Journal of Biological Chemistry 285(13): 9383-9389

Wu, W.; He, C.; Liu, C.; Cao, A.T.; Xue, X.; Evans-Marin, H.L.; Sun, M.; Fang, L.; Yao, S.; Pinchuk, I.V.; Powell, D.W.; Liu, Z.; Cong, Y. 2015: MiR-10a inhibits dendritic cell activation and Th1/Th17 cell immune responses in IBD. Gut 64(11): 1755-1764

Bryant, A.; Palma, C.A.; Jayaswal, V.; Yang, Y.Wa.; Lutherborrow, M.; Ma, D.Df. 2012: miR-10a is aberrantly overexpressed in Nucleophosmin1 mutated acute myeloid leukaemia and its suppression induces cell death. Molecular Cancer 11: 8

Ovcharenko, D.; Stölzel, F.; Poitz, D.; Fierro, F.; Schaich, M.; Neubauer, A.; Kelnar, K.; Davison, T.; Müller-Tidow, C.; Thiede, C.; Bornhäuser, M.; Ehninger, G.; Brown, D.; Illmer, T. 2011: MiR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia. Experimental Hematology 39(10): 1030-1042.E7

Liang, D.; Zhen, L.; Yuan, T.; Huang, J.; Deng, F.; Wuyahan; Zhang, H.; Pan, L.; Liu, Y.; The, E.; Yu, Z.; Zhu, W.; Zhang, Y.; Li, L.; Peng, L.; Li, J.; Chen, Y.-H. 2014: MiR-10a regulates proliferation of human cardiomyocyte progenitor cells by targeting GATA6. Plos one 9(7): E103097

Liao, C.-g.; Kong, L.-m.; Zhou, P.; Yang, X.-l.; Huang, J.-g.; Zhang, H.-l.; Lu, N. 2014: MiR-10b is overexpressed in hepatocellular carcinoma and promotes cell proliferation, migration and invasion through RhoC, uPAR and MMPs. Journal of Translational Medicine 12: 234

Liu, Z.; Zhu, J.; Cao, H.; Ren, H.; Fang, X. 2012: MiR-10b promotes cell invasion through RhoC-AKT signaling pathway by targeting HOXD10 in gastric cancer. International Journal of Oncology 40(5): 1553-1560

Sun, X.-J.; Liu, H.; Zhang, P.; Zhang, X.-D.; Jiang, Z.-W.; Jiang, C.-C. 2013: MiR-10b promotes migration and invasion in nasopharyngeal carcinoma cells. Asian Pacific Journal of Cancer Prevention: Apjcp 14(9): 5533-5537

Moriarty, C.H.; Pursell, B.; Mercurio, A.M. 2010: MiR-10b targets Tiam1: implications for Rac activation and carcinoma migration. Journal of Biological Chemistry 285(27): 20541-20546

Zeisel, M.B.; Pfeffer, S.éb.; Baumert, T.F. 2013: MiR-122 acts as a tumor suppressor in hepatocarcinogenesis in vivo. Journal of Hepatology 58(4): 821-823

Wu, X.; Wu, S.; Tong, L.; Luan, T.; Lin, L.; Lu, S.; Zhao, W.; Ma, Q.; Liu, H.; Zhong, Z. 2009: MiR-122 affects the viability and apoptosis of hepatocellular carcinoma cells. Scandinavian Journal of Gastroenterology 44(11): 1332-1339

Li, Y.; Masaki, T.; Lemon, S.M. 2013: MiR-122 and the Hepatitis C RNA genome: more than just stability. Rna Biology 10(6): 919-923

Villanueva, R.A.; Jangra, R.K.; Yi, M.; Pyles, R.; Bourne, N.; Lemon, S.M. 2010: MiR-122 does not modulate the elongation phase of hepatitis C virus RNA synthesis in isolated replicase complexes. Antiviral Research 88(1): 119-123

Fan, C.-G.; Wang, C.-M.; Tian, C.; Wang, Y.; Li, L.; Sun, W.-S.; Li, R.-F.; Liu, Y.-G. 2011: MiR-122 inhibits viral replication and cell proliferation in hepatitis B virus-related hepatocellular carcinoma and targets NDRG3. Oncology Reports 26(5): 1281-1286

García-Sastre, A.; Evans, M.J. 2013: MiR-122 is more than a shield for the hepatitis C virus genome. Proceedings of the National Academy of Sciences of the United States of America 110(5): 1571-1572

Fukuhara, T.; Matsuura, Y. 2012: MiR-122 participates in the cell tropism of hepatitis C virus. Uirusu 62(1): 1-8

Wen, J.; Friedman, J.R. 2012: MiR-122 regulates hepatic lipid metabolism and tumor suppression. Journal of Clinical Investigation 122(8): 2773-2776

Manfè, V.; Biskup, E.; Rosbjerg, A.; Kamstrup, M.; Skov, A.G.; Lerche, C.M.; Lauenborg, B.T.; Odum, N.; Gniadecki, R. 2012: MiR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma. Plos one 7(1): E29541

Nassirpour, R.; Mehta, P.P.; Yin, M.-J. 2013: MiR-122 regulates tumorigenesis in hepatocellular carcinoma by targeting AKT3. Plos one 8(11): E79655

Fabani, M.M.; Gait, M.J. 2008: MiR-122 targeting with LNA/2'-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates. Rna 14(2): 336-346

Chen, Y.; Wang, C.; Liu, Y.; Tang, L.; Zheng, M.; Xu, C.; Song, J.; Meng, X. 2013: miR-122 targets NOD2 to decrease intestinal epithelial cell injury in Crohn's disease. Biochemical and Biophysical Research Communications 438(1): 133-139

Lin, C.J.-F.; Gong, H.-Y.; Tseng, H.-C.; Wang, W.-L.; Wu, J.-L. 2008: MiR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochemical and Biophysical Research Communications 375(3): 315-320

Liu, A.M.; Xu, Z.; Shek, F.H.; Wong, K.-F.; Lee, N.P.; Poon, R.T.; Chen, J.; Luk, J.M. 2014: MiR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma. Plos one 9(1): E86872

Vaulont, S. 2011: MiR-122, a microRNA gatekeeper of iron homeostasis. Medecine Sciences: M/S 27(8-9): 704-706

Bandiera, S.; Pfeffer, S.éb.; Baumert, T.F.; Zeisel, M.B. 2015: MiR-122--a key factor and therapeutic target in liver disease. Journal of Hepatology 62(2): 448-457

Qiu, L.; Fan, H.; Jin, W.; Zhao, B.; Wang, Y.; Ju, Y.; Chen, L.; Chen, Y.; Duan, Z.; Meng, S. 2010: MiR-122-induced down-regulation of HO-1 negatively affects miR-122-mediated suppression of HBV. Biochemical and Biophysical Research Communications 398(4): 771-777

Jin, C.; Rajabi, H.; Kufe, D. 2010: MiR-1226 targets expression of the mucin 1 oncoprotein and induces cell death. International Journal of Oncology 37(1): 61-69

Wang, Y.; Yan, S.; Liu, X.; Zhang, W.; Li, Y.; Dong, R.; Zhang, Q.; Yang, Q.; Yuan, C.; Shen, K.; Kong, B. 2014: MiR-1236-3p represses the cell migration and invasion abilities by targeting ZEB1 in high-grade serous ovarian carcinoma. Oncology Reports 31(4): 1905-1910

Furuta, M.; Kozaki, K.-i.; Tanaka, S.; Arii, S.; Imoto, I.; Inazawa, J. 2010: MiR-124 and miR-203 are epigenetically silenced tumor-suppressive micro RNAs in hepatocellular carcinoma. Carcinogenesis 31(5): 766-776

Wang, C.; Feng, T.; Wan, Q.; Kong, Y.; Yuan, L. 2014: MiR-124 controls Drosophila behavior and is required for neural development. International Journal of Developmental Neuroscience: the Official Journal of the International Society for Developmental Neuroscience 38: 105-112

Weng, R.; Chin, J.S.R.; Yew, J.Y.; Bushati, N.; Cohen, S.M. 2013: MiR-124 controls male reproductive success in Drosophila. Elife 2: E00640

Kang, S.; Zhao, Y.; Hu, K.; Xu, C.; Wang, L.; Liu, J.; Yao, A.; Zhang, H.; Cao, F. 2014: MiR-124 exhibits antiproliferative and antiaggressive effects on prostate cancer cells through PACE4 pathway. Prostate 74(11): 1095-1106

Chen, J.S.; Pedro, M.S.; Zeller, R.W. 2011: MiR-124 function during Ciona intestinalis neuronal development includes extensive interaction with the Notch signaling pathway. Development 138(22): 4943-4953

Li, Y.; Zhang, Z.; Liu, X.; Huang, T.; He, W.; Shen, Y.; Liu, X.; Hong, K.; Cao, Q. 2014: MiR-124 functions as a tumor suppressor in the endometrial carcinoma cell line HEC-1B partly by suppressing STAT3. Molecular and Cellular Biochemistry 388(1-2): 219-231

Wei, J.; Wang, F.; Kong, L.-Y.; Xu, S.; Doucette, T.; Ferguson, S.D.; Yang, Y.; McEnery, K.; Jethwa, K.; Gjyshi, O.; Qiao, W.; Levine, N.B.; Lang, F.F.; Rao, G.; Fuller, G.N.; Calin, G.A.; Heimberger, A.B. 2013: MiR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Research 73(13): 3913-3926

Xia, J.; Wu, Z.; Yu, C.; He, W.; Zheng, H.; He, Y.; Jian, W.; Chen, L.; Zhang, L.; Li, W. 2012: MiR-124 inhibits cell proliferation in gastric cancer through down-regulation of SPHK1. Journal of Pathology 227(4): 470-480

Hu, C.-B.; Li, Q.-L.; Hu, J.-F.; Zhang, Q.; Xie, J.-P.; Deng, L. 2014: MiR-124 inhibits growth and invasion of gastric cancer by targeting ROCK1. Asian Pacific Journal of Cancer Prevention: Apjcp 15(16): 6543-6546

Li, K.K.W.; Pang, J.C.-s.; Ching, A.K.-k.; Wong, C.K.; Kong, X.; Wang, Y.; Zhou, L.; Chen, Z.; Ng, H.-k. 2009: MiR-124 is frequently down-regulated in medulloblastoma and is a negative regulator of SLC16A1. Human Pathology 40(9): 1234-1243

Qadir, A.S.; Um, S.; Lee, H.; Baek, K.; Seo, B.M.; Lee, G.; Kim, G.-S.; Woo, K.M.; Ryoo, H.-M.; Baek, J.-H. 2015: MiR-124 negatively regulates osteogenic differentiation and in vivo bone formation of mesenchymal stem cells. Journal of Cellular Biochemistry 116(5): 730-742

Gu, X.; Meng, S.; Liu, S.; Jia, C.; Fang, Y.; Li, S.; Fu, C.; Song, Q.; Lin, L.; Wang, X. 2014: MiR-124 represses ROCK1 expression to promote neurite elongation through activation of the PI3K/Akt signal pathway. Journal of Molecular Neuroscience: Mn 52(1): 156-165

Xie, L.-m.; He, R.-f.; Zhang, Z.-w.; Tang, Y.-y.; Luo, Z.-y. 2013: MiR-124 suppresses cell proliferation and invasion in gastric carcinoma and its mechanism. Zhonghua Zhong Liu Za Zhi 35(7): 497-500

Lv, X.-B.; Jiao, Y.; Qing, Y.; Hu, H.; Cui, X.; Lin, T.; Song, E.; Yu, F. 2011: MiR-124 suppresses multiple steps of breast cancer metastasis by targeting a cohort of pro-metastatic genes in vitro. Chinese Journal of Cancer 30(12): 821-830

Bitel, C.L.; Singh, V.; Frederikse, P.H. 2012: MiR-124, miR-125b, let-7 and vesicle transport proteins in squid lenses in L. pealei. Current Eye Research 37(5): 388-394

Sun, Y.; Zhao, X.; Zhou, Y.; Hu, Y. 2012: MiR-124, miR-137 and miR-340 regulate colorectal cancer growth via inhibition of the Warburg effect. Oncology Reports 28(4): 1346-1352

Zhou, Y.; Chen, K.-S.; Gao, J.-B.; Han, R.; Lu, J.-J.; Peng, T.; Jia, Y.-J. 2012: MiR-124-1 promotes neural differentiation of rat bone marrow mesenchymal stem cells. Zhongguo Dang Dai Er Ke Za Zhi 14(3): 215-220

Schumacher, S.; Franke, K. 2013: MiR-124-regulated RhoG: a conductor of neuronal process complexity. Small Gtpases 4(1): 42-46

Wang, N.; Liu, J.; Xie, F.; Gao, X.; Ye, J.-H.; Sun, L.-Y.; Wei, R.; Ai, J. 2015: MiR-124/ATF-6, a novel lifespan extension pathway of Astragalus polysaccharide in Caenorhabditis elegans. Journal of Cellular Biochemistry 116(2): 242-251

Li, W.; Wu, Y.-F.; Xu, R.-H.; Lu, H.; Hu, C.; Qian, H. 2014: MiR-1246 releases RTKN2-dependent resistance to UVB-induced apoptosis in HaCaT cells. Molecular and Cellular Biochemistry 394(1-2): 299-306

Martinez-Sanchez, A.; Murphy, C.L. 2013: MiR-1247 functions by targeting cartilage transcription factor SOX9. Journal of Biological Chemistry 288(43): 30802-30814

Shi, S.; Lu, Y.; Qin, Y.; Li, W.; Cheng, H.; Xu, Y.; Xu, J.; Long, J.; Liu, L.; Liu, C.; Yu, X. 2014: MiR-1247 is correlated with prognosis of pancreatic cancer and inhibits cell proliferation by targeting neuropilins. Current Molecular Medicine 14(3): 316-327

Kawano, S.; Nakamachi, Y. 2011: MiR-124a as a key regulator of proliferation and MCP-1 secretion in synoviocytes from patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 70(Suppl 1): I88-I91

Fowler, A.; Thomson, D.; Giles, K.; Maleki, S.; Mreich, E.; Wheeler, H.; Leedman, P.; Biggs, M.; Cook, R.; Little, N.; Robinson, B.; McDonald, K. 2011: MiR-124a is frequently down-regulated in glioblastoma and is involved in migration and invasion. European Journal of Cancer 47(6): 953-963

Lee, M.R.; Kim, J.S.; Kim, K.-S. 2010: MiR-124a is important for migratory cell fate transition during gastrulation of human embryonic stem cells. Stem Cells 28(9): 1550-1559

Lin, L.; Gu, X.; Liu, S.; Wang, X. 2014: MiR-124a promotes neurite outgrowth by inhibiting iASPP expression. Nan Fang Yi Ke da Xue Xue Bao 34(1): 31-35

Lu, S.-H.; Jiang, X.-J.; Xiao, G.-L.; Liu, D.-Y.; Yuan, X.-R. 2014: MiR-124a restoration inhibits glioma cell proliferation and invasion by suppressing IQGAP1 and β-catenin. Oncology Reports 32(5): 2104-2110

Boissart, C.; Nissan, X.; Giraud-Triboult, K.; Peschanski, M.; Benchoua, A. 2012: MiR-125 potentiates early neural specification of human embryonic stem cells. Development 139(7): 1247-1257

Foss, K.M.; Sima, C.; Ugolini, D.; Neri, M.; Allen, K.E.; Weiss, G.J. 2011: MiR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 6(3): 482-488

Ji, H.-L.; Song, C.-C.; Li, Y.-F.; He, J.-J.; Li, Y.-L.; Zheng, X.-L.; Yang, G.-S. 2014: MiR-125a inhibits porcine preadipocytes differentiation by targeting ERRα. Molecular and Cellular Biochemistry 395(1-2): 155-165

Ufkin, M.L.; Peterson, S.; Yang, X.; Driscoll, H.; Duarte, C.; Sathyanarayana, P. 2014: MiR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia. Leukemia Research 38(3): 402-410

Che, P.; Liu, J.; Shan, Z.; Wu, R.; Yao, C.; Cui, J.; Zhu, X.; Wang, J.; Burnett, M.S.; Wang, S.; Wang, J. 2014: MiR-125a-5p impairs endothelial cell angiogenesis in aging mice via RTEF-1 downregulation. Aging Cell 13(5): 926-934

Banerjee, S.; Cui, H.; Xie, N.; Tan, Z.; Yang, S.; Icyuz, M.; Thannickal, V.J.; Abraham, E.; Liu, G. 2013: MiR-125a-5p regulates differential activation of macrophages and inflammation. Journal of Biological Chemistry 288(49): 35428-35436

Yang, X.; Bemis, L.; Su, L.-J.; Gao, D.; Flaig, T.W. 2012: MiR-125b Regulation of Androgen Receptor Signaling Via Modulation of the Receptor Complex Co-Repressor NCOR2. Bioresearch Open Access 1(2): 55-62

Feliciano, A.; Castellvi, J.; Artero-Castro, A.; Leal, J.A.; Romagosa, C.é; Hernández-Losa, J.; Peg, V.; Fabra, A.; Vidal, F.; Kondoh, H.; Ramón Y Cajal, S.; Lleonart, M.E. 2013: MiR-125b acts as a tumor suppressor in breast tumorigenesis via its novel direct targets ENPEP, CK2-α, CCNJ, and MEGF9. Plos one 8(10): E76247

Willimott, S.; Wagner, S.D. 2012: MiR-125b and miR-155 contribute to BCL2 repression and proliferation in response to CD40 ligand (CD154) in human leukemic B-cells. Journal of Biological Chemistry 287(4): 2608-2617

Zhang, L.; Ge, Y.; Fuchs, E. 2014: MiR-125b can enhance skin tumor initiation and promote malignant progression by repressing differentiation and prolonging cell survival. Genes and Development 28(22): 2532-2546

Kong, F.; Sun, C.; Wang, Z.; Han, L.; Weng, D.; Lu, Y.; Chen, G. 2011: MiR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1. Journal of Huazhong University of Science and Technology. Medical Sciences 31(4): 543

Liu, Z.; Liu, H.; Desai, S.; Schmitt, D.C.; Zhou, M.; Khong, H.T.; Klos, K.S.; McClellan, S.; Fodstad, O.; Tan, M. 2013: MiR-125b functions as a key mediator for snail-induced stem cell propagation and chemoresistance. Journal of Biological Chemistry 288(6): 4334-4345

Nyholm, A.M.; Lerche, C.M.; Manfé, V.; Biskup, E.; Johansen, P.; Morling, N.; Thomsen, B.M.ør.; Glud, M.; Gniadecki, R. 2014: MiR-125b induces cellular senescence in malignant melanoma. Bmc Dermatology 14: 8

Chen, J.; Fu, X.; Wan, Y.; Wang, Z.; Jiang, D.; Shi, L. 2014: MiR-125b inhibitor enhance the chemosensitivity of glioblastoma stem cells to temozolomide by targeting Bak1. Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine 35(7): 6293-6302

Jin, Z.; Xu, S.; Yu, H.; Yang, B.; Zhao, H.; Zhao, G. 2013: MiR-125b inhibits Connexin43 and promotes glioma growth. Cellular and Molecular Neurobiology 33(8): 1143-1148

Zhang, Z.; Chen, J.; He, Y.; Zhan, X.; Zhao, R.; Huang, Y.; Xu, H.; Zhu, Z.; Liu, Q. 2014: MiR-125b inhibits hepatitis B virus expression in vitro through targeting of the SCNN1A gene. Archives of Virology 159(12): 3335-3343

Wan, Y.; Sun, G.; Wang, Z.; Guo, J.; Shi, L. 2014: MiR-125b promotes cell proliferation by directly targeting Lin28 in glioblastoma stem cells with low expression levels of miR-125b. Neuroreport 25(5): 289-296

Wong, S.S.Y.; Ritner, C.; Ramachandran, S.; Aurigui, J.; Pitt, C.; Chandra, P.; Ling, V.B.; Yabut, O.; Bernstein, H.S. 2012: MiR-125b promotes early germ layer specification through Lin28/let-7d and preferential differentiation of mesoderm in human embryonic stem cells. Plos one 7(4): E36121

Shi, X.-B.; Xue, L.; Ma, A.-H.; Tepper, C.G.; Kung, H.-J.; White, R.W.d. 2011: MiR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate 71(5): 538-549

Zeng, Q.-h.; Xu, L.; Liu, X.-d.; Liao, W.; Yan, M.-x. 2013: MiR-125b promotes proliferation of human acute myeloid leukemia cells by targeting Bak1. Zhonghua Xue Ye Xue Za Zhi 34(12): 1010-1014

Goettsch, C.; Rauner, M.; Pacyna, N.; Hempel, U.; Bornstein, S.R.; Hofbauer, L.C. 2011: MiR-125b regulates calcification of vascular smooth muscle cells. American Journal of Pathology 179(4): 1594-1600

Lu, X.; Deng, M.; He, H.; Zeng, D.; Zhang, W. 2013: MiR-125b regulates osteogenic differentiation of human bone marrow mesenchymal stem cells by targeting Smad4. Zhong Nan da Xue Xue Bao. Yi Xue Ban 38(4): 341-346

Battista, M.; Musto, A.; Navarra, A.; Minopoli, G.; Russo, T.; Parisi, S. 2013: MiR-125b regulates the early steps of ESC differentiation through dies1 in a TGF-independent manner. International journal of molecular sciences 14(7): 13482-13496

Akhavantabasi, S.; Sapmaz, A.; Tuna, S.; Erson-Bensan, A.E. 2012: MiR-125b targets ARID3B in breast cancer cells. Cell Structure and Function 37(1): 27-38

Ferracin, M.; Bassi, C.; Pedriali, M.; Pagotto, S.; D'Abundo, L.; Zagatti, B.; Corrà, F.; Musa, G.; Callegari, E.; Lupini, L.; Volpato, S.; Querzoli, P.; Negrini, M. 2013: MiR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression. Molecular Cancer 12(1): 130

Lin, K.-Y.; Zhang, X.-J.; Feng, D.-D.; Zhang, H.; Zeng, C.-W.; Han, B.-W.; Zhou, A.-D.; Qu, L.-H.; Xu, L.; Chen, Y.-Q. 2011: MiR-125b, a target of CDX2, regulates cell differentiation through repression of the core binding factor in hematopoietic malignancies. Journal of Biological Chemistry 286(44): 38253-38263

Li, Q.; Pan, Z.; Wang, X.; Gao, Z.; Ren, C.; Yang, W. 2014: MiR-125b-1-3p inhibits trophoblast cell invasion by targeting sphingosine-1-phosphate receptor 1 in preeclampsia. Biochemical and Biophysical Research Communications 453(1): 57-63

Klusmann, J.-H.; Li, Z.; Böhmer, K.; Maroz, A.; Koch, M.L.; Emmrich, S.; Godinho, F.J.; Orkin, S.H.; Reinhardt, D. 2010: MiR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. Genes and Development 24(5): 478-490

Wen, P.; Cao, H.; Fang, L.; Ye, H.; Zhou, Y.; Jiang, L.; Su, W.; Xu, H.; He, W.; Dai, C.; Yang, J. 2014: MiR-125b/Ets1 axis regulates transdifferentiation and calcification of vascular smooth muscle cells in a high-phosphate environment. Experimental Cell Research 322(2): 302-312

Yu, Q.; Liu, S.-L.; Wang, H.; Shi, G.; Yang, P.; Chen, X.-L. 2014: MiR-126 Suppresses the proliferation of cervical cancer cells and alters cell sensitivity to the chemotherapeutic drug bleomycin. Asian Pacific Journal of Cancer Prevention: Apjcp 14(11): 6569-6572

Meister, J.; Schmidt, M.H.H. 2010: MiR-126 and miR-126*: new players in cancer. Thescientificworldjournal 10: 2090-2100

Kim, W.; Lee, Y.; McKenna, N.D.; Yi, M.; Simunovic, F.; Wang, Y.; Kong, B.; Rooney, R.J.; Seo, H.; Stephens, R.M.; Sonntag, K.C. 2014: MiR-126 contributes to Parkinson's disease by dysregulating the insulin-like growth factor/phosphoinositide 3-kinase signaling. Neurobiology of Aging 35(7): 1712-1721

Yang, C.; Hou, C.; Zhang, H.; Wang, D.; Ma, Y.; Zhang, Y.; Xu, X.; Bi, Z.; Geng, S. 2013: MiR-126 functions as a tumor suppressor in osteosarcoma by targeting Sox2. International Journal of Molecular Sciences 15(1): 423-437

Feng, R.; Chen, X.; Yu, Y.; Su, L.; Yu, B.; Li, J.; Cai, Q.; Yan, M.; Liu, B.; Zhu, Z. 2010: MiR-126 functions as a tumour suppressor in human gastric cancer. Cancer Letters 298(1): 50-63

Ebrahimi, F.; Gopalan, V.; Smith, R.A.; Lam, A.K.-Y. 2014: MiR-126 in human cancers: clinical roles and current perspectives. Experimental and Molecular Pathology 96(1): 98-107

Jiang, L.; He, A.; Zhang, Q.; Tao, C. 2014: MiR-126 inhibits cell growth, invasion, and migration of osteosarcoma cells by downregulating ADAM-9. Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine 35(12): 12645-12654

Li, N.; Li, X.; Huang, S.; Shen, S.; Wang, X. 2013: MiR-126 inhibits colon cancer proliferation and invasion through targeting IRS1, SLC7A5 and TOM1 gene. Zhong Nan da Xue Xue Bao. Yi Xue Ban 38(8): 809-817

Sun, Y.; Bai, Y.; Zhang, F.; Wang, Y.; Guo, Y.; Guo, L. 2010: MiR-126 inhibits non-small cell lung cancer cells proliferation by targeting EGFL7. Biochemical and Biophysical Research Communications 391(3): 1483-1489

Miko, E.; Margitai, Z.án.; Czimmerer, Z.; Várkonyi, I.ó; Dezso, B.áz.; Lányi, A.ád.; Bacsó, Z.; Scholtz, B.át. 2011: MiR-126 inhibits proliferation of small cell lung cancer cells by targeting SLC7A5. Febs Letters 585(8): 1191-1196

Oglesby, I.K.; Bray, I.M.; Chotirmall, S.H.; Stallings, R.L.; O'Neill, S.J.; McElvaney, N.G.; Greene, C.M. 2010: MiR-126 is downregulated in cystic fibrosis airway epithelial cells and regulates TOM1 expression. Journal of Immunology 184(4): 1702-1709

Sun, Y.-q.; Zhang, F.; Bai, Y.-f.; Guo, L.-l. 2010: MiR-126 modulates the expression of epidermal growth factor-like domain 7 in human umbilical vein endothelial cells in vitro. Nan Fang Yi Ke da Xue Xue Bao 30(4): 767-770

Schmidt, Y.; Simunovic, F.; Strassburg, S.; Pfeifer, D.; Stark, G.B.ör.; Finkenzeller, G.ün. 2015: MiR-126 regulates platelet-derived growth factor receptor-α expression and migration of primary human osteoblasts. Biological Chemistry 396(1): 61-70

Felli, N.; Felicetti, F.; Lustri, A.M.; Errico, M.C.; Bottero, L.; Cannistraci, A.; De Feo, A.; Petrini, M.; Pedini, F.; Biffoni, M.; Alvino, E.; Negrini, M.; Ferracin, M.; Mattia, G.; Carè, A. 2013: MiR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma. Plos one 8(2): E56824

Aguado-Fraile, E.; Ramos, E.; Sáenz-Morales, D.; Conde, E.; Blanco-Sánchez, I.; Stamatakis, K.; del Peso, L.; Cuppen, E.; Brüne, B.; Bermejo, Mía.Laura.García. 2012: MiR-127 protects proximal tubule cells against ischemia/reperfusion: identification of kinesin family member 3B as miR-127 target. Plos one 7(9): E44305

Chen, J.; Wang, M.; Guo, M.; Xie, Y.; Cong, Y.-S. 2013: MiR-127 regulates cell proliferation and senescence by targeting BCL6. Plos one 8(11): E80266

Willers, I.M.; Martínez-Reyes, I.; Martínez-Diez, M.; Cuezva, Jé.M. 2012: MiR-127-5p targets the 3'UTR of human β-F1-ATPase mRNA and inhibits its translation. Biochimica et Biophysica Acta 1817(5): 838-848

Yang, M.; Shan, X.; Zhou, X.; Qiu, T.; Zhu, W.; Ding, Y.; Shu, Y.; Liu, P. 2014: MiR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2. Anti-Cancer Agents in Medicinal Chemistry 14(6): 884-891

Ivashchenko, A.T.; Issabekova, A.S.; Berillo, O.A. 2013: MiR-1279, miR-548j, miR-548m, and miR-548d-5p binding sites in CDSs of paralogous and orthologous PTPN12, MSH6, and ZEB1 Genes. Biomed Research International 2013: 902467

Li, M.; Fu, W.; Wo, L.; Shu, X.; Liu, F.; Li, C. 2013: MiR-128 and its target genes in tumorigenesis and metastasis. Experimental Cell Research 319(20): 3059-3064

She, X.; Yu, Z.; Cui, Y.; Lei, Q.; Wang, Z.; Xu, G.; Xiang, J.; Wu, M.; Li, G. 2014: MiR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma. Oncology Reports 32(3): 957-964

Witman, N.; Heigwer, J.; Thaler, B.; Lui, W.-O.; Morrison, J.I. 2013: MiR-128 regulates non-myocyte hyperplasia, deposition of extracellular matrix and Islet1 expression during newt cardiac regeneration. Developmental Biology 383(2): 253-263

Liu, J.; Yan, J.; Zhou, C.; Ma, Q.; Jin, Q.; Yang, Z. 2015: MiR-1285-3p acts as a potential tumor suppressor miRNA via downregulating JUN expression in hepatocellular carcinoma. Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine 36(1): 219-225

Guo, X.; Cao, C.; Sun, J.; Zhang, D.; Liu, L.; Wu, D. 2014: MiR-128a is up-regulated in hepatocellular carcinoma and promotes tumor cell proliferation by targeting RND3. Nan Fang Yi Ke da Xue Xue Bao 34(10): 1408-1413

Kotani, A.; Ha, D.; Hsieh, J.; Rao, P.K.; Schotte, D.; den Boer, M.L.; Armstrong, S.A.; Lodish, H.F. 2009: MiR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221. Blood 114(19): 4169-4178

Fesler, A.; Zhai, H.; Ju, J. 2014: MiR-129 as a novel therapeutic target and biomarker in gastrointestinal cancer. Oncotargets and Therapy 7: 1481-1485

Wu, J.; Qian, J.; Li, C.; Kwok, L.; Cheng, F.; Liu, P.; Perdomo, C.; Kotton, D.; Vaziri, C.; Anderlind, C.; Spira, A.; Cardoso, W.V.; Lü, J. 2010: MiR-129 regulates cell proliferation by downregulating Cdk6 expression. Cell Cycle 9(9): 1809-1818

Wang, D.; Luo, L.; Guo, J. 2014: MiR-129-1-3p inhibits cell migration by targeting BDKRB2 in gastric cancer. Medical Oncology 31(8): 98

Du, Y.; Wang, D.; Luo, L.; Guo, J. 2014: MiR-129-1-3p promote BGC-823 cell proliferation by targeting PDCD2. Anatomical Record 297(12): 2273-2279

Kang, M.; Li, Y.; Liu, W.; Wang, R.; Tang, A.; Hao, H.; Liu, Z.; Ou, H. 2013: MiR-129-2 suppresses proliferation and migration of esophageal carcinoma cells through downregulation of SOX4 expression. International Journal of Molecular Medicine 32(1): 51-58

Chen, X.; Ruan, A.; Wang, X.; Han, W.; Wang, R.; Lou, N.; Ruan, H.; Qiu, B.; Yang, H.; Zhang, X. 2014: MiR-129-3p, as a diagnostic and prognostic biomarker for renal cell carcinoma, attenuates cell migration and invasion via downregulating multiple metastasis-related genes. Journal of Cancer Research and Clinical Oncology 140(8): 1295-1304

Endo, Y.; Toyama, T.; Takahashi, S.; Yoshimoto, N.; Iwasa, M.; Asano, T.; Fujii, Y.; Yamashita, H. 2013: MiR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer. Endocrine-Related Cancer 20(1): 91-102

Li, X.; Wang, H-liang.; Peng, X.; Zhou, H-fang.; Wang, X. 2012: MiR-1297 mediates PTEN expression and contributes to cell progression in LSCC. Biochemical and Biophysical Research Communications 427(2): 254-260

Lee, E.K.; Lee, M.J.; Abdelmohsen, K.; Kim, W.; Kim, M.M.; Srikantan, S.; Martindale, J.L.; Hutchison, E.R.; Kim, H.H.; Marasa, B.S.; Selimyan, R.; Egan, J.M.; Smith, S.R.; Fried, S.K.; Gorospe, M. 2011: MiR-130 suppresses adipogenesis by inhibiting peroxisome proliferator-activated receptor gamma expression. Molecular and Cellular Biology 31(4): 626-638

Zhang, S.-j.; Feng, J.-f.; Wang, L.; Guo, W.; Du, Y.-w.; Ming, L.; Zhao, G.-q. 2014: MiR-1303 targets claudin-18 gene to modulate proliferation and invasion of gastric cancer cells. Digestive Diseases and Sciences 59(8): 1754-1763

Ma, S.; Tang, K.H.; Chan, Y.P.; Lee, T.K.; Kwan, P.S.; Castilho, A.; Ng, I.; Man, K.; Wong, N.; To, K.-F.; Zheng, B.-J.; Lai, P.B.S.; Lo, C.M.; Chan, K.W.; Guan, X.-Y. 2010: MiR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 7(6): 694-707

Park, J.-K.; Henry, J.C.; Jiang, J.; Esau, C.; Gusev, Y.; Lerner, M.R.; Postier, R.G.; Brackett, D.J.; Schmittgen, T.D. 2011: MiR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor. Biochemical and Biophysical Research Communications 406(4): 518-523